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Abstract 
Recent years have seen important advances in the area of T cell-based therapy for 
human malignancies. Epstein Barr virus-associated tumours like Hodgkin's 
lymphoma provide important models in this field. If aT cell-based therapy is to be 
effective however, T cells must be capable of trafficking to the tumour. To address 
this, the molecular mechanisms of T cell homing to Hodgkin's Lymphoma were 
explored. 
Chemokine and adhesion receptors were examined on infiltrating T cells. CXCR3, 
CXCR4, and CCR7 were expressed on major T cell populations with CXCRS, 
CXCR6, CCR4, and CCR5 on minor populations. Tumour cells expressed CXCL10, 
CXCL12 and CCL21. Vessels expressed ICAM-1, CXCL12, CCL17 and CCL21. 
Tumour cell lines secreted factors that mediated chemotaxis of lymphoblasts in vitro 
and TIL demonstrated chemotaxis to CXCL12 but not CCL17. VAP-1 was expressed 
on vessels and a tissue-binding assay was evaluated to examine VAP-1 function. 
T cell clones generated as part of an existing clinical trial of adoptive T cell therapy 
were found to express a polarised Tcl phenotype (CXCR3, CXCR6 and CCR5), 
which was typically independent of target antigen specificity, CD4/CD8 and donor 
status. However, lack of CCR7 expression and an inability to capture to VCAM-1 in a 
chemokine dependent manner suggested that clones expanded in vitro using existing 
protocols may be inefficient at trafficking to tumour tissue and thus may require 
modification of their homing phenotype. 
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Chapter 1. Introduction 
1.1 An overview of lymphocyte trafficking in the immune system 
Within the human body it has been estimated that there are some 500 billion 
lymphocytes, of which about half are T cells. 90 % of those are aß T cells and in a 
young person some 70 % are naive T cells. The repertoire of T cell receptor (TCR) 
specificities has been estimated at being between 25-100 million different receptors 
(Arstila et al., 1999). A conservative estimate therefore suggests only 6000 T cells in 
the human body share the same T cell receptor specificity (TCR). A fundamental 
question is how these 6000 cells ever encounter their cognate antigen in such a short 
space of time and confer protection? In the context of this thesis the question is 
refined to how such T cells ever locate antigen in association with tumours and how 
might this be exploited therapeutically. To begin to answer such questions it must be 
recognised that activated immune effector cells are not free to randomly roam the 
body but instead are programmed, channelled or compartmentalised in terms of their 
migratory capacity. Naive T cells continuously circulate between the systemic 
circulation and secondary lymphoid tissue as part of immune surveillance for foreign 
antigen. (Butcher, 1991; Picker and Butcher, 1992). Naive T cells encounter antigens 
in lymph nodes when antigen from peripheral sites such as the skin or the gut is taken 
up by tissue resident professional antigen presenting cells (APCs). In their tissue- 
resident, immature state dendritic cells (DC) display enhanced antigen uptake and can 
process exogenous antigen by phagocytosis or Fc receptor mediated endocytosis and 
become activated. This activated DC then upregulates cell surface homing receptors 
that allow it to respond to a gradient of chemoattractant signals in lymphatics thereby 
promoting trafficking into local draining lymphatics. Within the confines of the 
draining lymph node the rare antigen specific T cell scans T zone interdigitating DCs 
1 
for its cognate antigen. If recognition does not occur the T cell eventually drains from 
the node and enters back into the systemic circulation via the thoracic duct. If the T 
cell engages its target antigen presented by the appropriate HLA allele then activation 
and clonal expansion ensue. Resulting effector lymphocytes are reprogrammed in 
their migratory phenotype and selectively traffic to the site in which the antigen was 
encountered. In addition to an effector response, a long lasting memory response may 
be generated with the differentiation of long-lasting memory T cells which promote 
enhanced responses to subsequent rechallenge with the same antigen. 
Lymphocyte trafficking into tissue is dependent on a multistep adhesion cascade 
(Figure 1.1) that allows lymphocytes that are rapidly flowing in the systemic 
circulation to adhere to the vascular endothelium (Butcher, 1991). Transient tethering 
interactions allow lymphocytes to roll along the endothelium, sampling the 
endothelial glycocalyx for factors that trigger signalling events rapidly promoting an 
increase in both affinity and avidity of integrin-mediated adhesion to integrin ligands 
on the endothelium. The cell is then able to transmigrate through the endothelial 
barrier and penetrate the basement membrane. Within the tissue interstitium 
lymphocytes respond to a complex chemoattractant network that promotes directed 
migration. If infiltrating T lymphocytes encounter cells expressing the appropriate 
target antigen, then the T cell can interact via its TCR and associated adhesion and 
costimulatory molecules to mediate effector functions such as target cell lysis. 
2 
Figure 1.1 The multistep adhesion cascade 
Lymphocyte trafficking into tissue is dependent on a multistep adhesion cascade that 
allows lymphocytes that are rapidly flowing in the systemic circulation to adhere to 
the vascular endothelium (Butcher 1991). Transient tethering interactions allow 
capture and rolling of the lymphocyte. This promotes lymphocyte sampling of the 
endothelial glycocalyx for chemokines that trigger an increase in both affinity and 
avidity of integrin-mediated adhesion to Ig superfamily ligands expressed by the 
endothelium. The cell is then poised to transmigrate through the endothelial barrier 
and penetrate the basement membrane. Within the tissue interstitium lymphocytes 
respond to a complex chemoattractant network that promotes directed migration to 
discrete microenvironments. T cells interact with target cells expressing appropriate 
target antigens via the T cell receptor (TCR) and associated adhesion and 
costimulatory molecules to mediate target cell lysis. 
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1.2 Lymphocyte trafficking mechanisms. 
1.2.1 The adhesion cascade. 
1.2.1.1 Tethering/rolling adhesion. 
Lymphocytes overcome the problem imposed by high shear stress in the systemic 
circulation (0.05 Pa) by interacting with the vascular endothelium via a series of 
transient tethering interactions that allow the lymphocyte to roll rapidly along the 
vessel wall, but slow enough (40 µm/s) to sample the luminal surface for factors 
displayed by the endothelial proteoglycan (Tanaka et al., 1993). The selectin family 
and their ligands classically mediate this initial tethering interaction (Figure 1.2). 
The selectin family consists of three members: L(leukocyte)-selectin (CD62L), 
P(platelet)-selectin and E(endothelial)-selectin. L-selectin was defined by the 
antibody MEL14 that prevented lymphocyte binding to high endothelial venules in 
mouse secondary lymphoid organs (Gallatin et al., 1983). E-selectin was identified by 
raising the antibody H18/7 to cytokine-or endotoxin-activated human umbilical vein 
endothelial cells (HUVEC) and demonstrating blocking of neutrophil adhesion 
(Bevilacqua et al., 1987). P-selectin was detected as a plasma membrane component 
of a granules in platelets and later shown to be expressed in Weibel-palade bodies in 
endothelial cells (Bonfanti et al., 1989; McEver et al., 1989). 
1.2.1.1.1 Structural features of selectins. 
Selectins are calcium dependent C-type lectins that contain a plant C-type lectin 
domain of approximately 120 residues (Bevflacqua et al., 1989). Experiments with 
chimeric selectins demonstrate the lectin domain is critical for ligand binding (Erbe et 
al., 1992). Selectins contain an epidermal growth factor (EGF) like domain of 35-40 
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Figure 1.2 Selectins and their ligands. 
The selectin family consists of L(leukocyte)-selectin, P(platelet)-selectin and 
E(endothelial)-selectin (A). Selectins contain a plant C-type lectin domain of 
approximately 120 residues, an epidermal growth factor (EGF) like domain of 35-40 
residues containing 6 cysteines that are conserved with the EGF family of proteins. 
There are between 2-9 consensus repeats (--60 residues) with homology to 
complement binding proteins. Selectins have a transmembrane and a cytoplasmic C- 
terminal domain (B). Selectins bind to o-glycan decorated core proteins (C). Figures 
reprinted from (A and B) http: //bme. virginia. edu/ley/ and (C) http: //www. med. osaka- 
u. ac. jp/pub/orgctl/www/memberihirata. html 
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residues containing 6 cysteines that are conserved with the EGF family of proteins. 
Furthermore, there are between 2-9 consensus repeats (-60 residues) with homology 
to complement binding proteins (Bevilacqua et al., 1989). The number of these 
domains determines the length of the selectin. Deleting these domains in P-selectin 
abolishes function (Patel et al., 1995). Finally, selectins have a transmembrane and a 
cytoplasmic C-terminal domain. 
1.2.1.1.2 Molecular interactions between Selectins and their ligands. 
Attempts to identify and define selectin ligands have been hampered by the fact that 
they bind a range of O-glycan decorated protein scaffolds. This includes CD34 (Puri 
et al., 1995), podocalyxin (Sassetti et al., 1998), and endomucin (Samulowitz et al., 
2002) in human tonsil and G1yCAM-1 (Lasky et al., 1992), CD34 (Baumheter et al., 
1993), Sgp 200 (Hemmerich et al., 1994a) and endomucin (Samulowitz et al., 2002) 
in murine lymph nodes. These 0-glycan structures are extensively modified by 
glycosyltransferases which can use several sugar nucleotide substrates to form either 
a or ß glycosidic bonds. Posttranslational modifications include sialylation (use of 
CMP-sialic acid), and fucosylation (use of GDP-fucose). For example G1yCAM-1 has 
four associated sulphated monosaccharides that constitute part of the G1yCAM-1 
recognition site (Hemmerich et al., 1994a) and form a core of Sialyl Lewis X and its 
analogues, which bind selectins (Foxall et al., 1992). Recent gene knockout studies 
have more accurately defined L-selectin ligands expressed on high endothelial 
venules (HEV) within secondary lymphoid organs. L-selectin binding to its ligands is 
dependent on at least two fucosyl transferases (Homeister et al., 2001) and one 
sulfotransferase (van Zante et al., 2003) in synthesising the L-selectin recognising 
carbohydrate chains. 
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1.2.1.1.3 Enzymatic modification of selectin ligands. 
1.2.1.1.3.1 Core O-glycan synthesis. 
Initiation of O-glycan synthesis (Figure 1.3) is mediated by addition of N-acetyl 
galactosamine (Ga1NAc) to serine/threonine residues within the protein scaffold by a 
number of Ga1NAc transferases (Ga1NAc-Ts) (Schachter and Brockhausen, 1989). 
Chain initiation proceeds with branch specific modification. Core 1 glycans are 
sialylated, or elongated and then sialylated. Core 1 O-glycans are also modified to 
Core 2 O-glycans. Other glycosyltransferases and sulphotransferases then provide 
terminal modifications. 
Three core 2 G1cNAc transferases have been identified and targeted deletion of 
G1cNAcT-I has been characterised (Ellies et al., 1998). Lymphocyte homing is 
essentially unaffected in these mice, however neutrophil P-selectin ligand activity is 
deficient. The role in E-selectin ligand activity is unclear. Scaffold proteins were 
purified from G1cNAcT-I deficient mice. Analysis of the purified glycans identified 
novel core 1 extended glycans implying the existence of a relevant core 1 03- 
G1cNAcT. Sequence alignment of EST databases enabled the characterisation of a 
core 1 ß3-G1cNAcT expressed within high endothelial venules (F EV) (Yeh et al., 
2001). Reconstitution experiments with this transferase, GST-3, FucTVII and a 
scaffold protein demonstrated enhanced L-selectin dependent tethering under 
conditions of shear flow. 
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Figure 1.3 Enzymatic modifications of selectin ligands 
Initiation of O-glycan synthesis is typically mediated by addition of N-acetyl 
galactosamine (Ga1NAc) to serine/threonine residues within the protein scaffold by a 
number of Ga1NAc transferases (Ga1NAc-Ts) (A). Chain initiation proceeds with 
branch specific modification. Core 1 glycans are sialylated (B), or elongated and then 
sialylated (C). Core 1 O-glycans are also modified to Core 2 O-glycans. Other 
glycosyltransferases and sulphotransferases then provide terminal modifications (D). 
The sialyl lewis x motif is circled. Figure is adapted from Annu Rev Biochem. 
2003; 72: 643-91. Epub 2003 Mar 27. A genetic approach to Mammalian glycan 
function. 
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1.2.1.1.3.2 Sialylation. 
Three sialyl transferases (ST3Ga1-III, ST3Gal-IV, and ST3Gal-VI) form 2-3 sialic 
acid linkages and sialylate oligosaccharides in vitro that are likely to be important in 
selectin mediated adhesion. Targeted deletion of ST3 Gal-IV has resulted in a defect 
in E and P-selectin mediated adhesion in vitro, whereas only E-selectin dependent 
adhesion was defective in an in vivo model of neutrophil rolling (Ellies et al., 2002). It 
is possible that ST3Gal-VI is important and gene-targeting experiments are warranted. 
1.2.1.1.33 Sulphation. 
The importance of sulphation in selectin mediated adhesion was originally 
demonstrated by employing the metabolic inhibitor chlorate (Hemmerich et al., 
1994b). Sulphotransferases transfer sulphate from the donor phosphadenosine 
phosphosulphate and probing sequence databases identified candidate 6-0 
sulphotransferases. The cDNA for GST-3 (ISST) was subsequently identified and its 
expression was restricted to REV in mouse lymph nodes (Hiraoka et al., 1999; 
Kimura et al., 1999). In addition, reconstitution experiments transfecting chinese 
hamster ovary (CHO) cells with CD34 (or G1yCAM-1), FucT-VII (discussed below) 
and GST-3 provided greater L-selectin activity than with FucT-VII alone (Bistrup et 
al., 1999). 
The recent analysis of a GST-3 deficient mouse demonstrated increased rolling and 
reduced adherence to HEV (van Zante et al., 2003). There was a reduction in the 
amount of incorporated sulphate from CD3.4, and G1yCAM-1 isolated from these 
animals and there were reduced levels of the MECA-79 epitope (which constitutes 
part of HEV expressed peripheral node addressin [PNAD]). Furthermore, GST-3 and 
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core 2 GlcNacT deficient mice help to define the MECA-79 epitope and it is this 
combination that cooperatively regulates L-selectin rolling (Hiraoka et al., 2004). 
1.2.1.1.3.4 Fucosylation. 
Evidence for the role of fucosylation in the synthesis of selectin ligands has been 
definitively demonstrated by the characterisation of targeted gene deletions of two 
fucosyltransferases. FucTIV and FucTVII are both expressed in leukocytes and are 
required for a-1,3 fucosylation of O-glycans. FucTVII deletion was first characterised 
and demonstrated to produce a LAD II (discussed in section 1.2.1.2.4) like deficiency 
in mice including blood leukocytosis, a deficit in E and P-selectin counter-receptor 
activity and compromised neutrophil homing (Maly et al., 1996). This was 
recapitulated in vitro with reconstitution studies transfecting this transferase with a 
suitable protein core (i. e. CD34), GST-3, and a core 2 transferase. Although FucTVII 
accounted for a considerable defect in leukocyte homing, there was still residual 
homing. Upon generation of a double gene knockout of both fucosyltransferases a 
more severe phenotype was observed, this time with a paucity of lymph node 
lymphocytes as they were unable to traffic to secondary lymphoid organs (Homeister 
et al., 2001). 
1.2.1.2 Firm adhesion. 
1.2.1.2.1 Integrin family members and their endothelial counter-receptors. 
To convert leukocyte rolling along the vascular endothelium into firm and stable 
arrest, activation of cell surface integrins must occur. Integrins are activated and bind 
adhesion molecules belonging to the immunoglobulin superfamily expressed by the 
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vascular endothelium (Figure 1.4). Integrins are a family of cell surface type I 
heterodimers consisting of an a and 0 chain (Pribila et al., 2004). 
01, ß2 and (37 integrins are the predominant integrins for lymphocyte adhesion and ß2 
integrins are exclusively expressed on leukocytes. These integrins are expressed on 
the majority of leukocytes populations but have weak interactions with their counter 
receptors unless they are triggered into a high affinity conformational state or/and 
have increased lateral mobility in the plasma membrane. 
1.2.1.2.1.1 61 integrins. 
The ß1 integrins were discovered in the context of T cell activation and have a 
delayed increase in expression upon mitogen simulation of cells (Hemler et al., 1985). 
They predominantly bind to the extracellular matrix (ECM) and this interaction 
occurs through recognition of the residues Arg-Gly-Asp (RGD) contained within 
ECM proteins like fibronectin and vitronectin (Shimizu et al., 1990). a4ß1 (also 
known as VLA-4) is the exception in that it binds fibronectin via an alternative amino 
acid sequence, EILDV (Mould et al., 1990). a4ß1 is distinctive as it binds ECM 
fibronectin, and a cell surface receptor, vascular cell adhesion molecule-1 (VCAM-1) 
(Elices et al., 1990). VCAM-1 is a member of the Ig superfamily and has alternate 
spliced forms, including a seven Ig-like domain form, and an alternatively spliced six 
Ig-like domain form (Osborn et al., 1989). Binding to VCAM-1 is mediated by 
recognition of the first and fourth amino-terminal Ig-like domains (Vonderheide and 
Springer, 1992). The five other a chains that pair with ß1 subunits are expressed on 
lymphocytes and are important in lymphocyte-stromal interactions with ECM. 
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Figure 1.4 Integrins and their ligands. 
Generalised structure of cell surface expressed ligands for lymphocytes. Reprinted 
from fundamental Immunology, 4`h edition, William Paul. 
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1.2.1.2.1.2 ß2 integrins. 
Members of this family have a 02 chain in association with aL, aM, aD or aX. aLß2 
(LFA-1) is perhaps the most crucial integrin heterodimer in this class, binding 
predominantly to the 90-115 kDa counter-receptor ICAM-1 (Marlin and Springer, 
1987). ICAM-1 is a member of the immunoglobulin superfamily and contains 5 Ig 
domains to which the first two amino terminal domains mediate LFA-1 binding 
(Stanley et al., 1994). ICAM-1 is extensively glycosylated and expression on the 
vasculature is dependent upon activation. IL-10, TNF-a, IFN-y (Pober et al., 1986), 
endotoxin (Munro et al., 1991) and phorbol esters (Dustin et al., 1986) induce ICAM- 
1 expression. In addition, LFA-1 also binds ICAM-2, which contains only two 
extracellular Ig domains homologous to the first two Ig domains of ICAM-1 
(Staunton et al., 1989). ICAM-2 is constitutively expressed on resting endothelium, as 
well as inflamed vessels (Nortamo et al., 1991). aMß2 (Mao-1) is expressed on a 
subset of T cells and binds ICAM-1 through interactions with the third Ig domain 
(Diamond et al., 1991). aDß2 can bind ICAM-3 (Van der Vieren et al., 1995), 
whereas aXß2 binds ICAM-1 (Blackford et al., 1996) although their role in T cell 
adhesion in vivo is less clear. 
1.2.1.2.1.3 X137 integrins 
The ß7 chain can only pair with two known a chains, namely a4 and aE. Both are 
expressed at low levels on lymphocytes but are increased upon activation. a4ß7 is 
important in mucosal homing and binds to the ligand MadCAM-1 (Berlin et al., 
1993). MadCAM is heavily glycosylated and has three extracellular Ig domains (the 
N-terminal first two domains are homologous with ICAM-1 and VCAM-1) (Briskin 
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et al., 1993). On HEVs (Briskin et al., 1997) in peyers patches it mediates L-selectin 
mediated tethering because MadCAM-1 in the context of L-selectin activity acts as a 
scaffold protein for O-glycans (Berg et al., 1993). MadCAM-1 is differentially spliced 
and this can alter the glycosylation status of this core scaffold protein. Indeed, the 
unglycosylated form of MadCAM-1 is deficient in L-selectin mediated activity (Berg 
et al., 1993). a407 is able to bind VCAM-1 and fibronectin although the affinity of 
this receptor for these ligands is lower (Andrew et al., 1994). aEß7 is expressed on 
intra-epithelial lymphocytes and mediates T-cell-epithelial interactions by binding 
epithelial expressed E-cadherin. 
1.2.1.2.2 Structural features of integrins 
The crystallisation of integrin heterodimers and isolated integrin binding domains has 
enabled a structural analysis of integrin function (Randi and Hogg, 1994; Xiong et al., 
2002). Integrin heterodimers are non-covalently associated and contain an 
extracellular domain that has an a chain of - 940 residues and aß chain of - 640 
residues. Integrins consist of a globular headpiece that binds ligand. The headpiece is 
attached to a 500-residue stalk region that consists of three ß-sandwich domains 
including a so-called thigh, calf 1 and calf 2 domain (Figure 1.5). 
The a subunit consists of seven ß propeller domain repeats of approximately 60 
residues each, of which in half of a chain integrins lies an inserted I-domain between 
domains two and three. This I-domain containing subset of a chains comprises a 
f 
conserved region of approximately 200 residues that contain a dinucleotide binding 
(or "Rossmann fold") fold (Lee et al., 1995). The I-domain contains six major a 
helices surrounded by a single ß sheet (containing one anti-parallel and five parallel 
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Figure 1.5 Integrin structural features. 
A number of a subunits contain an I-domain insertion (dotted line). Asterisks show 
Mg2+ (blue) and Ca2+ (red) binding sites. Lines below the stick diagrams depict 
disulfide bonds. (B) Organisation of the domains is based on three-dimensional 
crystal structure data. Reprinted from Immunol Rev. 2002 Aug; 186: 141-63. Integrin 
activation and structural rearrangement. Takagi J, Springer TA. 
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strands). Divalent cations are located in the top of this domain and co-ordinate five 
side chains from three different loops. This functional unit comprises the metal ion 
dependent associated site (MIDAS), which comprises the metal coordinating residues 
and the surrounding metal binding site. Heterodimers containing this motif require 
Mg2+ (or Mn2) for function and experiments deleting the I-domain of the a chain of 
integrins result in an inactive heterodimer (Michishita et al., 1993). Conversely, 
isolation of the I-domain alone demonstrated complete ligand binding activity (Randi 
and Hogg, 1994). The ß subunit has fifty N-terminal residues that contain seven 
cysteines that restrain the integrin in the inactive conformer. 
All ß chains contain an I-like region that has structural homology with the I domain of 
a chains. Structural studies of aVß3 in complex with ligand mimetic peptide 
demonstrate this domain has extensive contacts with the peptide (Xiong et al., 2002). 
The domain has a characteristic DXSXS motif analogous to the MIDAS motif in the a 
subunit and has weak homology to the I-domain. Functionally, this I-like domain 
binds directly to ligand in heterodimers that do not contain an I-domain in the a chain 
and indirectly influence I-domain containing integrins. This region is a hotspot for 
mutations that abrogate the association of ß2 chains with a chains in LAD (discussed 
below). Flanking either side of this domain is a hybrid domain comprising aß 
sandwich structure that contains two covalent links between the I-like and hybrid 
domains. Contiguous with this region is an I-EGF domain consisting of cysteine rich 
repeats that provides structural rigidity and transmits structural motion. Activation 
antibodies to integrin heterodimers tend to bind this region. Finally, there is a (3 tail 
domain at the C-terminus that is cysteine rich and disulphide links the a helix with aß 
sheet to confer structural rigidity. 
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1.2.1.2.3 Affinity modulation versus clustering. 
Two modes of regulating integrin binding to their counter receptors have been 
recognised. It was thought that increased binding of integrins was due to an increase 
in the affinity of the heterodimers due to a shift in its conformation. More recently it 
has been recognised that heterodimers, upon activation with chemokine or TCR 
triggering (for T cells), cluster into patches on the cell surface membrane. Numerous 
signalling pathways have been implicated in each modality of integrin activation and 
a further discussion of this will be detailed later (section 1.2.1.3.2). A number of 
observations implicated clustering as an important mechanism in integrin activation. 
This included the observation that active LFA-1 clustered on cells that expressed this 
integrin and that treatment of cells with phorbol esters allowed LFA-1 to become 
more mobile in the plasma membrane (Kucik et al., 1996). 
1.2.1.2.4 Genetic disorders of integrin mediated adhesion. 
Analyses of rare genetic disorders resulting in impaired leukocyte adhesion have 
aided the elucidation of the pathways important in integrin function in vivo. A number 
of related disorders have been described. The leukocyte adhesion deficiency (LAD-1), 
described over twenty years ago, results in an increased susceptibility to bacterial 
infection. The defect is caused by a number of point mutations in the gene of the 02 
chain that impairs expression (Kishimoto et al., 1987). LAD-2 patients have defective 
biosynthesis of fucosylated glycans, which contain the carbohydrate ligands for both 
endothelial and leukocyte selectins (Etzioni et al., 1992). More recently a LAD-3 
disorder has been identified that demonstrates defects in G-protein coupled signalling, 
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specifically a defect in Rap! activation and impaired stabilisation of integrins 
(Kinashi et al., 2004). 
1.2.1.3 Triggering. 
1.2.1.3.1 The role of chemokines and their receptors in integrin activation. 
Integrin activation is crucial for firm adhesion of leukocytes to the vasculature and 
subsequent entry into the tissue compartment. It has become increasingly apparent 
that chemokines are potent mediators of this event. Chemokines comprise a large 
family of at least 43 members and are small chemotactic cytokines (10-14 kDa) 
defined by their amino acid composition (Rot and Von Andrian, 2004). There are two 
major families, the CC and CXC family members denoted by a tetra-cysteine motif, 
where either the first two cysteines are separated from each other by a non-conserved 
amino acid or lie adjacent to each other. In addition, the molecules CX3CL1 
(separated by three non -conserved residues), XCL1 and XCL2 (both lack two of the 
cysteines that would normally constitute the tetra-cysteine motif) are included in the 
family (Bazan et al., 1997). The NH2 terminus of some CXC chemokines contains a 
Glu-Leu-Arg (ELR) motif, preceding the first cysteine residue. Members that contain 
this motif are potent promoters of angiogenesis. The chemokine family possess a 
range of biological functions including proliferation, apoptosis, maturation and 
differentiation but focus will be restricted to their role in adhesion and migration. 
Chemokines mediate their effects by binding seven spanning G-protein coupled 
receptors (binding affinity 10-8/10"9 M). A family of 19 chemokine receptor family 
members have been described (Figure 1.6). Original studies of chemokine dependent 
integrin activation in leukocytes were performed with neutrophils (Buyon et al., 1988) 
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Figure 1.6 Chemokines and their receptors. 
Solid (agonist) and dashed (antagonist) chemokines bind to their corresponding 
receptors. The dashed-dotted line that connects CXCR3 with CCL1I represents a 
nonagonist-nonantagonist binding interaction. The bars next to individual chemokine 
numbers reflect the colours assigned to their apposite receptors (A). Rot A, von 
Andrian UH. Reprinted from Chemokines in innate and adaptive host defence: basic 
chemokinese grammar for immune cells. Annu Rev Immunol. 2004; 22: 891-928. 
There are two major families, the CC and CXC family members denoted by a tetra- 
cysteine motif. The first two cysteines are separated from each other by a non- 
conserved amino acid or lie adjacent to each other. In addition, the molecules 
CX3CL1/Fractalkine (separated by three non -conserved residues), 
XCL1/Lymphotactin and XCL2 (both lack two of the cysteines that would normally 
constitute the tetra-cysteine motif) are included in the family (Bazan et al. 1997) (B). 
Reprinted from Prog Retin Eye Res. 2004 Jul; 23(4): 435-48. The role of chemokines 
and their receptors in ocular disease. Wallace GR, John Curnow S, Wloka K, Salmon 
M, Murray Pl. 
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and subsequently, studies with lymphocytes demonstrated a role for chemokines in 
triggering arrest on vascular endothelium in secondary lymphoid organs (Bargatze 
and Butcher, 1993). Chemokine receptors are coupled to Gai proteins, and their 
effects can be inhibited by pertussis toxin due to ADP ribosylation of the a subunit 
preventing association with the receptor. It was later demonstrated that chemokines 
were differentially expressed in a range of tissues and often presented in the context 
of glycosaminoglycans (GAGs) (Tanaka et al., 1993). 
Recent studies highlight the importance of studying chemokine mediated integrin 
adhesion in the context of physiological shear stresses. Chemokines under static 
conditions can mediate adhesion that does not occur under flow where inadequate cell 
surface receptor levels, receptor affinity or coupling to signalling pathways exist. 
Flow based adhesion assays have demonstrated the differential ability of CCR4 
ligands CCL17 and CCL22 to mediate VIA-4 dependent adhesion of T cells to 
VCAM-1 (D'Ambrosio et al., 2002). The increased on-off rate of CCL22 receptor 
engagement appears to be important in this process and is not appreciable in static 
adhesion assays. In addition, CCL22 rapidly mediates CCR4 receptor desensitisation 
whereas CCL17 does not (Mariani et al., 2004). Extrapolation of such results, 
however, must be carefully considered with respect to the expression of chemokines 
in situ. Vascular localisation of CCL22 has not been detected at sites where this 
pathway would be important (i. e. the skin) and a more detailed characterisation of 
endothelial-expressed chemokines in situ is required. The expression of apical 
chemokines in the context of GAGS promötes the induction of firm adhesion. 
However, more recently chemokines have been implicated in tethering and diapedesis 
as well as the triggering step of lymphocyte homing (Cinämon et al., 2001). 
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1.2.13.2 Potential signalling mechanisms. 
The mechanisms underlying inside-out signalling for the triggering of integrins by 
chemokine receptors has until recently been poorly characterised. A number of 
putative pathways are emerging. 
The GTPase RhoA becomes activated upon CXCL8 treatment of neutrophils and has 
been implicated in experiments pre-treating neutrophils and lymphocytes with a C3 
transferase exoenzyme that specifically inhibits RhoA (Laudanna et al., 1996). The 
resulting loss of adhesion to VCAM-1 (and fibrinogen) implicates RhoA in VILA-4 
and Mac-1 dependent adhesion of lymphocytes and neutrophils respectively. 
Supporting these findings, experiments employing inhibitory peptides to block the 
effector domains of RhoA highlight a role for this protein in activation of integrin 
high affinity states and cell surface lateral mobility. (Giagulli et al., 2004). 
PKC t is an atypical PKC family member and in studies pretreating neutropils with 
CXCL8, a rapid translocation to the cell membrane was observed (Laudanna et al., 
1998). This was inhibited either with inhibitory peptides to PKC l; (abolishing 
neutrophil binding to fibrinogen) or treatment with C3 exoenzyme that abolished 
recruitment of the kinase to the membrane. Inhibitory peptides were also employed in 
studies of lymphocyte adhesion to ICAM-1 demonstrating a critical role in 
modulating the lateral mobility but not affinity of LFA-1 (Giagulli et al., 2004). 
I' 
PI3 kinase (P13K) is important in lymphocyte adhesion as indicated by inhibition 
studies which abrogate chemokine induced adhesion to ICAM-1, but importantly only 
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at low density of ICAM-1 [500-1500 sites/µm2] (Constantin et al., 2000). P13K 
modulates lateral mobility of integrin heterodimers rather than modulating integrin 
affinity. 
The involvement of Rap-1 in LFA-1 dependent adhesion has recently been 
highlighted. In T cells, chemokine or antigen stimulated activation of Rap-i resulted 
in co-localisation with LFA-1. Expression of a constitutively active Rap-1 increased 
the affinity and avidity of LFA-1 for ICAM-i. This interaction was dependent on the 
GTP bound form of RAP-1. A yeast two-hybrid screen identified an association with 
a protein RAPL and the resulting complex co-immunoprecipitated with LFA-1. 
Furthermore binding was abolished upon mutation of specific lysines within the a 
chain of LFA-1 (Katagiri et al., 2003). 
1.2.1.4 Transendothelial migration/Diapedesis. 
The final and least well understood stage of the adhesion cascade involves 
transendothelial migration (TEM) (or diapedesis) of leukocytes across the vascular 
endothelium and penetration of the basement membrane into the tissue interstitium . 
In most circumstances leukocytes pass between adjacent endothelial cells via 
interactions with endothelial junctions, however it has also been suggested that under 
some circumstances they can directly traverse endothelial cells by a transcellular route 
or preferential entry sites at tricellular junctions (Burns et al., 2000). A number of 
molecules have been implicated in transmigration of leukocytes through endothelial 
junctions. 
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CD31 has been implicated for a number of years in the transmigration of leukocyte 
subsets. Blocking antibodies to this receptor have demonstrated significant blocking 
of transmigration (approximately 90 %) (Bogen et al., 1994). However, TEM is never 
completely abrogated and targeted deletion of this receptor in mice does not 
significantly affect inflammatory recruitment (Duncan et al., 1999). CD31 is an 
alternatively spliced member of the Ig superfamily and is expressed on a number of 
cell types including leukocytes and endothelial cells (Wong et al., 2000). Homophilic 
interactions between endothelial and leukocyte expressed CD31 (through Ig domains 
1 and 2) mediate TEM (Sun et al., 1996). Intravital microscopy demonstrated this 
homophilic interaction subsequently upregulates a601 (Dangerfield et al., 2002), 
which in association with matrix metalloproteinases (MMPs), mediates penetration of 
the basement membrane into the tissue parenchyma. 
Another member of the Ig superfamily of proteins has also recently been implicated in 
TEM. The junctional adhesion molecule (JAM) family of proteins comprises three 
family members. JAM-A is expressed on epithelia and to a lesser extent on endothelia 
(Martin-Padura et al., 1998). It is concentrated at tight junctions but is expressed on 
the apical surface with cytokine treatment. In addition, it is also expressed by 
leukocytes and can form homophilic interactions either between adjacent endothelial 
cells or between leukocytes and endothelium. Interestingly, JAM-A also binds LFA-1 
and has been implicated in adhesion as well as TEM (Ostermann et al., 2002). JAM-B 
has a more restricted expression pattern principally on HEVs of secondary lymph 
nodes (Palmeri et al., 2000). JAM-B mediates homophilic interactions like JAM-A 
but in addition binds two leukocyte ligands, namely JAM-C (Arrate et al., 2001) and 
VLA-4 (Cunningham et al., 2002). JAM-C does not make homotypic interactions but 
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binds JAM-B (Cunningham et al., 2002) and Mac-1 (Santoso et al., 2002). Its role in 
adhesion and TEM requires clarification. 
CD99 is a cell surface receptor that is 0-glycosylated and expressed on T cells and 
endothelium. like CD31 it forms homotypic interactions (demonstrated in studies of 
monocytes) and antibody blockade impairs TEM (Schenkel et al., 2002). Blockade 
results in partial TEM across the junction and CD31 combined with CD99 blockade 
completely abolishes TEM. 
At adherens junctions, the cadherin VE-cadherin has been implicated in TEM. This 
cadherin associates with cytosolic catenins (through its cytoplasmic tail) for 
functional activity and deletion of the cytoplasmic tail results in reduced adhesion 
(Navarro et al., 1995). Over-expression of this mutant acts as a dominant negative. 
Antibodies to VE-cadherin increase vascular permeability and advance homing in 
vitro and in vivo (Gotsch et al., 1997). Studies employing adenoviral-mediated 
infection of HUVEC with a VE-cadherin-GFP fusion protein have demonstrated 
removal of this molecule from junctions during neutrophil TEM (Shaw et al., 2001). 
Vascular adhesion protein (VAP-1) (170 kDa) is expressed on endothelial cells. It is 
upregulated at sites of inflammation in vivo but is largely unresponsive to 
proinflammatory cytokine treatment in vitro. It was detected by a monoclonal 
antibody (clone 1B2) raised against human synovial endothelium and was 
subsequently shown to mediate lymphocyte binding to HEVs in secondary lymph 
nodes (Salmi and Jalkanen, 1992). VAP-1 is glycosylated and neuraminidase 
treatment reduces binding. VAP-1 was implicated in tethering, however recent studies 
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employing in vitro flow assays of T cell adhesion to primary liver endothelial 
monolayers implicates VAP-1 in both adhesion (with ICAM-1 and VCAM-1) and 
TEM (Lalor et al., 2002). In addition, neutrophil TEM in an in vivo inflammatory 
model was abolished by inhibition of VAP-1 (Koskinen et al., 2004). The mechanism 
of VAP-1 dependent TEM is unclear but tantalising hints to a mechanism are 
suggested by the observation that this receptor has enzymatic activity (Smith et al., 
1998). Specifically, semicarbazide inhibitors abrogate the monoamine oxidase activity 
of the receptor. The ligand for this molecule is unknown although it has been 
suggested that VAP-1 catalyses the deamination of primary amines on the surface of 
lymphocytes. 
Other molecules including occludins (Oshima et al., 2003), claudins (Nitta et al., 
2003), CD146 (Solovey et al., 2001) and integrins like a2ß1 and a5ß1 (Lampugnani 
et al., 1991) have been associated with TEM (based on expression) however the 
significance of these results requires further investigation. 
1.2.2 Tissue specific homing. 
Tissue specific homing of lymphocytes was implied from the observation that 
lymphocytes isolated from a particular tissue or draining lymph node when 
transferred into the peripheral blood, tend to traffic back to the same location. Indeed, 
it has been demonstrated that dendritic cells from Peyer's patches (but not other 
secondary lymphoid) imprint on T cells the ability to selectively traffic to the small 
intestine (Mora et al., 2003). V 
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Homing in secondary lymphoid organs has been extensively characterised and 
confirms a number of features of the multistep adhesion cascade. Lymphocytes have 
two main access routes into secondary lymphoid organs, via the afferent lymphatics 
or High endothelial venules (HEVs). The bulk of lymphocytes gain efficient access 
through HEVs, however activated lymphocytes and mature dendritic cells can exit 
tissues via lymphatics and enter into local draining LN. The mechanism of 
lymphocyte specific trafficking through HEVs is well characterised. There is a 
requirement for L-selectin expression for tethering (Gallatin et al., 1983) (as blocking 
antibodies to L-selectin or peripheral node addressin (PNAd) block adhesion), CCL19 
and CCL21 (and to a lesser extent CXCL12/SDF-1) for activation (Stein et al., 2000) 
and LFA-1-ICAM-1 interactions for firm adhesion (Warnock et al., 1998) This is 
exemplified by the fact that other leukocyte subsets are deficient in trafficking to 
secondary lymphoid organs. Granulocytes express L-selectin and LFA-1 but not 
CCR7. Dendritic cells express CCR7 and LFA-1 but not L-selectin consistent with 
their requirement to enter via lymphatics rather than HEV. Effector T cells show low 
levels of both CCR7 and L-selectin together with high expression of LFA-1, CXCR3 
and CCRS which targets their homing to sites of inflammation. However, so-called 
central memory T cells which lack immediate effector function express CCR7 and L- 
selectin enabling them to recirculate between the blood and the lymphatics (Sallusto 
et al., 1999). 
The importance of the CCR7-CCL19/CCL21 pathway was demonstrated in the plt/plt 
(paucity of LN T cells) mouse (Nakano et aJ;, 1997). This mouse fails to develop 
normal lymph nodes and was subsequently found to lack the genes for CCL19 and the 
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CCL21ser form. Subsequently, CCRT1 deficient mice were generated confirming the 
importance of this pathway (Forster et al., 1999). 
Tissue specific homing to other organs has been best documented for skin and gut. 
Lymphocytes that traffic to the skin are characterised by high expression of CIA 
(Picker et al., 1990). This O-glycan linked receptor mediates tethering interactions 
with dermal venular expressed E-selectin, which can be blocked with the HECA-452 
mAb (Berg et al., 1991). Activation of integrins is mediated by CCR4 which binds to 
CCL17/TARC and in flow based models CLA+ T cells undergo CCR4 dependent 
arrest on ICAM-1 (Campbell et al., 1999). Recent studies support a role for CCR8 in 
physiological trafficking to the skin (Schaerli et al., 2004). 
Lymphocytic infiltration of the small intestine is critically dependent on lymphocyte 
binding to endothelial expressed MAdCAM-1 (Berlin et al., 1993). Whereas naive T 
cell use L-selectin to bind MAdCAM-1 in mesenteric lymph nodes, the recruitment of 
memory T cells to the gut is dependent on an integrin, a4ß7 expressed by mucosal 
lymphocytes, which can also bind to MAdCAM-1 to mediate arrest. Furthermore, 
CCR9 is expressed on these lymphocytes allowing them to respond to the chemokine 
TECK/CCL25 (Zabel et al., 1999) the expression of which is restricted to the small 
bowel epithelium and mucosal vessels. 
1.2.3 Microenvironmental homing. 
1.2.3.1 T cell polarisation. 
Upon penetration of the basement membrane and access to the tissue interstitium, 
lymphocytes are poised to respond to an array of chemotactic cues that guide them to 
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specific microenvironments. They migrate through matrix by rearranging cytoskeletal 
actin and polarising their structure upon exposure to chemoattractants (Vicente- 
Manzanares et al., 1998). This polarisation of structure allows attachment of the 
leading edge to the substratum with concomitant detachment of the uropod (rear end). 
This interaction is combined with myosin-based contraction that generates traction 
(Rey et al., 2002). Moreover, These events allow the cell to move forward with 
renewed extension of the leading edge in an F-actin dependent manner. 
There is a marked difference between non-polarised lymphocytes that maintain a 
homogenous distribution of cell surface receptors and polarised lymphocytes that 
demonstrate an asymmetric plane consisting of a leading edge and a uropod. Both cell 
surface and intracellular components are localised to these distinct regions of the 
lymphocyte. The leading edge consists of an enriched source of cytoskeletal 
components including F-actin, myosin light chain and talin (Vicente-Manzanares et 
al., 2002). The leading edge is also enriched in GM-3-marked lipid rafts (Gomez- 
Mouton et al., 2001), chemokine receptors including (CXCR4, CCR5, and CCR2) 
(Nieto et al., 1997) and have clusters of ß1 integrins. The uropod is a slender region 
that extends from the substratum and consists of receptors like CD43, CD44, ICAM-1 
(del Pozo et al., 1995) and PSGL-1 (Bruehl et al., 1997) as well as 
ezrin/radixin/moesin cytoskeletal components (Serrador et al., 1997). The polarized 
lymphocyte is then able to migrate into a specific subcompartment of the tissue 
responding to this chemoattractant network. In the context of lymphoid organs, 
lymphocytes are densely packed within a largely cellular environment with little 
interaction with the ECM. Indeed, collagen fibrils are sheathed in a reticular network. 
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Conversely, T cells within peripheral tissues are extensively in contact with collagen 
and other ECM proteins. 
1.2.3.2 Microenvironmental homing. 
The most comprehensively characterised organ with respect to microenvironmental 
positioning is the lymph node. The importance of CXCR5 and CCR7 has been shown 
in several murine models. CXCR5''' B cells were able to enter the spleen and Peyer's 
patches but were unable to exit the interfollicular T-zone as they could not respond to 
follicular expressed BCA-1/CXCL13 (Forster et al., 1996). In addition, CXCR5 in 
collaboration with CCR7, positions B cells at the T-B interface. B cell activation 
results in upregulation of CCR7 and movement to this boundary responding to T zone 
expressed CCL19/CCL21. Retroviral mediated gene transfer (and overexpression) of 
B cells with CXCR5 prevented this (Reif et al., 2002). The importance of CXCR5- 
CCR7 axis is also true for a subset of follicular homing CD4+ T cells that express the 
marker CD57 and migrate to this T-B interface upon antigen stimulation to mediate 
T-dependent B cell responses (Kim et al., 2001). 
1.2.3.3 Leukocyte emigration. 
Much is known regarding leukocyte infiltration of tissues with respect to adhesion to 
the vascular endothelium. However, the mechanism of exit of leukocytes from tissue 
has remained elusive. Investigations with the drug FTY720 have revealed the 
importance of the sphingosine-1-phosphate (SIP) pathway in mediating lymphocyte 
emigration from lymphoid organs as treatment of mice with this drug severely reduces 
lymphocyte egress and results in marked lymphopenia (Mandala et al., 2002). The 
phosphorylated form of the drug binds 4 of the 5 sphingosine-1 phosphate receptors 
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ýI nkmann et al., 2002). Targeted disruption of sphingosine-1 phosphate receptor 1 (Bn 
in mice haematopoietic cells severally impairs their exit from the thymus and other 
lymphoid organs and FTY720 downregulates these receptors and impairs S1P 
dependent exit (Matloubian et al., 2004). 
1.2.4 Leukocyte infiltration of human tumours. 
Many tumours consist of leucocyte infiltrates often comprising macrophages, T cells, 
and in some tumours additionally eosinophils, B cells, NK cells and granulocytes. The 
presence of these cells in tumours can correlate with prognosis. Macrophage 
infiltration of tumours is often associated with poor prognosis (Bingle et al., 2002). 
Lymphocytic infiltration of tumours has been associated with positive clinical 
prognosis in ovarian cancer (Zhang et al., 2003) and colorectal carcinoma 
(Diederichsen et al., 2003). Conversely, in HL tumours, the presence of granzyme 
expressing CTLS correlates with a poor clinical outcome (Oudejans et al., 1997; ten 
Berge et al., 2001). In spite of a complex association between leukocyte infiltrates and 
cancer prognosis, the presence of such cells in tumours like HL, allows us to 
determine the mechanisms these cells employ to enter tumours, and to exploit these 
pathways for immunotherapy. 
1.3 Cellular based immunotherapies for the treatment of human cancer. 
Currently one in three people in their lifetime will be diagnosed with invasive cancer. 
Conventional therapy consists of surgery, radiotherapy or chemotherapy. These 
treatments only cure half of all individuals treated, and thus a fourth modality of 
cancer therapy, immunotherapy, is being devised. It aims to alter the body's immune 
system such that it recognises and destroys tumour cells. 
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Immunotherapy in recent years has had a resurgence of interest with the success of 
monoclonal antibody therapy (i. e. Rituximab), in the treatment of particular cancers. 
A disadvantage of this kind of therapy, however, is the inability of antibody therapy to 
penetrate solid tumours. In addition, the therapy is of a passive nature and does not 
confer long lasting immunity to the tumour. In the last two decades, investigations 
into the use of cellular based therapies for the treatment of cancers refractive to 
conventional treatment have been sought. Clearly a complete account of 
immunotherapies is beyond the scope of this thesis, however, a discussion of 
strategies, both active and passive in the generation of T cell responses to tumours 
will be considered. 
13.1 Active strategies. 
To confer long lasting immunity to tumours, various vaccination strategies have been 
explored. A brief description of some of the active cellular strategies that may induce 
anti-tumour T cell responses will be discussed. 
1.3.1.1 Tumour cells. 
Classically autologous or allogeneic tumour cells (or cell extracts) were employed for 
immunisation purposes. A caveat to this approach is the inability of these cells to 
efficiently induce immune responses. To circumvent this patients have been 
vaccinated with genetically modified tumour cells. Strategies examined include 
transduction of tumour cells with cytokines and growth factors including GM-CSF, 
IL-2, TNFa, IL-12 and IFN-y (Colombo and Rodolfo, 1995) as well as immune co- 
stimulatory molecules including CD80 and CD86 (Loskog et al., 2002). 
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1.3.1.2 Protein/peptide based vaccines 
With the identification of novel tumour antigens there exists the possibility of 
vaccinating patients with specific proteins or peptides derived thereof. An advantage 
of a peptide strategy is the ease of manufacture but it is dependent on prior knowledge 
of the epitope and its restricting allele. High frequencies of CD8+ T cells were 
detected in five HLA A2 patients following immunisation with peptide derived from 
the melanoma tumour antigen gp100 (Powell and Rosenberg, 2004; Rosenberg et al., 
1998). Alternative approaches employed recombinant virus to deliver short MAGE-1 
and MAGE-3 sequences that coded for peptides presented by HLA class I. In four 
patients with regression, three demonstrated specific CTL responses (Karanikas et al., 
2003). In addition to existing epitopes, known epitopes can also be mutated to 
produce a peptide that binds HLA with higher affinity and is more immunogenic 
(Linard et al., 2002). 
An advantage of whole protein vaccines is the ability of the cell to degrade and 
present a range of peptides on HLA molecules including ones that are 
uncharacterised. This is particularly pertinent for putative epitopes targeted by CD4+ 
T cells, that until recently have been largely ignored. The ability to manufacture 
recombinant protein presents considerable financial and regulatory issues, however an 
example of such an approach includes vaccination with a fusion protein containing the 
C-terminal CD4 epitope rich region of EBNA-1 fused to full length LMP2. This is 
currently being evaluated in a phase I clinical trial for Nasopharyngeal carcinoma 
(Taylor et al., 2004). f` 
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1.3.1.3 Antigen presenting cell based vaccines. 
Of particular interest recently has been the potential therapeutic vaccination of cancer 
patients with a professional antigen-presenting cell (APC) (exemplified by the 
dendritic cell) that has enhanced ability to prime T cell responses. The ability to 
purify these APCs from blood (or bone marrow) and pulse with antigen has re-ignited 
the possibility of a successful therapeutic vaccination approach for treating cancer 
(Marten et al., 2002). Antigen can be delivered to APCs exogenously in the form of 
peptide, whole protein or tumour cell lysate. Alternatively, tumour antigens can be 
expressed endogenously following infection of APC with recombinant virus or 
transfection with purified RNA or DNA. 
In melanoma, sixteen patients were vaccinated with blood derived DCs pulsed with 
tumour lysate or a peptide cocktail. Specific CTL were recruited to the DTH 
challenge site with objective responses in five patients (Nestle et al., 1998). Another 
melanoma trial vaccinated eleven patients (stage IV melanoma) with a MAGE-3A1 
peptide. This induced specific CTL in 8/11 patients and regression of metastasis in six 
patients (Thurner et al., 1999). A major advantage of this approach is that DCs in 
principle can prime naive T cell responses and can induce immunological memory to 
the tumour. A limitation is the current requirement for ex vivo loading of DCs with 
tumour antigen. The ability to vaccinate DCs in vivo would greatly enhance the 
applicability of this strategy. 
13.2 Passive strategies. 
The holy grail of cancer immunotherapy is to therapeutically (or even 
prophylactically) vaccinate cancer patients and induce potent and sustained immunity 
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to the tumour. In many ways studies of adoptive cellular transfer (ACT) of large 
numbers of high avidity tumour specific T cells is the benchmark by which 
vaccination based approaches must be compared. To this end, a number of studies 
have investigated the use of ACT in the treatment of cancer. In this treatment regime, 
anti-tumour cells are isolated and expanded to high frequencies (101) ex vivo. These 
cells can be optimally activated and reinfused back into the patient. 
Early studies of ACT employed lymphokine activated killer (LAK) cells to eradicate 
tumours (Grimm et al., 1982) and anti-tumour activity was demonstrated with the 
infusion of LAK cells with IL-2 (Rosenberg et al., 1987). It was later recognised that 
IL-2 alone was as efficacious (Rosenberg et al., 1993). A second generation of ACT 
involved isolation and expansion of tumour-infiltrating lymphocytes (TIL) in high 
dose IL-2 (- 1000 IU/ml). These cells provided anti-tumour activity in the treatment 
of melanoma and renal cell carcinoma (Figlin et al., 1997; Topalian et al., 1988). In 
these early studies, the antigen specificity of these cells was uncertain and 
concomitant administration of high dose IL-2 had side effects including vascular leak 
syndrome (Rosenstein et al., 1986). More recently, thirteen patients were treated with 
autologous T cells and high dose IL-2 with nonmyeloablative conditioning. 
Oligoclonal populations of MART-1 or gp100 TIL were generated, and following 
infusion these cells persisted in vivo and trafficked to tumour deposits. Objective 
partial responses were observed in six patients (Dudley et al., 2002). 
EBV is associated with several human tumours (including HL). These tumours 
provide an important model system in which to evaluate T cell therapies as the T cell 
response to this virus has been extensively characterised. Studies of EBV associated 
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post transplant lymphoma have demonstrated both the safety and efficacy of treating 
patients with EBV specific T cells (Papadopoulos et al., 1994; Rooney et al., 1995; 
Rooney et al., 1998b). 39 patients received prophylactic infusions of polyclonal CTL 
lines. No patients developed lymphoma following stem cell transplantation. This 
compared with 12 % from the control group. In two patients who declined 
prophylactic treatment, cells were infused after diagnosis of lymphoma. In both cases 
there was resolution of the tumour. Interestingly, Infused T cells remained in the 
circulation for more than three months (several years if measured by PCR). 
In PTLD, EBV expresses a full latent gene program including immunodominant 
antigens and therefore is a best case for adoptive T cell therapy (Figure 1.7). Other 
EBV malignancies express a more restricted latency program that excludes the 
immunodominant antigens (Figure 1.7). Indeed, EBV positive HL and NPC tumours 
express subdominant antigens (Deacon et al., 1993; Fahraeus et al., 1988) although 
promisingly T cell responses to epitopes from these proteins have been detected in the 
peripheral blood of healthy donors and weak responses detected in a minority of HL 
and NPC patients (Chapman et al., 2001; Lee et al., 2000) (Figure 1.8). As yet there is 
no evidence of relevant antigen specific cells at the site of HL and NPC tumours. 
However, the ability to generate the relevant cells for ACT provides a suitable 
rationale for the selective expansion of T cell clones directed against epitopes from 
these proteins. CTL lines from 11/15 HL patients were successfully produced by LCL 
reactivation (Rooney et al., 1998a). Interestingly, levels of TCR ý chain were low in 
peripheral T cells but increased in established CTL lines. Three patients were infused 
(with gene marked cells) with minimal clinical responses. One patient had pleural 
effusions, which contained enrichment of the marker gene compared with peripheral 
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Figure 1.7 EBV latency states in human tumours. 
The latent infection of primary human B lymphocytes in vitro (LCL) is classed as a 
latency III pattern with the expression of the full complement of latent proteins 
including EBNA 1, EBNA 2, EBNA 3A, EBNA 3B, EBNA 3C, EBNA -LP (leader 
protein), LMP1, LMP2A and LMP2B as well as BARTs (spliced Bam A rightward 
transcripts) and two EBERs (nonpolyadenylated RNAs). This latent program is 
detected in post transplant lymphoproliferative disease (PTLD). Other EBV 
associated malignancies demonstrate the existence of two other latency programs. A 
latency I phenotype is present in Burkitt's lymphoma with the expression of EBNA 1 
protein, EBERs and BARTs. A Latency II pattern exhibits expression of EBNA 1, 
LMP1 and LMP2 as well as EBERs and BARTs and is typical of Hodgkin's 
lymphoma and NPC. 
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Figure 1.8 T cell epitopes defined in HL-associated proteins. 
CD4 and CD8 T cell target proteins expressed in HL tumours are represented with the 
corresponding mapped epitopes and restricting alleles. nd=not done. Adapted from 
Lee 2002. 
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Target Epitope sequence Amino HLA 
protein acid restriction 
residues 
CD8+ T cell 
targets 
LMP1 YLLEMLWRL 125-133 A*0201 
LMP1 YLQQNWWTL 159-167 A*0201 
LMP2 PYLFWLAAI 131-139 A23 
LMP2 IEDPPFNSL 200-208 B*40011 
LMP2 RRRWRRLTV 236-244 B*2704 
LMP2 LLWTLVVLL 329-337 A*0201 
LMP2 WTLVVLLI 331-338 B63 
LMP2 SSCSSCPLSK 340-349 All 
LMP2 FLYALALLL 356-364 A*0201 
LMP2 TYGPVFMCL 419-427 A24 
LMP2 CLGGLLTMV 426-434 A*0201 
LMP2 VMSNTLLSAW 442-451 A25 
LMP2 LLSAWILTA 447-455 A*0203 
LMP2 LTAGFLIFL 453-461 A*0206 
CD4+ T cell 
targets 
EBNA1 RRPQKRPSCIGCKGT 71-85 nd 
EBNA1 RPFFHPVGEADYFEY 403-417 nd 
EBNA1 VPPGAIEQGPADDPGEGPST 429-448 nd 
EBNA1 DGGRRKKGGWFGRHR 455-469 nd 
EBNA1 NPKFENIAEGLRALL 475-489 DR11 
EBNA1 LRALLARSHVERTTD 485-499 nd 
EBNA1 VYGGSKTSLYNLRRGTALAI 509-528 nd 
EBNA1 TSLYNLRRGTALAI 515-528 DR1 
EBNA1 NLRRGTALAIPQCRL 519-533 nd 
EBNA1 PQCRLTPLSRLPFGM 529-543 nd 
EBNA1 APGPGPQPGPLRESIVCYFM 544-563 nd 
EBNA1 LRESIVCYFMVFLQTHIFAE 554-573 nd 
EBNA1 MVFLQTHIFAEVLKD 563-577 DR15 
EBNA1 VLKDAIKDLVMTKPAPTCNI 574-593 nd 
EBNA1 RVTVCSFDDGVDLPPWFPPM 594-613 nd 
EBNA1 DGEPDMPPGAIEQGPADDPG 424-443 nd 
EBNA1 KTSLYNLRRGIALAIPQCRL 514-533 nd 
EBNA1 PTCNIKATVCSFDDGVDLPP 589-608 nd 
LMP1 LWRLGATIWQLLAFF 130-144 nd 
LMP1 SGHESDSNSNEGRHH 212-226 nd 
LMP1 TDGGGGHSHDSGHGG 340-354 nd 
LMP2 STVVTATGLALSLLL 149-163 nd 
LMP2 SSYAAAQRKLLTPV 169-182 nd 
LMP2 VLVMLVLLILAYRRRWRRLT 224-243 nd 
LMP2 STEFIPNLFCMLLL 385-398 nd 
blood. Two patients had an initial reduction in peripheral blood EBV load. These 
initial investigations highlight some of the challenges of generating high avidity, 
tumour specific T cells from patients with HL. 
133 Monitoring immune responses to tumours. 
Regardless of the therapeutic strategy employed, it is vital to have an accurate and 
sensitive measure of the immune response. Previous readouts of this included the 
observation of delayed type hypersensitivity responses or measuring cytolytic activity. 
These methods are of low sensitivity or require in vitro manipulation and correlate 
poorly with clinical outcome. Recently, a number of sensitive assays that require little 
in vitro manipulation have been employed. 
For studies of adoptive cellular therapy (ACT) infused cells can be tracked by 
infecting them with a retrovirus expressing a marker gene like neomycin. The marker 
gene is integrated into the genome and marked cells can be tracked by PCR 
(Economou et al., 1996). Safety issues include a lack of knowledge of where the 
marker gene will integrate within the host genome. However, incorporation of a 
suicide gene like thymidine kinase (from herpes simplex virus) enables destruction of 
the marked cells by treating patients with gancyclovir if the infused cells become 
abnormal (Junker et al., 2003). An obstacle to employing thymidine kinase is the 
possible immunogenicity of transgene-induced cells as well as the requirement for 
drug selection (Riddell et al., 1996). An alternative approach involved transducing T 
cells with a nerve growth factor receptor,, and a Fas based suicide construct. 
Transduced cells were then isolated by immunomagnetic selection (Berger et al., 
2003). 
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Alternatively, if knowledge of the TCR ß chain sequence is known, then sensitive real 
time PCR can be employed to track clonally expanded antigen specific populations 
expressing a specific TCR clonotype, by using a 5' primer specific for the Vß subtype 
and a constant region specific reverse primer. Indeed, the skewing of clonotypic 
responses can be assessed by analysing TCR Vß cDNA clones using 5'rapid 
amplification of cDNA ends (RACE) (Boudinot et al., 2002). An alternative to 
realtime PCR is the use of Vß specific antibodies, which provides multiparametric 
characterisation of antigen specific T cell populations (Khan et al., 2002). 
HLA- peptide tetramers have revolutionised the analysis of antigen specific immune 
responses and such reagents can be employed where the antigen specificity and the 
restricting allele are known (Altman et al., 1996). The use of tetramer or multimer 
reagents in the in situ analysis of specific T cells in tissues is currently being pursued 
with some success (Haanen et al., 2000). 
The immune response can be monitored functionally and this has been aided in 
particular with the use of the sensitive ELISpot assay for release of functional 
cytokines like IFN-y from individual cells (Czerkinsky et al., 1988) and intracellular 
cytokine staining (Jung et al., 1993). Typically the monitoring of these responses has 
been performed on peripheral blood samples. Although technically challenging it is 
also important to characterise the nature of the response at the site of the tumour, as 
tumour specific T cells will have ideally trafficked to tumour deposits rather than 
remain in the peripheral circulation. 
fý 
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1.3.4 Caveats and future challenges for cell-based therapies. 
1.3.4.1 Are T-cells of sufficient avidity and specificity? 
The recent ability to transfer functional TCR from one T cell to another clone and 
express functional TCR a and ß chains of T cells has greatly enhanced the feasibility 
of generating T cells of a required specificity and avidity. A library of cloned a and 0 
chains could be generated and retrovirally transduced into T cells programming the 
appropriate specificity (Clay et al., 1999). Safety issues must be taken into 
consideration including the possible misspairing of transduced a and ß chains with 
endogenous chains resulting in a chimeric TCR. Other options include the production 
of allorestricted T cells specific for an allo-HLA/peptide complex. For example, T 
cells from a HLA A2 negative donor stimulated with a HLA A2 target expressing 
appropriate peptide can produce allorestricted clones that are of high avidity and 
specificity that were not deleted during ontogeny (Munz et al., 1999). 
1.3.4.2 Do T cells traffic to the tumour site? 
The ability of T cells to traffic to the tumour site is critical for an anti-tumour 
response. Gene-marking studies and labelling of cells with indium-111 indicate that 
tumour reactive T cells can be detected at melanoma deposits after infusion (Fisher et 
al., 1989). In addition to tracking T cells it may also be desirable to modify their 
homing. For example, Induced expression of CXCR4 on T cells in leukaemia or bone 
marrow metastatic tumours should facilitate their recruitment in bone marrow where 
the CXCR4 ligand CXCL12 is highly expressed (Aiuti et al., 1997). Furthermore, 
expression of CXCRS might facilitate localisation of T cells to BCA-1 expressing 
follicles in the treatment of follicular lymphoma (Husson et al., 2002). Finally, 
expression of CXCL1 by melanoma cells may allow them to recruit CXCR2 
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transduced T cells (Kershaw et al., 2002). Vaccination based approaches do not allow 
for the ex vivo modification of T cells and thus the route and mode of vaccination is 
likely to be critical in the nature (e. g. specificity of homing) of immune effectors 
generated. 
13.43 Do T-cells retain function at the site of the tumour? 
There is evidence that if anti tumour T cells gain entry to the tumour milieu they may 
encounter an environment that is hostile to an effective anti-tumour response 
including the presence of the anti-inflammatory cytokine IL-10 (de Waal Malefyt et 
al., 1991). This may be due to the direct impairment of T cell function. For example, 
in colorectal carcinoma (Yoong and Adams, 1998) and HL (Rooney et al., 1998b), 
isolated TIL demonstrated reduced expression of the TCR signalling chain 
t compared with controls. Alternatively, altered T cell function might occur at the 
level of the dendritic cell with impaired ability to prime T cell responses. Infiltrating 
macrophages are able to produce TGFß and PGE2 that can suppress DC function 
(Fadok et al., 1998) and the expression of IL-10 by the tumour (at least in murine 
models) can tolerise the resident DC population (Yang and Lattime, 2003). 
Furthermore, it has been suggested that regulatory T cells are present at the site of 
tumours including HL (Marshall et al., 2004) and are a potent source of 
immunosuppression in the tumour. 
14 The aetiology and pathology of Hodgkin's lymphoma. 
1.4.1 Pathology of Hodgkin's lymphoma. 
Hodgkin's lymphoma (HL) is an unusual cancer that is characterised by a paucity of 
neoplastic tumour cells, namely the Hodgkin and Reed-Sternberg cells (H-RS) which 
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comprise less than 1% of the tumour mass. These cells have an abundant cytoplasm 
typically with 2-3 nuclei, each with a prominent nucleolus. There is a non-neoplastic 
infiltrate that consists of lymphocytes, plasma cells, histiocytes, and eosinophils. The 
tumour often has extensive areas of fibrosis. The presence of H-RS cells per se is not 
diagnostic of HL, as they have been observed in infectious mononucleosis, non- 
Hodgkin's lymphomas as well as some carcinomas and sarcomas (Iacobuzio-Donahue 
et al., 2002; Lukes et al., 1969). Rather, it is the presence of these cells in the context 
of the background inflammatory infiltrate that provides the diagnosis of HL. 
1.4.1.1 HL subtypes 
The REAL WHO classification (Harris et al., 1994) subdivides HL into classical HL 
and nodular lymphocyte predominant HL (a distinct clinical and aetiological disease). 
Classical HL is subdivided into four types including Nodular sclerosing (NSHL), 
mixed cellularity (MCHL), lymphocyte rich (LRHL) and lymphocyte depleted HL 
(LDHL). 
MCHL comprises approximately 25 % of HL cases and is the subtype most frequently 
associated with EBV (60-70 % of cases) (Glaser et al., 1997). It consists of abundant 
normal inflammatory cells with comparatively frequent numbers of H-RS cells (5-15 
H-RS cells per high-powered field). MCHL patients are typically elderly and present 
with symptoms including fever, sweats, weight loss and often have abdominal 
involvement and advanced disease. This subtype is more common in the developing 
world. 
LDHL is rare (less than 1%) and recently some cases have been reclassified as non- 
Hodgkin's lymphomas. It typically presents as advanced disease and 
histopathologically is characterised by tumour cells that outnumber normal cells. 
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NSHL is the most common subtype (60-70% of HL cases) although it is less common 
in the developing world. It is equally represented amongst men and women and tends 
to present in young adults and adolescents. It has a good prognosis although this 
subtype can be subdivided into two variants, NSI (low grade) and NSII (high grade) 
defined in terms of the degree of fibrosis and number of H-RS cells. NSHL has two 
defining features, namely the presence of collagen bands that divide the node into 
nodules and the presence of H-RS variants called lacunar cells that stand out from the 
reactive infiltrate when fixed in formalin based fixatives. 
A recent subtype has been identified and included in the REAL classification scheme. 
Lymphocyte rich classical HL has H-RS cells that have the immunophenotype of 
other classical HL subtypes (CD30+, CD15+, CD20-, CD45-) but has an infiltrate 
similar to non-classical LPHL (i. e. B cells rather than T cells) and a clinical 
presentation resembling LPHL. This subtype can have a nodular or diffuse pathology 
and resemble NSHL, MCHL or LPHL. H-RS cells are rare and eosinophilia is 
typically not observed. 
Non-classical nodular lymphocyte predominant Hodgkin lymphoma (nLPHL) is 
distinct both clinically and aetiologically. It comprises 5-10 % of HL cases and is 
typically observed in children or the elderly. It is more common in men (3: 1). The 
pathology consists of effacement of the Lymph node architecture with an abundance 
of normal polyclonal B cells. Interspersed within this background are H-RS variants 
called lymphocytic and histiocytic (or L+Hlpopcom) cells. These cells have 
multilobed nuclei and there is little fibrosis within the tissue. 
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1.4.2 Aetiology of HL and its association with EBV 
Hodgkin's lymphoma is considered a disease derived from germinal centre B cells. 
When B cells enter the germinal centre they are selected for productive non-self 
reacting B cells and are rescued from apoptosis. Normally, B cells enter the dark zone 
of the germinal centre and undergo the germinal centre reaction characterised by 
somatic hypermutation of Ig V genes. This reaction increases antibody affinity and 
those cells that express low affinity or self-reactive B cell receptors (BCR) are deleted 
by apoptosis. H-RS cells are rescued from apoptosis in spite of crippling mutations 
that allow Ig V gene rearrangement but abolish functional BCR gene expression 
(Kuppers et al., 1994). The surviving cell is defective in expression of the normal B 
cell program including the lineage markers BCR, CD20 or CD79a. In addition, 
mutations in the octamer region of the Ig promotor may result in an inability of 
transcription factors to bind to this region (Theil et al., 2001). Complimenting this is 
the lack of Ig specific transcription factors detected in HL cells (both cultured and 
primary) (Stein et al., 2001). Somewhat paradoxically, although H-RS cells are 
typically germinal centre B cell derived, the B lineage developmental expression of 
Pax5 is absent (Hertel et al., 2002). The T lineage marker Notchl (and GATA3) is 
expressed and counteracts PaxS possibly halting the B cell program (Jundt et al., 
2002). 
Apoptosis of B cells produced in the germinal centre reaction is mediated by a Fas 
dependent mechanism. Studies on two H-RS cell lines indicate that they may be 
resistant to Fas mediated killing in spite of functional Fas expression (Re et al., 2000). 
H-RS cells however express inappropriate levels of c-FLIP, which is anti-apoptotic 
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and prevents expression of the apoptotic program (Dutton et al., 2004; Thomas et al., 
2002). 
H-RS cells maintain deregulated expression of transcription factors including NFKB 
which is constitutively active in H-RS cell lines (Bargou et al., 1996). This activity 
enhances proliferation and reduces sensitivity to apoptosis that can be relieved 
experimentally by introducing a dominant negative IKBa that prevents nuclear 
translocation of NFkB (Bargou et al., 1997). In addition, it was demonstrated that a 
proportion of cases have mutations in IKBa or gene amplification of the NFKB/Rel 
locus (Cabannes et al., 1999; Joos et al., 2002). These observations implicate the 
NFxB pathway in deregulated H-RS cell growth and survival. 
Additional transcriptional deregulation has also been described in H-RS cells and 
includes members of the STAT family of which STAT3 is constitutively expressed, 
independently of IL-6 dependent JAK activation (Kube et al., 2001). Furthermore, 
STAT6 is constitutively expressed and is dependent on IL -13 expression, which is 
expressed with its receptor on these cells (Skinnider et al., 2002). 
AP1 is another transcription factor that is constitutively expressed and regulates the 
cell cycle regulator cyclin D2 (Mathas et al., 2002). In summary, a number of putative 
pathways have been disrupted in HL to facilitate escape from apoptosis and allow 
clonal proliferation. 
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1.4.2.1 A role forEBV 
EBV has been implicated in 40 % of HL cases as an aetiological agent in the 
development of HL (Glaser et al., 1997). Primary infection with EBV occasionally 
results in infectious mononucleosis (IM), IM patients are 2-3 times more likely to 
develop HL. Furthermore, antibody titres to EBV are elevated in HL patients (Mueller 
et al., 1989). At the molecular level, EBV gene or protein expression (detected by ISH 
or IHC) is detected in the tumour cells (Herbst et al., 1991; Wu et al., 1990). EBV 
positive HL cells express a restricted latency program including the Qp promotor 
driven nuclear antigen EBNA1 (required for maintenance of the viral episome) and 
the latent membrane proteins LMP1, LMP2a and LMP2b, as well as BamH1A 
transcripts (Deacon et al., 1993). LMP-1 behaves as a constitutively active CD40 
driving NFxb pathways and upregulating bcl-2 and A20 (Gires et al., 1997). 
Furthermore, transgenic expression of LMP1 in mouse models confirms the 
oncogenic nature of this protein with the development of B cell lymphomas 
(Kulwichit et al., 1998). IMP-2a shuts down signalling through the B cell receptor 
(BCR) by competing for tyrosine kinases that bind ITAM regions of the BCR 
signalling chain. This blocks B cell activation and entry of EBV into the lytic cycle 
and concomitantly substitutes for the BCR by constitutively activating pro-survival 
downstream signalling components (Caldwell et al., 1998). 
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1.5 Rationale and plan of investigation. 
Recent years have seen important advances in the area of T cell therapy for human 
malignancies. EBV-associated tumours like HL occupy a key position as models in 
this field. This thesis addresses the possibility of aT cell-based therapy for HL, by 
exploring the molecular mechanisms of T cell homing to this tumour. The work has 
focused on two main areas of research: 
1) Identification of chemokines, chemokine receptors and adhesion molecules that 
mediate T cell recruitment into HL. 
a) Immunohistochemical and flow cytometric studies. 
Using frozen HL tumour biopsies, tumour cell suspensions and available cell lines, 
flow cytometry and immunohistochemistry was used to study the expression of (i) a 
panel of chemokines and their receptors, and (ii) integrins, selectins and their 
corresponding ligands to determine which might contribute to the cellular infiltrate. 
Staining of HL biopsies was compared with reactive lymph nodes and TILs from 
other tumours. For chemokine receptors expressed on infiltrating T cells, 
immunohistochemical studies were performed to determine whether the relevant 
chemokines were present on the tumour cells and the vascular endothelium. 
Endothelial tissue within HL biopsies was examined by immunohistochemistry for 
expression of adhesion receptors. In complimentary studies, expression of the ligands 
for these receptors was determined on the tumour infiltrating lymphocytes (TILs). 
Adhesion receptor expression on the tumour was also assessed as this may determine 
whether aT cell is retained at the tumour site. 
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b) Functional studies. 
Using available cell lines derived from HL tumour biopsies, the ability of individual 
chemokines to mediate T cell migration in an in vitro chemotaxis assay was studied. 
These studies used activated T cells derived from healthy laboratory donors expanded 
in vitro with interleukin-2. 
Following the immunohistochemical studies outlined above, adhesion molecules of 
interest were tested functionally in an in vitro tumour tissue-binding assay using 
activated T cells and HL biopsy sections in the presence and absence of relevant 
blocking antibodies. 
2) Analysing the expression and function of these molecules on T cells expanded in 
vitro for adoptive T cell therapy. 
Having identified molecules that appear to mediate T cell recruitment into HL 
tumours, it is important to determine whether these molecules are expressed and 
function correctly on clones prepared for adoptive T cell therapy. EBV or melanoma 
tumour antigen specific T cell clones were isolated for this purpose and expanded to 
large numbers using a Rapid Expansion Protocol (REP). These clones were studied 
both by flow cytometry and using the functional assays for chemotaxis and cell 
adhesion. T cells were sampled at different time points during the REP and under 
different culture conditions to determine the optimal stage at which cells could be 
infused for an adoptive therapy. 
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Chapter 2: Materials and Methods 
2.1 Materials. 
2.1.1 Clinical material. 
Snap frozen tissue sections from 10 HL cases were kindly provided by Prof. John 
Crocker (Heartlands hospital, Birmingham, UK) (Table 2.1). Paraffin-embedded 
sections (10 HL cases) were obtained from Dr. Paul Murray, (University of 
Birmingham, Birmingham, UK) (Table 2.1). For flow cytometric analysis of tissue 
infiltrating lymphocytes, cell suspensions from HL cases were kindly provided by 
Prof. Ruth Jarrett (University of Glasgow, Glasgow, UK) (Table 2.1). Tonsil explants 
were obtained from Mr. Adrian Drake Lee (Queen Elizabeth hospital, Birmingham, 
UK). Clinical material from patients with colorectal carcinoma was kindly obtained 
by Dr. Beatrix Hunter (University of Birmingham, Birmingham, UK). Clinical 
material from patients with Renal cell carcinoma was provided by Dr. Ciaran Lynch 
(University of Birmingham, Birmingham, UK). T cells clones generated for a clinical 
trial of adoptive T cell therapy were provided by Dr. Steve Lee (University of 
Birmingham, Birmingham, UK) (Table 2.2). All clinical material was obtained after 
having obtained prior informed consent and ethical approval (South Birmingham 
research ethics committee LREC 5493,5673 and MRECO1/0/58). 
2.1.2 Buffers, media and solutions. 
Phosphate-buffered saline (pH 7.4) : (Oxoid, Basingstoke, UK) 160 mM NaCl, 3 
mM KC1,8 mM disodium hydrogen phosphate, 1 mM potassium dihydrogen 
phosphate in H2O. The pH was adjusted to pH 7.4 with HC1 (Fisher chemicals, 
Loughborough, UK). 
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Patient HL Subtype FBVstatus" Material collected 
2996-92 Nodular sclerosis FBV ne ative Snap fioeen sections 
15208-94 Nodular sclerosis EBV ne ative Snap frozen sections 
6840-96 Nodular sclerosis ? Snap frown sections 
687-97 Nodular sclerosis ? Snap frozen sections 
10783-98 Nodular sclerosis EBV ne ative Snap frozen sections 
5371-99 Nodular sclerosis ? Snap frozen sections 
14175-96 L hoc e predoninant ? Snap frozen sections 
5756-91 Lymphocyte predominant FBV ne ative Snap frozen sections 
1258-95 Mimed cellukirity EBV-positive Snap frozen sections 
10242-98 Mixed cellularity ? Snap frozen sections 
95-3167 Nodular sclerosis EBV ne ative Fomnalin fixed sections 
96-4154 Nodular sclerosis EBV ne ative Fonnalin fixed sections 
97-6460 Nodular sclerosis FBV ne ative Fonralin fixed sections 
95-2452 Nodular sclerosis FBV ne ative Fonralin fixed sections 
95-8906 L hoc e predominant EBV-ne ative Formalin fixed sections 
96-2136 B5 Mixed cellularity FBV ositive Formalin fixed sections 
96-4643 B5 Mixed cellularity FBV ositive Formalin fixed sections 
97-2861 Mixed cellula ' FBV ne ative Formalin fixed sections 
96-1699 B5 Mixed cellularity EBV ositive Fomaalin fixed sections 
97-5512 Mixed cellula ' FBV ne ative Fomialin fixed sections 
3051 Mixed cellula ' ? Cell suspensions 
6277 Nodular sclerosis ? Cell suspensions 
5783 Nodular sclerosis EBV-negative Cell suspensions 
5706 Nodular sclerosis )~BV ne ative Cell suspensions 
6452 Nodular sclerosis FBV ne ative Cell suspensions 
6687 Mixed cellularity ? Cellsuspensions 
6766 Nodular sclerosis EBV ositive Cell suspensions 
6808 Nodular sclerosis ? Cellsuspensions 
6740 Nodular sclerosis ? Cell suspensions 
a EBV status of tumour determined by in situ hybridization for EBER1 expression. 
Table 2.1 HL patient details. 
Patient Cancer Clone Target 
Antigen 
Epitope Amino Acid 
Residues 
HLA 
Restiction 
CD4/CD8 
T18 NPC 16 EBNA1 NPKFENLAEGLRA. LL 475-489 DR11 CD4 
T18 NPC 106 EBNA1 NPKFENLkKLRAILL 475-489 DRI I CD4 
T19 Melanoma 11 NYFSO-I UKFFIVSG 121-130 DR4 CD4 
T19 Melanoma 29 NYESal VLLKEFTVSG 121-130 DR4 CD4 
T19 Melanoma 77 NYESO-1 VLLKFFTVSG 121-130 DR4 CD4 
T19 Melanoma 91 NYFSO-I MIKFFTVSG 121-130 DR4 CD4 
T19 Melanoma 110 NYESO-1 ViLKffTVSG 121-130 DR4 CD4 
T19 Melanoma 112 NYESal VLiKf'TVSG 121-130 DR4 CD4 
T23 Melanoma 156 MACE-AI SLFRAVITK 96-104 A3 CD8 
T27 HL 15 LMP2 FLYAIALI. L 356-364 A2 CD8 
T27 HL 41 LMP2 FLYAL i7L 356-364 A2 CD8 
T27 HL 114 IMP1 YLLEMILWRL 125-133 A2 C D8 
T27 HL 174 LMP2 ILWTLVVLL 329-337 A2 CD8 
T27 HL 183 IMP2 LLWTLVVIL 329-337 A2 CD8 
T29 Melanoma 73 NYESO-I SLLMWTTQCFL 157-167 A2 CD8 
T29 Melanoma 121 MACE-Al LLKYRAREPVTKAE 114-127 DR13 CD4 
T30 Melanoma 19 NYFSO-I TIRLT 119-138 DR4 CD4 
T30 Melanoma 179 Tyrosinase QNIII.. SNAPLCPQFP 56-70 DR4 CD4 
T30 Melanoma 311 MACE-3 TSYVKVII-IHMMGSG 281-295 DR11 CD4 
Table 2.2 Details of T cell clones generated for infusion therapy. 
0.05 M Tris buffered saline (pH 7.4): 50 mM tris(hydroxymethyl)aminomethane 
(Sigma-Aldrich, Gillingham, UK), 139 mM NaCI (Sigma-Aldrich, Gillingham, UK) 
in H2O. The pH was adjusted to pH 7.4 with HCl (Fisher chemicals, Loughborough, 
UK) 
0.01 M Citrate buffer (pH 5.8): 10 mM citric acid (Sigma-Aldrich, Gillingham, UK) 
in H2O. The pH was adjusted to pH 5.8 with NaOH (Fisher chemicals, 
Loughborough, UK). 
Complete medium: RPMI 1640,10 % foetal calf serum (heat inactivated, Invitrogen, 
Renfrew, UK), 2 mM glutamine (Sigma-Aldrich, Gillingham, UK), 100 gg/ml 
streptomycin (Sigma-Aldrich, Gillingham, UK), 100 IU/ml penicillin (Sigma-Aldrich, 
Gillingham, UK). 
PHA blast media: Complete medium supplemented with 30 % MLA 144 
supernatant, 50 IU/ml rhIL-2 (Chiron, Middlesex, UK). 
MACS buffers: 
Running buffer: PBS, 2mM EDTA, 0.5% BSA (Miltenyi biotech, Bisley, UK). 
Rinsing solution: PBS, 2mM EDTA (Miltenyi biotech, Bisley, UK). 
Cleaning solution: 70 % v/v ethanol. 
Naphthol AS-MX substrate: 0.2 µg/ml naphthol AS-MX phosphate (Sigma-Aldrich, 
Gillingham, UK), 1/50 dimethylformamide (Sigma-Aldrich, Gillingham, UK), 
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1mg/ml fast red salt (Sigma-Aldrich, Gillingham, UK), 1 mM Levamisole (Sigma- 
Aldrich, Gillingham, UK). 
2.2 Methods. 
2.2.1 Tissue manipulation. 
2.2.1.1 Tissue collection and preparation. 
Fresh tumour or control biopsy material was collected within 1 hour of explantation 
from patients. Explants were cut into i-cm3 blocks, snap-frozen in embedding media 
(Cryo-M-Bed, Bright, Huntingdon) in liquid nitrogen and stored at -70 °C until 
further use. Paraffin embedded explants were processed in the department of 
pathology. This was kindly done by Gary Reynolds (University Hospital Birmingham, 
Birmingham, UK). 
2.2.1.2 Isolation of lymphocytes from tissue 
Tissue explants were collected, rinsed with RPMI 1640 to remove any traces of blood 
and then disaggregated using a scapel or Medimachine (Dako, Ely, UK). Samples 
were then either used immediately for phenotypic investigations or cell suspensions 
were centrifuged on Ficoll density gradients to purify mononuclear cells and stored 
frozen at -180 °C (described below). 
2.2.2 Cell culture and manipulation. 
2.2.2.1 Cryopreservation of cells 
Cells suspensions were chilled on ice for 20 minutes and collected by centrifugation 
(538 g/ 5 minutes). The cell pellet was resuspended in 1 ml ice-cold media (RPMI 
1640,10 % DMSO (Fisher scientific, Horsham, UK), 30 % FCS (Invitrogen, 
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Renfrew, UK) and added to a pre chilled cryovial. The vial was stored overnight at - 
80 °C. The vial was transferred to long-term storage over liquid nitrogen at -180 °C. 
Cells were recovered by rapid thawing of the vial at 37 °C. The cell suspension was 
transferred to a 15 ml tube and cold RPMI was added drop wise to cells to a volume 
of 5 ml. The cells were collected by centrifugation. The pellet was washed a second 
time in complete media. 
2.2.2.2 Isolation of PBL from whole blood 
Heparinised venous blood was taken from healthy adults and patients. This was 
diluted 1: 1 with RPM! 1640 and layered 2: 1 on lymphoprep density gradient solution 
(Robbins scientific, Wilmslow, UK) in 50 ml sterile universals, and centrifuged at 758 
g for 30 minutes. (no brake) at room temperature. The mononuclear cells were 
removed from the density gradient and washed at 538 g for 10 min, 355 g for 5 
minutes and 254 g for 5 minutes with RPMI 1640. A cell count was performed using 
a haemocytometer and lymphocyte viability was determined by Trypan-blue 
exclusion: equal volumes of 0.4 % Trypan-blue solution (Sigma-Aldrich, Gillingham, 
UK) and lymphocyte suspension were mixed, put into the haemocytometer chamber 
and examined using light microscopy. In all experiments the cell viability was 97- 
99%. 
2.2.2.3 Immunomagnetic cell sorting 
Cells were washed in RPMI 1640 and collected by centrifugation (255 g, 5 minutes). 
Cells were resuspended at 70 x 106 cells/ml in buffer (PBS, 2% FCS, 1 mM EDTA). 
100 µl/ml of CD8 enrichment cocktail (Stemcell technologies, London, UK) was 
added to the suspension and incubated for 15 minutes at room temperature. 60 µl/ml 
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of magnetic colloid (Stemcell technologies, London, UK) was added to the 
suspension and incubated for 15 minutes at room temperature. The CD8+ fraction was 
collected by passing the cell suspension through an AutoMACS (Milteny biotech, 
Bisley, UK) machine (running depleteS program). 
2.2.2.4 Generation and expansion of T lymphoblasts. 
Peripheral blood lymphocytes were resuspended at 1x106 cells/ml in PHA blast media 
(see above) supplemented with 10 µg/ml PHA (Bio-stat, Stockport, UK). Cells were 
subsequently maintained and expanded in PHA blast media (without PHA) by feeding 
every 3-4 days. 
2.2.2.5 Rapid expansion of T cells clones (REP) 
T cell clones demonstrating specific recognition of antigen-positive targets in an 
ELISpot assay were selected. 5x104 Clones were expanded in 14-day cycles by using 
anti-CD3 antibody (OKT3, Orthoclone; Janssen-Cilag, High Wycombe, UK) at 30 
ng/ml, irradiated (4000 rads) mixed allogeneic PBL (106 cells/ml), irradiated (4000 
rads) allogeneic lymphoblastoid cell lines (2 x 105 cells/ml), and IL-2 (Chiron, 
Middlesex, UK) at 50 IU/ml every 3 days. The anti CD3 antibody was only added to 
the culture on day 0 of the REP cycle (and was washed off on day 4-5 of the cycle). 
For studies of resting and activation of T cell clones the following conditions were 
employed: 
1. Resting experiments were performed on day 14. Cells were washed thoroughly and 
resuspended in complete medium. After 24 hours, cells were collected and analysed 
by flow cytometry. 
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2. Activation experiments were performed on day 14. Cells were collected, 
resuspended in complete medium supplemented with 200 ng/ml of anti CD3 and anti 
CD28 (Pharmingen, Oxford, UK). After 24 hours, cells were collected and analysed 
by flow cytometry. 
3. Day 14 cells were immediately analysed by flow cytometry. 
2.2.2.6 Cell lines. 
The H-RS cell lines used in this study were obtained from J. Wolf, V. Diehl, and H. 
Kamesaki. HD-LM2,1540, and L428 derive from advanced cases of nodular sclerosis 
subtype, whereas KM-H2 and L1236 were derived from advanced cases of mixed 
cellularity subtype; all of the lines are EBV genome negative. L591 is an EBV 
positive cell line and was obtained from the ATCC. This cell line was established 
from a pleural effusion of a female patient with nodular sclerosing HL. All HL cell 
lines were cultured in complete medium at densities between 0.2-1 x 106 cells/ml. 
Lymphoblastoid cell lines (LCL) were kindly provided by healthy laboratory donors 
and were generated in vitro by transformation of B cells using the standard EBV 
isolate B95.8. LCLs were maintained in complete medium. 
2.23 Phenotypic analysis of homing markers. 
2.2.3.1 Antibodies and related reagents. 
Details of primary antibodies employed are in table 2.3. 
2.2.3.2 Flow cytometry. 
57 
Target Antien Company Clone S cies/Iso 
OCR1 R&D 53504.111 Mouse I(b 
CCR2 R&D 48607.121 Mouse 1 G2b 
CCR3 R&D 61828.111 Rat I G2a, x 
OCR4 Pharnnn en 1GI Mouse I GI 
OCR5 Phamingen 2D7/CCR5 Mouse I G2a, x 
CCR6 R&D 53103.111 Mouse I G2b 
CCR7 Phanrnn en 3D12 Rat I G2a, x 
CXCR3 Pharnin en 1C6/CXCR3 Mouse IgGI, x 
CXCR4 R&D 44716.111 Mouse IgG2b 
CXCR5 R&D 51505.111 Mouse I GZb 
CXCR6 R&D 56811.111 Mouse I Qb 
IFA-1 Pharnin en HI111 Mouse I Gl, x 
PSGG1 Phannin en KPIr1 Mouse I Gl, x 
VIA- DAKO P409 Mouse IgGI, x 
CIA Phamingen HECA-452 Rat 1 M, kappa 
LrSFLECI'IN Phannin en DREG-56 Mouse IgGI, x 
BETA 7 Phamin en FIB504 Rat I G2a, x 
CXCL12 R&D 79018 Mouse IgGI, x 
ICAM-1 Gift S. Shaw 84H10 Mouse IgGI, x 
VCAM-1 Gift W. Newnan 2G7 Mouse IgGI, x 
CD31 Diaclone B-B38 Mouse I G1, x 
CD30 DAKO Ber-H2 Mouse I G1, x 
VAP-1 Gft M. Salmi 1B2 Mouse I Gl, x 
Table 2.3 Primary monoclonal antibodies employed in study. 
Secondary reagent Company 
Alexi Fluor 350 goat anti-mouse IG L) Molecular Probes 
Alexi Fluor® 350 goat anti-rabbit IG +L Molecular Probes 
Ale, Fluor® 594 goat anti-house IM chain) Molecular Probes 
Alexi Fluor® 594 goat anti-rabbit IG +L Molecular Probes 
Anti-fluorescein/Oregon Geen® goat IgG fraction Ale, as Fluor® 488 conjugate Molecular Probes 
Anti-Goat IG (whole molecule TRITC antibody produced in rabbit Sigma-Aldrich 
Anti-Mouse IG whole molecule TRITC antibody produced in goat Si ma-Aldrich 
Goat Anti-Mouse I Ghuman ads. -BIOT Southern biotech 
Goat Anti-Mouse I G2b human ads. -BIOT Southern biotech 
Goat Anti-Rat IL mouse ads BIOT Southern biotech 
Rabbit Anti-Goat I +L BLOT Southern biotech 
Streptavidin Alexa Fluor® 488 conjugate Molecular Probes 
Streptavidin Alexa Fluor® 594 conjugate Molecular Probes 
Table 2.4 Secondary reagents employed in study. 
Cells were washed twice (PBS /2 % FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of antibody in a final volume of 50 µl. The reaction was incubated on 
ice for 30 minutes. The cells were washed twice in PBS /2% FCS. Second and third 
step antibodies were also incubated on ice for 30 minutes. Cells were either analysed 
immediately or fixed in 2% paraformaldyhde (Fisher scientific, Horsham, UK). Flow 
cytometry was performed on a Coulter Epics XL flow cytometer (Beckman Coulter) 
using System II software (Beckman Coulter). Analysis was performed using the 
software package WinMDI (Written by Joe Trotter, 1993-1998; trotter@scripps. edu). 
2.2.3.3 Immunohistochemistry and Immunofluorescence. 
2.2.3.3.1 Cryosectioning. 
4-10 µm thick sections were cut by placing tissue blocks in a cryostat (20 °C) for 20 
minutes prior to sectioning (Clinicut 4000-001, Bright instruments, Huntingdon, UK). 
Sections were cut and thaw mounted onto vector bond coated slides (Vectorbond 
reagent, Vector Laboratories, Peterborough, UK), and dried for an hour at room 
temperature. Sections were wrapped in foil and stored at -80 °C for up to 6 months. 
2.2.3.3.2 Fixation. 
Snap frozen tissue sections were fixed for 10 minutes in 100 % acetone (at room 
temperature) (Fisher scientific, Horsham, UK). 
2.2.3.3.3 Antigen retrieval. 
Paraffin-embedded sections were deparaffinised in two changes of xylene (Fisher 
scientific, Horsham, UK), and rehydrated in two changes of 95 % ethanol. Slides 
(Surgipath, Peterborough, UK) were then washed in running tap water and 
endogenous peroxidase blocked with 3% H202 (Sigma-Aldrich, Gillingham, UK) in 
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methanol for 10 minutes. Slides were briefly washed in tap water and immersed in 
0.01 M citrate buffer (see above). Slides were heated in a conventional microwave 
oven for 20-50 minutes at 800 watts. Buffer was allowed to cool for 10 minutes and 
slides were washed in tap water briefly. 
2.2.33.4 Blocking. 
Optional blocking steps were performed to reduce background staining. Non-specific 
binding of secondary reagents was reduced by diluting secondary reagents in buffer 
(TBS or PBS) + 20 % normal serum (Dako) from the same species as the secondary 
antibody. Endogenus avidin/biotin activity was reduced with a blocking kit (Dako). 
Endogenous alkaline phosphatase activity was reduced with 1 mM levamasole. 
(Sigma-Aldrich, Gillingham, UK) 
2.2.3.3.5 Incubation with primary antibodies. 
Sections were rehydrated in PBS (or TBS for alkaline phosphatase based detection) 
and incubated overnight at 4 °C (or room temperature for ih. ) with the primary 
antibody in an appropriate dilution in PBS (or TBS). All incubations of tissue with 
antibody were carried out in a moisture box to prevent sections from drying out. 
Polyclonal antibodies to chemokines were purchased from R&D systems. 
2.2.3.3.6 Indirect two and three-step staining /substrate visualisation. 
Alkaline phosphatase based staining: 
After washing off unbound primary antibodies in TBS, sections were incubated for 45 
minutes at room temperature with rabbit anti-mouse immunoglobulins (Dako) diluted 
1: 25 with TBS. After washing in TBS, the sections were incubated for 45 minutes at 
room temperature with alkaline phosphatase-anti-alkaline phosphatase complex 
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(APAAP) (Dako) diluted 1: 50 in TBS. Sections were washed and the monoclonal 
antibody was detected using the alkaline phosphatase substrate solution containing 
fast red substrate. This consisted of 10 mg Naphthol-Phosphate AS-MX, free acid 
(Sigma-Aldrich, Gillingham, UK) dissolved in 1 ml of N, N-Dimethlyformamide 
(Sigma-Aldrich, Gillingham, UK), 50 µl of 1M Levamisole (Sigma-Aldrich, 
Gillingham, UK) and 49 ml TBS, pH 8.2.50 mg Fast red salt (Sigma-Aldrich, 
Gillingham, UK) was added to the buffer, which was filtered immediately before 
incubating with the sections for 15 minutes. The sections were rinsed with distilled 
water. 
Peroxidase based staining: 
After washing off unbound primary antibodies in PBS, Bound antibody was detected 
using a standard ABC immunoperoxidase method (Universal vectastain Elite ABC 
kit, Vector Laboratories, Peterborough, UK) (for mouse IgG primary antibodies) or 
HRP-conjugated anti goat and anti rabbit Ig (to detect rabbit and goat IgG secondaries 
respectively) and visualized with the 3,3 diaminobenzidine-based detection reaction 
(Sigma-Aldrich, Gillingham, UK). 
Fluorescent based staining: 
After washing off unbound primary antibodies in PBS, bound antibody was detected 
employing appropriate fluorophore conjugated secondary reagents at pre-titred 
concentrations (Table 2.4). 
2.23.3.7 Nuclear staining. 
Nuclei were counterstained with Mayers' Hematoxylin (BDH, Poole, UK). 
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2.2.3.3.8 Mounting. 
For Immunohistochemistry, Sections were mounted with a coverslip and aqueous 
based mounting media (Immunomount, Shandon, Runcorn, UK) and air-dried before 
microscopic examination. For Immunofluorescence, sections were mounted with 
Prolong antifade mounting media (Cambridge biosciences, Cambridge, UK). 
2.2.3.3.9 Controls. 
Tonsil was used as a positive control. Negative controls consisted of consecutive test 
sections in which primary antibody was replaced with non-immune serum of the same 
subclass (for polyclonal antibodies) (R&D systems) or concentration- and isotype- 
matched negative control antibodies (for monoclonal antibodies) (Dako). 
2.2.3.4 Microscopy. 
Immunohistochemical images were recorded by brightfield microscopy (Zeiss- 
Axiovert 25, Welwyn Garden City, UK) with SPOT software v2.1(Diagnostic 
instruments, Sterling Heights, USA) Immunofluorescent images were recorded by 
confocal microscopy (Zeiss ISM510) employing laser lines at 351,488 and 543 nm. 
Individual images were merged to provide a composite. 
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2.2.4 Functional Assays. 
2.2.4.1 Flow-based adhesion Assay. 
To determine the effects of physiological blood flow on lymphocyte adhesion, glass 
capillary tubes (Camlab Ltd, Cambridge, UK) were coated with 5µg/ml purified 
VCAM-1 (R&D systems, Abingdon, UK) (lh/37°C) and co-immobilised with 
CXCL9,10, and 11 (0-1000 ng/ml) (1h/37°C) (PeproTech EC Ltd, London, UK). 
This was connected to the flow system as previously described (Lalor et al, 1997). 
Lymphocytes (106 cells/ml) were perfused through the microslide at a shear stress of 
0.05 Pa. Adherent lymphocytes were observed by phase-contrast microscopy using an 
Olympus 1X50 inverted microscope (Olympus Ltd., Southall, Middlesex, UK). 
Adhesion was converted to cells per square millimeter and corrected for the number 
of lymphocytes perfused (i. e. adherent cells per square millimeter per 106 perfused). 
Phase contrast video recordings made during lymphocyte perfusion were analysed 
off-line to determine the percentage of rolling cells, statically adherent cells, and total 
adhesion. Rolling cells moved slowly over the microslide surface during 5-10 s of 
observation, while stationary adherent cells made no discernable movement over the 
same period. 
2.2.4.2 Tissue binding assay. 
Cryostat sections (10 µm) of control or tumour tissue were cut onto vectorbond coated 
glass slides and fixed in acetone for 10 minutes. IL-2 expanded lymphoblasts were 
adjusted to a concentration of 107 cells/ml in medium (RPMI 1640 and 0.5 % BSA 
(Sigma-Aldrich, Gillingham, UK)). Sections were preincubated with control mAb or 
blocking mAb for 30 minutes at room temperature before addition of 100 p1 of cell 
suspension to each section with constant rotation (60 rpm) for 30 minutes at 4 T. 
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Sections were gently washed with cold PBS to remove nonadherent lymphocytes and 
fixed in acetone for 10 minutes. Vascular endothelium and adherent lymphocytes 
were identified by anti-CD31 immunostaining, and developed with APAAP and fast 
red. The sections were counterstained with Mayer's Hematoxylin (BDH, Poole, UK). 
The assays were done in the presence of a concentration and isotype matched control 
mAb or blocking concentrations (50 gg/ml) of mAb. Experiments were performed in 
triplicate and the number of lymphocytes adherent to vascular endothelium (detected 
with anti-CD31 or VAP-1) was counted using an ocular grid on every section. 100 
vessels were randomly selected and counted on every tissue section. The number of 
lymphocytes adherent to endothelium in the presence of control mAb defined 100 % 
binding, and the number binding to vascular endothelium in the presence of blocking 
mAb was expressed as a percentage of this. 
2.2.4.3 Transwell Chemotaxis assays. 
Cells were washed twice in RPMI 1640 and enumerated. The pellet was incubated 
with 100pCi Na251Cr04 for 1 to 2 hours (Amersham, Little Chalfont, UK) at 37 °C/ 5 
% CO2. The cells were washed twice with RPMI 1640 (to remove any unincorporated 
chromium). Cells were resuspended at 5X 106 cells/ml in RPMI 1640/0.5 % BSA and 
100 µl of cell suspension was added to the upper chamber of a 3-µm pore size 
transwell filter (Appleton woods, Birmingham, UK). The transwell was then added to 
the well of 24 well Tissue culture plate containing 600 µl stimulus. The transwell 
chamber was incubated at 37°C/ 5% CO2 for 1-6 hours and the migrated cell 
population was quantitated using a gamma counter (Packard Cobra Gamma counter, 
GMI, Albertville, USA). The assay was performed in triplicate with the mean and 
standard deviation calculated. Background migration was assessed by using 
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chemotaxis media alone as a stimulus and 100 % migration was defined by adding 
100 µl of cell suspension directly to the bottom of the chamber. Recombinant human 
chemokine was purchased from R&D systems (Abingdon, UK). 
2.2.5 Statistical Analysis. 
Statistical analyses were performed using Graphpad InStat (San Diego, CA, USA). 
HL patient flow cytometry data were analysed using One Way Analysis of Variance 
or Students t test. Patient clones were analysed by Mann-Whitney rank sum or 
Kruskal-Wallis tests. Statistical advice was provided by Dr Cindy Billingham from 
the clinical trials unit at the University of Birmingham. 
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Chapter 3: A phenotypic and functional characterisation of T cells 
infiltrating Hodgkin's lymphoma. 
3.1 Introduction. 
T cells infiltrate tumours such as HL, and knowledge of the mechanisms employed by 
T cells to gain access to the tumour environment is important if novel cell based 
therapies are to be rationally generated and evaluated. A plethora of chemokines have 
been implicated in the pathogenesis of HI., including CXCL10/IP10, CXCL9/MIG, 
CCIS/RANTES, CCL3/M1P1a and CCL11/eotaxin based on increased transcript 
expression in tumour biopsies compared to LN controls (Teruya-Feldstein et al., 
1999). Of particular interest was the finding that TGF-ß produced by H-RS cell lines 
can induce secretion of eotaxin by resident fibroblasts which may account for the 
influx of eosinophils and T cells expressing the receptor CCR3 (Jundt et al., 1999). 
CCL17/TARC expression was reported on the H-RS cells themselves and might 
directly recruit CCR4+ T2 cells to the tumour (van den Berg et al., 1999). 
To accurately define the relevant pathways in T cell recruitment to HL tumours, a 
comprehensive analysis of chemokine receptor expression on freshly isolated T cells 
was undertaken. To analyse the microenvironmental location of chemokine receptor 
expressing T cells, a triple immunofluorescence staining protocol was developed. 
With identification of highly or differentially expressed receptors, expression of the 
corresponding ligands was examined in situ. To dissect which receptor-ligand 
pathways were physiologically relevant, functional migration assays were developed. 
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3.2 Results. 
3.2.1 The homing phenotype of intratumoural T cells. 
3.2.1.1 CD3+/CD4+ T cells comprise the major T cell sub population within HL 
tumours. 
To analyse T cell populations in tumour infiltrates, flow cytometry was employed to 
analyse staining for the T cell markers CD3 and CD4 (Figure 3.1A). This was 
compared with isotype-matched controls to determine the proportion of CD3+/CD4+ 
cells (Figure 3.1B). The cell suspensions were kindly provided by Prof. Ruth Jarrett 
for this study and suspensions were produced as described in the materials and 
methods section (section 2.2.1.2). 
Several comparative groups were studied to look for HL specific markers including 
inflamed tonsil (TL) as a reactive LN control and TIL isolated from two solid tumours 
(Colorectal (CRC) and renal cell carcinoma (RCC)). T cells from HL tumours (n=9) 
were predominantly CD4+ (82 ± 10 % SD) (Figure 3.1C). TL T cells (n=3) expressed 
a similar proportion of CD4 (78 ± 12 % SD), as did CRC TIL (76 ± 16 % SD) (Figure 
3.1C). No significant difference was observed in the expression of CD4 between HL, 
TL, and CRC tumours (Figure 3.1C). 
In RCC, T cell expression of CD4 from TIL was reduced (56 ±3% SD) compared 
with HL tumours although this did not reach statistical significance due to the small 
sample size (Figure 3.1C). The CD3+/CD4- populations within these tumours likely 
comprise CD3+/CD8+ T-cells and have been classified as such during this 
investigation. 
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Figure 3.1 Phenotypic analysis of CD4 expression on freshly isolated tumour 
infiltrating T cells. 
Flow cytometry was employed to identify CD3+ and CD4+ populations (A) and to 
determine the expression of the CD4 antigen on the CD3+ T cell population compared 
with isotype controls (B). The proportion of CD3+/CD4+ T cells within the CD3+ 
population from different tissues was determined (C). 
Cells were washed twice (PBS/2 % FCS), collected (538 g /5 minutes), and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with 
saturating concentrations of anti CD3-PC5 (clone UCHT1) and anti CD4-PE (clone 
13B8.2) conjugated antibodies in a final volume of 50 µl. The reaction was incubated 
on ice for 30 minutes. The cells were then washed twice in PBS/2 % FCS. Cells were 
either analysed immediately or fixed in 2% paraformaldehyde. Cell analysis was 
done by flow cytometry. Lymphocytes were gated based on forward and side scatter 
profiles (A). Results were analysed with the software package WinMDI. Data 
represent mean ± SD percentage positive cells gated on the CD3+ population. Tissue 
infiltrating lymphocytes were isolated from HL (n=9), TL (n=3), CRC (n=5), and 
RCC (n=2) tissue. 
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3.2.1.2 A comparison of Chemokine receptor expression between tumour derived T 
cells and control T-cells implicate specific pathways of T cell recruitment. 
Cells gated in the R2 and R3 region were further employed to look at subset specific 
expression of chemokine receptors (Figure 3.1A) on freshly isolated HL T cell 
populations. For comparison, HL T cells were compared with T cells from TL tissue. 
3.2.1.2.1 CXC chemokine receptors. 
CXCR3 was expressed on 47 ± 17 % SD of HL-derived CD3+ T cells with increased 
expression on CD8+ (74 ± 15 % SD) versus CD4+ (40 ± 20 % SD) subpopulations (p 
<0.01 ANOVA) (Figure 3.2). In TL, CXCR3 was also expressed predominantly on 
CD8+ cells (p < 0.01 ANOVA) (Figure 3.2) but overall fewer TL-derived T cells 
expressed this receptor (23 ±8% SD CD3+ T cells) (p =<0.05 t test) (Figure 3.2). 
Equally, levels of expression of CXCR3 were lower in TL-derived T cells than in HL 
TIL (Figure 3.4). 
CXCR4 was expressed on the majority of CD4+ and CD8+ T cells in HL (84 ± 15 % 
SD) and TL (74 ± 10 % SD) (Figure 3.2). However, levels of expression were higher 
on HL-derived T cells (p<0.05 t test) (Figure 3.3,3.4). 
CXCRS expression varied between individual HL cases (Figure 3.4) but was 
predominantly expressed on CD4+ (42 ± 21 % SD) rather than CD8+ T cells (18 ± 10 
% SD) (p< 0.05, ANOVA) (Figure 3.2). Similar results were obtained with TL- 
derived T cells (Figure 3.2). 
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Figure 3.2 Phenotypic analysis of chemokine receptor expression on freshly 
isolated tumour infiltrating T cells. 
Flow cytometry was employed to determine the proportion of chemokine receptor 
positive cells on T cell subsets from HL tumours. The mean percentage positive cells 
of the total population were determined for CXC (left panels) and CC (right panels) 
chemokine receptors. HL T cells were compared with TL, CRC, and RCC T cells. 
Cells were washed twice (PBS/2 % FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. . Cells were 
incubated with pre- 
titred concentrations of chemokine receptor antibodies or isotype controls (mIgGi, 
CXCR3, CCR4; mlgG2a, CCR5; mIgG2b, CXCR4, CXCR5, CXCR6, CCRI, CCR2, 
CCR6; rIgG2a, CCR3, CCR7) in a final volume of 50 µl. The reaction was incubated 
on ice for 30 minutes. The cells were washed twice in PBS/2 % FCS. Visualisation 
was achieved with either anti-mouse or anti-rat IgG (biotin conjugated) followed by 
streptavidin Alexa 488. Cells were washed and incubated with normal mouse serum 
for 20 minutes. Finally, cells were incubated with saturating concentrations of anti 
CD3-PC5 (clone UCHT1) and anti CD4-PE (clone 13B8.2) conjugated antibodies. 
The reaction was incubated on ice for 30 minutes. The cells were then washed twice 
in PBS/2 % FCS. Cells were either analysed immediately or fixed in 2% 
paraformaldehyde. Cell analysis was done by flow cytometry. Results were analysed 
with the software package WinMDI. Data represent mean + SD. Significant 
differences between T cell subsets were determined by one-way ANOVA with post- 
test. Tissue infiltrating lymphocytes were isolated from HL (n=9), TL (n=3), CRC 
(n=5), and RCC (n=2) tissue. 
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CXCR6 was expressed on 21 ± 14 % SD of HL-derived CD8+ T cells (Figure 3.2). 
TL-derived T cells also expressed this marker on a minority of CD8+ T cells, which 
was significantly greater than the CD4+ population (p < 0.05, ANOVA) (Figure 3.2). 
However, in both HL and TL, levels of expression were relatively low (Figure 3.3). 
3.2.1.2.2 CC chemokine receptor expression. 
Few if any T cells in HL or TL expressed CCR1, CCR2 or CCR3 (Figure 3.2. ). 
CCR4 was detectable on CD4+ T cells in HL although numbers of positive cells 
varied between cases (22 ± 16 % SD). In contrast, only a minority (8 ±3% SD) of 
CD3+ T cells in TL expressed this receptor (Figures 3.2 and 3.5). 
The frequencies of CCR5-expressing T cells were similar between HL and TL cases 
(- 20 %T cells) (Figure 3.2). In HL, equal proportions of CD4+ and CD8+ T cells 
expressed this receptor, whereas in TL more CD8+ T cells expressed CCR5 compared 
with CD4+ cells. (p< 0.05, ANOVA). This corresponded with higher cell surface 
levels of CCR5 on TL-derived CD8+ T cells (Figure 3.3). 
Few if any T cells in HL or TL expressed CCR6 (Figure 3.2. ). 
CCR7 expression was detectable on CD3+ T cells from both HL (59 ± 28 % SD) and 
TL (36 ± 13 %) with no difference between CD4+ and CD8+ subsets (Figure 3.2). 
Note that the frequency of CCR7+ T cells varied significantly between individual HL 
cases (20-80 %), as did levels of expression of this receptor (Figure 3.5). 
71 
Figure 3.3 Phenotypic analysis of chemokine receptor expression on freshly 
isolated tumour infiltrating T cells. 
Flow cytometry was employed to determine the MFI (total cell population) of 
chemokine receptor positive cells on T cell subsets from HL tumours. MFI was 
determined for CXC (left panels) and CC (right panels) chemokine receptors. HL T 
cells were compared with TL, CRC, and RCC T cells. 
Cells were washed twice (PBS/2 % FCS) and collected (538 g /5 minutes), 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. . Cells were incubated with pre- 
titred concentrations of chemokine receptor antibodies or isotype controls (mIgGi, 
CXCR3, CCR4; mIgG2a, CCR5; mIgG2b CXCR4, CXCR5, CXCR6, CCR1, CCR2, 
CCR6; rIgG2a, CCR3, CCR7) as described in the legend to figure 3.2. Cell analysis 
was done by flow cytometry. Results were analysed with the software package 
WinMDI. Data represent mean ± SD. Significant differences between T cell subsets 
were determined by one-way ANOVA with post-test. Tissue infiltrating lymphocytes 
were isolated from HL (n=9), TL (n=3), CRC (n=5), and RCC (n=2) tissue. 
72 
HL 
200 
150 0 CD3 
100 MCD4 
50 0 CD8 
0 
6, `Lý `yo Qbh `o 
Tonsil 
5040 
® CD3 
30   CD4 
20 ® CD8 
10 
0 
G'I'G (gyp G+G 
CRC 
350- 
300- 
250- 0 CD3 
200 3 CD4 
150 
® CD8 100 
50 
0 -, . 
i" 
I//I 
RCC 
500 
400 0 CD3 
300 0 CD4 
200 0 CD8 
100 
0 
e e0 GAG Gý'G GAG GAG 
70 
60 
50 
40 
30 
20 
10 
0 
HL 
Tonsil 
0 CD3 
 CD4 
0 CD8 
25 
20 
15 
0 CD3 
10 
  CD4 
® CD8 
5- 
0 
GýGýGGGGýhGGýoCOý 
CRC 
350 
300 
250 0 CD3 
200 
0 C. 150 
100 8 CD8 
50 
0 
t 
250 
200 
150 
100 
50 
0 
RCC 
13 CD3 
 CD4 
13 CD8 
Chemokine Receptor 
ýCýýýýgýýýgý`o 
ý, LaGý'ýýGý'e`LGý'ý^'Gý'ýaGý'ýýGý'ýýUý'ýý 
Gý Gý Cý 
Figure 3.4 Analysis of variation amongst individual HL and control samples for 
positively expressed CXC chemokine receptors. 
Flow cytometry was employed to determine the percentage positive cells of the total 
population and MFI (total cell population) of CXC chemokine receptors on T cell 
subsets from HL and TL cases (Figure 3.4A). Representative histograms from patient 
6766 denote percentage positive cells and MFI (total cell population) (Figure 3.4B). 
Cells were stained as in the legend to Figure 3.2. Cell analysis was done by flow 
cytometry. Results were analysed with the software package WinMDI. Tissue 
infiltrating lymphocytes were isolated from HL TIL (n=9), and TL (n=3). Values 
were corrected for background staining by subtracting the isotype control values. (+) 
Represent TL cases and (X) represent HL cases. 
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Figure 3.5 Analysis of variation amongst individual HL and control samples for 
positively expressed CC chemokine receptors. 
Flow cytometry was employed to determine the percentage positive cells of the total 
population and MFI (total cell population) of CC chemokine receptors on T cell 
subsets from HL and TL cases. (Figure 3.5A) Representative histograms from patient 
6766 denote percentage positive cells and MFI (total cell population) (Figure 3.5B) 
Cells were stained as in the legend to Figure 3.2. Cell analysis was done by flow 
cytometry. Results were analysed with the software package WinMDI. Tissue 
infiltrating lymphocytes were isolated from HL TIL (n=9), and TL (n=3). Values 
were corrected for background staining by subtracting the isotype control values. (+) 
Represent TL cases and (X) represent HL cases. 
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3.2.1.3 HL T cells have a distinct expression profile compared with T cells isolated 
from different tumours. 
Few studies have examined chemokine receptor expression on tumour infiltrating T 
cells. To determine whether the homing phenotype identified on HL-derived T cells is 
unique to this tumour or represents a phenotype generally expressed on tumour- 
infiltrating T cells, the analysis was extended to include TIL from CRC (n=5), and 
RCC (n=2). 
3.2.1.3.1 CXC chemokine receptors. 
CXCR3 expression on CRC TIL (39 ± 25 % SD) was similar to that seen with HL- 
derived TIL (Figure 3.2). However, CXCR3 was not detected on RCC TIL. 
CXCR4 was expressed on most CRC (82 ± 12 % SD) and RCC (97 ± 0.3 % SD) 
CD3+ T cells which is comparable with HL-derived TIL, (Figure 3.2). Cell surface 
levels of CXCR4 were particularly high on RCC T cells compared with T cells from 
all other tissues (Figure 3.3). 
CXCR5 expression on CRC-derived TIL (21 ± 17 % SD) was similar to that seen in 
HL and TL, although CD4+ T cells did not predominantly carry it. In contrast, few T 
cells in RCC expressed CXCRS (12 ±1% SD) (Figure 3.2) 
In contrast to HL -derived TIL, CRC T cells expressed CXCR6 on a large proportion 
(67 ± 23 % SD) of T cells, including both CD4+ and CD8+ subsets (Figure 3.2), with 
high levels of cell surface expression (Figure 3.3). RCC T cells were similar to HL T 
cells with few cells expressing CXCR6 (Figure 3.2). 
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3.2.1.3.2 CC chemokine receptors 
As in HL, few if any T cells in CRC and RCC expressed CCR1 or CCR3 (Figure 3.2). 
CCR2 was expressed on RCC-derived T cells (26 ±4% SD), with expression mainly 
restricted to CD4+ rather than CD8+ T cells (p<0.05, ANOVA) (Figure 3.2). CCR2 
was also expressed on a minor population of CRC TIL (13 ±7% SD) (Figure 3.2) 
although levels of expression were low in both tumour types (Figure 3.3). 
CCR4 was expressed on 22 ± 19 % of CD3+ T cells in CRC, which is similar to HL- 
derived TIL. In contrast, this receptor was expressed on few if any T cells in RCC 
(Figure 3.2). 
In HL, only 23 ±7% SD of T cells carried CCR5. In contrast, this receptor was 
expressed at high levels on the majority of T cells infiltrating CRC (74 ± 25 % SD) 
and RCC (88 ±2% SD) with similar results for both CD4+ and CD8+ subsets (Figure 
3.2 and 3.3). 
CCR6 was poorly represented on HL- and RCC-derived T cells, but was expressed on 
47 ± 25 % SD of CD3+ T cells in CRC (Figure 3.2). Expression in CRC was 
predominantly restricted to CD4+ rather than CD8+ T cells although this difference 
was not statistically significant due to the small sample size. 
CCR7 was highly expressed on HL-derived TIL but few if any CRC nor RCC-derived 
T cells carried this receptor. 
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3.2.1.4 Chemokine receptor expressing T cells are found in association with H-RS 
cells and the vasculature within HL microenvironments. 
Having identified chemokine receptors expressed on HL T cells by flow cytometry, it 
was important to confirm expression in situ and ascertain the relationship between T 
cells, tumour cells, and the vascular endothelium with respect to the expression of 
candidate chemokine receptors. 
The expression of CXCR3 in situ, by single IHC staining of paraffin biopsies of HL 
cases (n=10) was first evaluated (Figure 3.6). This revealed strong staining of the non- 
neoplastic infiltrate, with cells that resembled lymphoid cells, whereas, cells with the 
morphology of H-RS cells were negative (Figure 3.6A). TL was employed as a 
positive control (Figure 3.6B) and positive staining was compared with a 
concentration and isotype matched negative control (Figure 3.6C). 
To phenotype the CXCR3+ cells in detail, a triple fluorescent staining protocol was 
developed that worked on frozen tissue allowing the detection of multiple markers. 
This approach maximised the expression data that could be obtained from the clinical 
material available. For example, chemokine receptor expression could be determined 
on T cells, non-T cells and tumour cells, and the distribution of receptor positive cells 
within the tumour ascertained. This was particularly pertinent, as tissue morphology 
of some clinical material was poor, and ascertaining the cell type by morphology 
alone was problematic and observer dependent. An antibody to CD30 was employed 
to detect the rare H-RS cells and an antibody to CD3 allowed the detection of T cells. 
The appropriate chemokine receptor mAb was then stained in the third colour. 
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Figure 3.6 In situ expression of CXCR3 in HL. 
CXCR3 expression was examined by IHC (n=10) and IF (n=8) of paraffin and snap 
frozen biopsies. By IHC, CXCR3+ lymphoid cells were detected in the vicinity of 
cells having H-RS morphology (A). Staining was compared with positive control 
staining of hyperplastic TL (B) and concentration and isotype control staining from 
the same case (C). 
5 µm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pretreatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti -CXCR3 (clone I C6) (20 µg/ml) was incubated overnight (4 °C). 
Reactivity was visualised with the Vector Elite secondary detection kit. Colour 
development was achieved with the addition of DAB substrate. Images were recorded 
by brightfield microscopy. Original magnification x600 (A-C). 
CXCR3 expression was further investigated with triple IF staining for CD3 (blue), 
CD30 (green) and CXCR3 (red) (D). Individual images were merged to provide a 
composite with cells in pink representing CXCR3+ T cells. CXCR3+ T cells (pink) 
were also intimately associated with the vascular endothelium (green) (E) 
5µm cryostat sections were fixed in 100 % acetone. Sections were blocked in PBS/20 
% normal goat sera for 30 minutes. Staining was performed employing a 2-step 
protocol. Anti -CXCR3 (clone I C6) (20 µg/ml) was incubated overnight (4 °C). 
Reactivity was visualised by incubation with anti-mouse IgG1 (biotin conjugated) 
followed by streptavidin Alexa 594 (A). Sections were subsequently blocked with 
PBS+20 % normal mouse sera. Anti-CD30 FITC (clone Ber-H2) and anti-CD3 (rabbit 
Ig) was incubated at room temperature for 45 minutes. Visualisation was achieved 
with the addition of anti-FITC Alexa 488 (B) and anti-rabbit Alexa 350 (C) secondary 
reagents for the CD30 and CD3 antigens respectively. Images were recorded by 
confocal microscopy (Zeiss LSM510) employing laser lines at 351,488 and 543 nm.. 
Original magnification x630 (D, E). To examine the localisation of CXCR3 
expressing cells with the vasculature (E), anti-CD30 FITC was replaced with anti- 
CD31 (clone B-B38) (1/20). 
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Triple immunofluorescence and confocal microscopy was employed to analyse the 
expression of CXCR3 in 5 µm snap frozen sections (kindly provided by Prof. John 
Crocker, Heartlands hospital, Birmingham). Control experiments were initially 
performed to ensure cross reactivity of secondary reagents did not occur. In HL cases 
(n=8), CXCR3 reactivity could be detected on a large proportion of infiltrating T cells 
as well as non-T cells, but was absent from the tumour cells (Figure 3.6D). CXCR3+ 
T cells were also intimately associated with the vascular endothelium (by staining for 
the endothelial marker CD31) (Figure 3.6E), however the endothelium was negative 
for CXCR3. 
CXCR5 expression was detected by flow cytometry on freshly isolated T cells. 
Therefore, CXCR5 staining in situ was evaluated by single IHC staining (n=10) and 
was strongly expressed by the malignant H-RS cells (Figure 3.7A). Lymphoid cells 
were also reactive, and CXCR5 was observed on vascular endothelium including 
HEVs, which appeared to express higher levels than conventional vessels. This 
staining was compared with positive control staining in TL (Figure 3.7B), and isotype 
control staining from the same case (Figure 3.7C). Expression in situ was also 
assessed (n=8) with triple IF staining of snap frozen cases (Figure 3.7D). CXCR5 was 
detected on a proportion of T cells, as well as non-T cells, and strongly co-localised 
with CD30+ expressing H-RS cells. CXCR5 expressing T cells could be detected in 
the vicinity of H-RS cells. 
. 
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Figure 3.7 In situ expression of CXCRS in HL. 
CXCR5 expression was examined by IHC (n=10) and IF (n=8) in paraffin and snap 
frozen biopsies respectively. 
By IHC, CXCR5+ lymphoid cells were detected in the vicinity of cells having H-RS 
morphology (A). These H-RS cells strongly stained for CXCR5. Staining was 
compared with positive control staining of hyperplastic TL (B) and concentration and 
isotype negative control staining from the same case (C). 
5 pm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pre-treatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti -CXCR5 (clone 51505.111) (10 gg/ml) was incubated overnight (4 
°C). Reactivity was visualised with the Vector Elite secondary detection kit. Colour 
development was achieved with the addition of DAB substrate. Images were recorded 
by brightfield microscopy. Original magnification x600 (A, C) x200 (B) 
CXCR5 expression was further investigated with triple IF staining for CD3, CD30 
and CXCR5 (D). 
5µm cryostat sections were fixed in 100 % acetone. Sections were blocked in PBS/20 
% normal goat sera for 30 minutes. Staining was performed employing a 2-step 
protocol. Anti -CXCR5 (clone 51505.111) (10 gg/ml) was incubated overnight (4 °C). Reactivity was visualised by incubation with anti mouse IgG2b (biotin 
conjugated) followed by streptavidin Alexa 594 (A). Sections were subsequently 
blocked with PBS+20 % normal mouse sera. Anti-CD30 FITC (clone Ber-H2) and 
anti-CD3 (Rabbit) was incubated at room temperature for 45 minutes. Visualisation 
was achieved with the addition of anti-FITC Alexa 488 (B) and anti-rabbit Alexa 350 
(C) secondary reagents for the CD30 and CD3 antigens respectively. Images were 
recorded by confocal microscopy (Zeiss LSM510) employing laser lines at 351,488 
and 543 nm. Original magnification x630 (D). Individual images were merged to 
provide a composite. 
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3.2.1.5 The in situ expression of chemokine receptor ligands implicates specific 
receptor -ligand pathways for T cell homing in Hodgkin's lymphoma. 
Having identified chemokine receptors that are expressed on infiltrating T cells, 
immunohistochemical studies were performed to determine whether the relevant 
chemokines were present. 
Antibodies specific for a number of chemokines were tested either on formalin fixed 
or snap frozen HL cases. In order to make appropriate use of clinical material, 
antibodies were first selected based on their ability to stain control tissue (tonsil). 
Formalin fixed sections from 10 HL cases were examined for the expression of the 
CXCR3 ligand CXCL1O/IP-10 (Figure 3.8). This ligand was detected at high levels 
on most neoplastic tumours cells (Figure 3.8A), with strong cytoplasmic and 
membranous staining (Figure 3.8B). The vascular endothelium expressed this marker 
weakly if at all. Positive staining was compared with controls (Figure 3.8C, D) 
CXCL12/SDF-1 is the sole ligand for the receptor CXCR4 (Figure 3.9). In formalin 
fixed sections from HL cases (n=5), expression was strong in the tumour cells, with 
clear intracellular staining (Figure 3.9A). The receptor was also expressed on HEVs 
and vascular endothelia as well as macrophages, DCs and 30-40 % of lymphocytes 
(Figure 3.9B). As a positive control, the same antibody was used to stain tonsil tissue. 
(Figure 3.9C) CXCL12/SDF-1 reactivity was observed on macrophages within B cell 
follicles, DCs within the mantle zone, as well as paracortical HEVs, whereas it was 
absent from the majority of lymphoid cells. Positive control staining was judged by 
comparing with isotype control staining of HL cases (Figure 3.9D) 
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Figure 3.8 In situ expression of CXCL1O/IP10 in HL (n=10). 
Expression of CXCL10 chemokine was detected on H-RS cells (A). 
Immunoreactivity was detected in both the membrane and cytoplasm (B). This was 
compared with positive control staining in hyperplastic TL (C) and isotype negative 
control staining in HL tissue (D). 
5µm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pre-treatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti-CXCL10/IP10 (goat polyclonal) (5µg/ml) was incubated overnight 
(4°C). Reactivity was visualised by incubation with anti-goat IgG (peroxidase 
conjugated) followed by anti-rabbit IgG (peroxidase conjugated). Colour development 
was achieved with the addition of DAB substrate. Images were recorded by 
brightfield microscopy. Original magnification x600 (B, D) x400 (A, C). 
82 
Figure 3.8 In situ expression of CXCL10/IP10 in HL (n=10). 
Expression of CXCL10 chemokine was detected on H-RS cells (A). 
Immunoreactivity was detected in both the membrane and cytoplasm (B). This was 
compared with positive control staining in hyperplastic TL (C) and isotype negative 
control staining in HL tissue (D). 
5µm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pre-treatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti-CXCL10/IP10 (goat polyclonal) (511g/ml) was incubated overnight 
(4°C). Reactivity was visualised by incubation with anti-goat IgG (peroxidase 
conjugated) followed by anti-rabbit IgG (peroxidase conjugated). Colour development 
was achieved with the addition of DAB substrate. Images were recorded by 
brightfield microscopy. Original magnification x600 (B, D) x400 (A, C). 
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Figure 3.9 In situ expression of CXCL12/SDF-1 in HL (n=5). 
Expression of CXCL12/SDF-1 chemokine was detected on H-RS cells (A). 
CXCL12/SDF-1 was also expressed on the non-neoplastic lymphoid infiltrate and 
strongly expressed on HEVs (B). This was compared with positive control staining in 
hyperplastic TL (C) with staining of macrophages in the germinal centre and DC 
staining in the mantle zone regions. Isotype negative control staining of HL tissue was 
also performed (D). 
5µm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pre-treatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti SDF-1 (clone 79018) (10 µg/ml) was incubated overnight (4°C). 
Reactivity was visualised with the vector elite secondary detection kit. Colour 
development was achieved with the addition of DAB substrate. Images were recorded 
by brightfield microscopy. Original magnification x600 (A, B, D) x200 (C). 
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Expression of the CXCR5 ligand CXCL13BCA-1 was also examined in 10 formalin 
fixed HL cases and localised to the non-neoplastic infiltrate (Figure 3.10A). 
Expression by the tumour cells and vascular endothelium was absent. In control cases, 
staining of DCs in the mantle zone was observed (Figure 3.10B). Positive staining 
was compared with negative controls (Figure 3.10C) 
CCR4 was detected on HL T cells by flow cytometry, so we examined the expression 
of the ligand CCL17/TARC in tissue. Snap frozen sections (n=10) examined by IHC 
stained for CCL17/TARC on the vascular endothelium (Figure 3.11A) and in the 
malignant H-RS cells (Figure 3.11B). There was also reactivity within the lymphoid 
stroma (Figure 3.11A, B). In control cases, CCL17/TARC was detected on T zone 
HEVs (3.11C) and was absent in negative controls (Figure 3.11D). 
CCL21/SLC is one of two known ligands for CCR7. In HL cases (n=10) CCL21/SLC 
was detected on the vasculature (Figure 3.12A), DCs and some lymphoid cells, but 
was absent from tumour cells (Figure 3.12B). Positive control staining of tonsil 
tissues demonstrated strong expression by DCs (Figure 3.12C), as well as the vascular 
endothelia including HEVs, larger vessels and possibly on some lymphocytes. In 
addition, expression was confined to the paracortex with no expression in follicles. 
Positive control staining was compared with negative controls (Figure 3.12D) 
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Figure 3.10 In situ expression of CXCL13/BCA-1 in HL (n=10). 
Expression of CXCL13/BCA-1 chemokine was observed in the non-neoplastic 
lymphoid infiltrate but not the tumour cells (A). This was compared with positive 
control staining of lymphoid follicles in TL (B) and isotype negative control staining 
of HL tissue (C). 
5µm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pre-treatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti BCA-1 (goat polyclonal) (1 gg/ml) was incubated overnight (4°C). 
Reactivity was visualised by incubation with anti-goat IgG (peroxidase conjugated) 
followed by anti-rabbit IgG (peroxidase conjugated). Colour development was 
achieved with the addition of DAB substrate. Images were recorded by brightfield 
microscopy. Original magnification x600 (C) x400 (A) x200 (B). 
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Figure 3.11 In situ expression of CCL17/TARC in HL (n=10). 
Expression of CCL17/TARC chemokine was observed on the vascular endothelium 
(A) and the non-neoplastic lymphoid infiltrate as well as the tumour cells (B). This 
was compared with positive control staining in hyperplastic TL (C) and isotype 
negative control staining of HL tissue (D). 
5 gm snap frozen sections were thawed at room temperature and fixed in 100 % 
acetone. Endogenous peroxidase activity was blocked with 0.5 % H202 in methanol 
for 10 minutes, followed by a wash in tap water. Anti-TARC (goat polyclonal) (20 
µg/ml) was incubated overnight (4°C). Reactivity was visualised by incubation with 
anti-goat (peroxidase conjugated) followed by anti rabbit IgG (peroxidase 
conjugated). Colour development was achieved with the addition of DAB substrate. 
Images were recorded by brightfield microscopy. Original magnification x400 (A, B) 
x100 (C, D). 
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Figure 3.12 In situ expression of CCL21/SLC in HL (n=5). 
Expression of CCL21/SLC chemokine was observed on the vascular endothelium (A) 
but was absent on H-RS cells (B). This was compared with positive control staining 
of hyperplastic TL, with strong DC staining (C) and isotype negative control staining 
of HL tissue (D). 
5µm paraffin sections were dewaxed, rehydrated and endogenous peroxidase activity 
blocked with 0.5 % H202 in methanol for 10 minutes, followed by a wash in tap 
water. Microwave pre-treatment in 0.01 M citrate buffer, pH 5.8 (30 minutes) was 
performed. Anti-SLC (goat polyclonal) (1 gg/ml) was incubated overnight (4°C). 
Reactivity was visualised by incubation with anti-goat IgG (peroxidase conjugated) 
followed by anti-rabbit IgG (peroxidase conjugated). Colour development was 
achieved with the addition of DAB substrate. Images were recorded by brightfield 
microscopy. Original magnification x600 (A-D). 
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3.2.2 Functional studies of T cell chemotaxis in Hodgkin's lymphoma. 
3.2.2.1 Activated T cells migrate to factors produced by HL tumour cell lines in 
vitro. 
The identification of the relevant migration pathways in HL tumours was addressed 
by developing an in vitro chemotaxis assay. Ideally, freshly isolated tumour cells and 
T cells would be isolated from biopsies and T cell migration to the tumour cells would 
be ascertained by blocking putative pathways. This is technically difficult for a 
number of reasons. 1) It is difficult to isolate sufficient cells of high enough purity 
from small biopsies. 2) Primary cultures of H-RS cells are difficult to work with, as 
the cells are prone to cell death. To overcome these problems, a panel of HL -derived 
cell lines were used. They were initially tested for their ability to secrete factors that 
mediated chemotaxis of activated lymphoblasts (derived from peripheral blood 
lymphocytes of healthy donors after activation with rIL-2 (50 IU/ml) and 
phytohemagglutinin (10 ng/ml) for 5 days (Figure 3.13)). 
The migration assay was validated in a series of experiments using healthy donor 
derived T cells to recombinant CXCL12/SDF-1 (Figure 3.13A). These initial pilot 
experiments were important to establish parameters such as transwell pore filter size, 
the optimal number of cells to be loaded into the top chamber, the incubation time for 
chemotaxis, and the best methods of counting migrating cell numbers (in a manner 
that was observer independent) (Described in section 2.2.4.3). Peak migration 
responses (- 40-50 %) were typically observed at 200-ng/ ml for CXCL12/SDF-1. 
Recombinant human CXCL12/SDF-1 (200 ng/ml) was employed as a positive control 
in this tumour cell assay because CXCR4 is expressed on a majority of lymphoblasts 
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Figure 3.13 HL cells secrete chemotactic factors for activated lymphocytes in 
vitro. 
Optimization of assay conditions was performed using recombinant human 
CXCL12/SDF-1 (A). HL cells were cultured for 3 days in complete medium and 
culture supernatants were removed and tested for their ability to induce lymphoblast 
chemotaxis from healthy donors (B). 
Donor derived lymphoblasts were washed twice in RPMI 1640 and enumerated. The 
pellet was incubated with 100 µCi [51Cr]04 for 1 to 2 hours at 37 °C/5 % C02. The 
cells were washed twice with RPMI 1640 to remove any unincorporated chromium. 
Cells were resuspended at 5X 106 cells/ml in RPMI 1640/0.5 % BSA and 100 µl of 
cell suspension were added to the upper chamber of a transwell filter (3 µm pore size). 
The transwell was added to the well of 24 well Tissue culture plate containing 600 µl 
supernatant or diluted recombinant chemokine. The transwell chamber was incubated 
at 37 °C/ 5% C02 for 3 hours and the migrated cell population was enumerated with 
a y-counter. 
Data represent mean ± SD of triplicate determinations. Background migration was 
assessed; with chemotaxis media alone as a stimulus and 100 % migration was 
defined by adding 100 gl of cell suspension directly to the bottom of the chamber. 
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(Figure 3.13B). 40 % of lymphoblasts migrated into the bottom chamber. Migration to 
conditioned HL cell supernatants was weaker than the positive control but greater 
than background migration to media alone. The EBV positive cell line 1.591 induced 
the highest levels of migration of lymphoblasts with a 6-7-fold increase in migration 
over background. Both KMH2 and L1236 supernatants also stimulated chemotactic 
responses from lymphoblasts. Responses to DEV were not observed. In summary, 
activated T cells showed dose-dependent chemotactic responses to supernatants from 
HL lines in vitro, providing evidence to support the hypothesis that HL cells secrete 
lymphocyte chemotactic factors. 
To begin to identify the chemotactic factors that mediated T cell migration in these 
studies, activated lymphoblasts were subsequently tested for migration to HL cell 
lines in the presence of specific blocking antibody. Work focused on CXCR3 as this 
receptor is highly expressed on HL-derived TIL and the corresponding ligands 
CXCL10/IP10 (Figure 3.8) and CXCL9/MIG (Ohshima et al., 2002) are expressed by 
H-RS cells in tumour tissue. Saturating concentrations (50 pg/ml) of anti-CXCR3 
antibody (IC6) were used to block CXCR3-mediated T cell migration but a consistent 
blocking effect could not be demonstrated (data not shown). 
3.2.2.2 Chemotaxis of TIL to purified chemokines. 
Freshly isolated TIL from HL biopsies (n=5) were analysed for chemotaxis to purified 
chemokine to identify functional chemokine receptors. CXCL12/SDF-1 was tested as 
the receptor CXCR4 was expressed on am jority of TIL (as determined by flow 
cytometry). 4/5 biopsies provided TIL that migrated to recombinant CXCL12/SDF-1 
over background levels (Figure 3.14A). Approximately 10 % of TIL migrated to 
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Figure 3.14 Chemotaxis of TIL to purified CXCL12 and CCL17. 
Freshly isolated TIL from HL biopsies (n=5) were tested for chemotaxis to 
recombinant human CXCL12/SDF-1 (200ng/ml) (A) and CCL17/TARC (100ng/ml) 
(B) using PBL and a CCR4+ T cell clone (T29 c73) as positive controls respectively. 
TIL were washed twice in RPMI 1640 and enumerated. Chemotaxis assays were done 
according to the legend for Figure 3.13. Data represent mean ± SD of triplicate 
determinations. Background migration was assessed; with chemotaxis media alone as 
a stimulus and 100 % migration was defined by adding 100 µ1 of cell suspension 
directly to the bottom of the chamber. 
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CXCL12/SDF-1 although levels reaching 18 % of the total input population were 
observed for case HD6452. This was compared with PBL from a healthy donor where 
44 % of cells migrated to CXCL12/SDF-1. 
Migration of HL TIL to CCL17/TARC was also examined as the receptor CCR4 was 
detected on a minor population of HL T cells (Figure 3.14B). Compared with a CCR4 
expressing T cell clone (T29 c73), where 24 % of cells migrated, there was no 
detectable migration of TIL to CCL17/TARC over background levels. 
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3.3 Discussion. 
The premise for this investigation was that select T cell populations are recruited to 
HL tumours in response to a specific pattern of chemokine expression by the tumour. 
Chemokine receptor expression was studied on freshly isolated T cells from HL 
tumours and compared with tonsil T cells, and T cells from two solid organ tumours. 
In this way, the complex chemokine network implicated in the recruitment of the non- 
neoplastic infiltrate could be restricted to those pathways relevant to T cell 
recruitment. 
The infiltrate was comprised predominantly of CD4+ T cells and this was similar to 
control T cells from tonsil and TIL from colorectal and renal tumours. Previous 
studies have reported that the HL infiltrates consist mainly of CD4+ T cells typically 
at a ratio of 4: 1 with the CD8+ population (Kandil et al., 2001), but in 
immunocompromised patients, this can increase to 6: 1 (Skinnider and Mak, 2002). H- 
RS cells often have a rosette of CD4+ T cells intimately associated with them, 
typically of a Tin phenotype. Laser capture microdissected CD4+ T cells in 
association with H-RS cells have been analysed with respect to TCR repertoire and 
consist of a polyclonal population arguing against a tumour specific response (Roers 
et al., 1998). CD8+ T cells are a minority and do not directly associate with the 
tumour cells. Although CD8+ T cell responses to tumour antigens have been detected 
in the circulation of HL patients, such responses at the site of the tumour have never 
been detected (Chapman et al., 2001). 
A comparatively restricted pattern of chemokine receptor expression was observed on 
HL TIL. In HL, members of the CXC family of chemokine receptors that were 
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expressed include CXCR3, CXCR4, CXCR5 and CXCR6. For the CC chemokine 
family, CCR4 and CCR5 were expressed on small populations of T cells. In contrast, 
CCR7 was expressed on a majority of T cells. 
CXCR3 is typically expressed on activated T cells and Tin effector cells. This 
receptor is implicated in recruitment of effector cells to many if not all inflammatory 
sites and it is likely that this receptor licenses T cells to gain entry into these sites 
(Kunkel et al., 2002). We detected CXCR3+ T cells by confocal microscopy 
intimately associated with both the tumour cells and the vascular endothelium. 
Expression of the CXCR3 ligand CXCL1O/IP10 was strongly detected by the 
neoplastic tumour cells (although expression on the vasculature was absent in the 
cases examined). CXCR3 has two other ligands, CXCL9/MIG and the more recently 
cloned CXCL11/ITAC. 
Expression of CXCL9/MIG has been reported in HL tumours (Teruya-Feldstein et al., 
1999). This ligand was upregulated in HL tissue compared with control tissue, and 
had the highest level of expression in the mixed cellularity subtype. The tumour cells 
and some of the surrounding inflammatory cells were positive. The authors reported 
that CXCL9/MIG positive H-RS cells had a higher frequency of CXCR3 positive 
cells associated with them compared with CXCL10/IP10 positive cases. Furthermore, 
EBV positive cases had more intense staining of tumour cells. Vascular endothelial 
expression of CXCL9/MIG has not been reported. 
CXCL11/ITAC expression has not been reported in HL and warrants investigation. 
Thus, either of these two chemokines might mediate activation-induced arrest on the 
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vascular endothelium, considering the association of CXCR3 high T cells with the 
vasculature. 
A transwell chemotaxis assay was developed, employing conditioned supernatants 
from HL tumour cell lines as a stimulus and lymphoblasts as the responding cell 
population. The rationale was to demonstrate lymphocyte migration to Hodgkin's 
tumour cells, and dissect the relevant pathways in vitro, particularly whether CXCR3 
mediated T cell homing to H-RS cells. Direct studies of primary T cell migration to 
primary H-RS cells were not feasible for the reasons highlighted earlier. However, 
one published study investigated the migration of primary HL cell suspensions to 
recombinant human chemokine (Buri et al., 2001), and reported strong chemotactic 
responses to the CXCR3 ligand CXCL10/IP-10, and the CCR5 ligand 
CCIS/RANTES, with weak responses to CCL4/MIP 1 ß, and no response to 
CCL2/MCP-1. 
Our work demonstrates the ability of HL cell lines to secrete factors that stimulate 
migration of lymphoblasts. Similar studies in a hepatoma model system successfully 
demonstrated migration responses to HepG2 supernatants of TIL (Yoong et al., 1999). 
Migration responses to supernatants from this cell line were sufficient for blocking 
studies to be undertaken. This study revealed CXCR3 and CCR5 dependent homing 
mechanisms to the HepG2 tumour cell line in keeping with the phenotype of primary 
ex vivo T cells isolated from this hepatic neoplasm. In our system however, the levels 
of migration were relatively weak. 
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CXCR4 was expressed on most T cells from all tumours and was functional in vitro. 
CXCR4 has been implicated in bone marrow trafficking (Petit et al., 2002), in 
retaining T cells in inflammatory sites including the synovium of patients with 
Rheumatoid arthritis (Buckley et al., 2000). Of particular interest in the context of 
HL, is a recent report describing a role for CXCR4 in central memory T cell homing 
to LNs (Scimone et al., 2004). CXCR4 is expressed on virtually all haematopoietic 
cells however levels of this receptor are regulated with T cell activation (Colantonio 
et al., 2002). We detected CXCL12/SDF-1 expression in HL tumours with strong 
expression by the H-RS cells, endothelium, macrophages and DCs. These results are 
in contrast to one report demonstrating CXCL12/SDF-1 transcript expression by the 
reactive cells but not by the tumour cells (Hopken et al., 2002). This difference in 
transcript and protein expression might be explained by the observation that 
chemokines are known to be transcytosed (Middleton et al., 1997), and perhaps the 
reactive cells secrete chemokines that are later transported and presented by other cell 
types. 
CXCRS is expressed on a subset of CD4+ T cells and regulates their positioning in 
secondary lymphoid organs at the T-B zone interface, facilitating B cell survival and 
function (Kim et al., 2001b). In HL tumours, this receptor was restricted to the CD4+ 
subset and showed variation between cases. It will be important to determine the 
functional significance of CXCR5+ T cells in HL tumours with respect not only to 
homing but also to their influence on tumour cell survival and function. Do CXCR5 T 
cells regulate H-RS cell function as they do B cell function in normal lymphoid sites? 
Although HL tumours did not express CXCL13/BCA-1 themselves, the surrounding 
infiltrate did. Could this be a mechanism by which the tumour evades the immune 
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response? Namely, by recruiting T cells that facilitate tumour cell survival and 
proliferation rather than target cell lysis. 
CXCR6, although weakly expressed on HL T cells, was nevertheless enriched in the 
CD8+ population. This receptor is associated with a TH, or Tcl phenotype and T cells 
expressing CXCR6 are enriched at tissue sites of inflammation (Kim et al., 2001a). 
Expression of this receptor mirrors that of CCRS (Unutmaz et al., 2000) in that they 
are co-ordinately regulated. The ligand for CXCR6 is the recently cloned CXCL16. 
CXCL16 is similar to fractalkine in that it is a membrane-anchored chemokine. It is 
expressed on antigen presenting cells including cells of the B cell and macrophage 
lineage (Matloubian et al., 2000). To date, the expression of this ligand has not been 
investigated in HL, but with CXCR6 expression on a fraction of infiltrating CD8+ T 
cells, it will be important to discern the importance of this pathway. 
At the beginning of this study CCR4 had been proposed to be an important pathway 
in the recruitment of T cells to HL tumours based on the observation that the ligand 
for CCR4, TARC, was detected by serial analysis of gene expression (SAGE) on the 
L1236 cell line (van den Berg et al., 1999). Subsequent in situ hybridisation of HL 
sections demonstrated expression of the mRNA and later the protein by H-RS tumour 
cells of all subtypes except non-classical cases. Furthermore, hybridisation of a CCR4 
probe demonstrated expression of CCR4 transcript in the surrounding non-neoplastic 
infiltrate. Convincing antibody staining for CCR4 is lacking with some reports 
identifying CCR4 staining on only a minority of cells (Ohshima et al., 2002) Thus, the 
assumption has been that CCR4+ Ti T cells surround H-RS cells in response to a 
gradient of CCL17/TARC (or CCL22/MDC). This is based on the assumption that 
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T cells are associated with CCR4 expression in vivo. Our studies demonstrated that 
CCR4+ was expressed on a minority of T cells in HL by flow cytometry, although we 
failed to demonstrate chemotaxis of HL TIL in vitro compared with a CCR4+ T cell 
clone as a positive control. An antibody to CCR4 was tested in HL tissue (data not 
shown). Positive staining was not detected. However, the lack of a suitable positive 
control tissue (i. e. inflamed skin) precluded determination of the CCR4 status in HL. 
Expression of the ligand CCL17/TARC in H-RS cells however, was demonstrated in 
agreement with previously published reports (Ohshima et al., 2003; van den Berg et 
al., 1999). This implies that CCR4 pathways are unlikely to dominate bulk T cell 
recruitment to HL tumours. However, within the tumour microenvironment, 
CCL171TARC expressing H-RS cells may promote chemotaxis of a small population 
of CCR4+ T cells. 
CCR5 like CCR4 was expressed on a minority of cells. CCRS has a number of ligands 
including CCLS/RANTES, which is expressed by T cells, macrophages and 
endothelial cells in both hyperplastic TL and HL cases (Maggio et al., 2002). The 
tissue distribution of CCR5+ T cells in HL tumours requires clarification but one 
study has reported CCRS expression on approximately half of non-neoplastic 
leukocytes (Buri et al., 2001). In addition, flow cytometry of CD3+ T cells from cell 
suspensions identified CCR5 on 30 % of cells with more on CD4+ (44 %) than CD8+ 
(10 %) cell. (Buri et al., 2001) This is similar to our findings where CCR5 was 
expressed on 20 % of cells although there was no difference in the proportion 
expressed on CD4+ or CD8+ T cells. The authors also reported CCR3 expression on 
15 % of CD3+ T cells, which was upregulated, compared with their controls. In 
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contrast, our study revealed no expression of CCR3 on T cells when correcting for 
isotype control staining. 
In the context of homeostatic secondary lymphoid homing, CCR7 mediates 
recruitment of naive and central memory T cell populations (Stein et al., 2000) CCR7 
binds endothelial expressed CCL21/SLC triggering activation dependent arrest. CCR7 
T cells then responds to CCL19/ELC directing them through the tissue. In HL, the 
expression of CCR7 on T cell populations is second only to CXCR4 and is expressed 
on both CD4+ and CD8+ populations. Whether these CCR7+ populations represent 
cells with effector function is unclear and requires investigation, as there was no 
differential expression of CCR7 between tumour and control T cells. The CCR7 
ligand CCL21/SLC was strongly expressed on the vascular endothelium, 
interdigitating DCs, and some lymphoid cells but not by the tumour cells. This agrees 
with a previous report looking at transcript expression of CCL21/SLC by ISH, where 
the authors detected expression by the reactive cells but not the tumour cells (Hopken 
et al., 2002). In a similar manner, CCL19/ELC was also reported to be absent from 
the tumour cells but present in the reactive infiltrate (Hopken et al., 2002). The 
expression of these CCR7 ligands by the reactive cells and vessels but not the H-RS 
cells implies that H-RS cells do not directly recruit CCR7+ T cells. However, CCR7 
dependent vascular adhesion is likely to be required for adhesion from the circulation. 
We compared HL TIL with TIL from solid organ tumours and this allowed us to 
make a number of preliminary observations regarding the expression of homing 
markers on T cells from colorectal and renal tumours. Colorectal T cells express 
CXCR3, CXCR4, CXCR5, CXCR6, CCR5 and CCR6 and a minority express low 
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levels of CCR4. It is surprising that CCR4 was detected in CRC as it has classically 
been considered a skin homing marker (Campbell et al., 1999). However, the levels of 
CCR4 were low and unlikely to be functionally important as CCR4 function depends 
on cell surface levels (Soler et al., 2003). The combination of CCR5 and CXCR3, 
likely represent a TH1 population of cells. In RCC, only CXCR4 and CCR5 were 
detected on a majority of T cells. However, it should be noted that these cells were 
isolated by collagenase digestion of tumour tissue, which is known to affect the 
expression of chemokine receptors including CXCR3 (Prof. David Adams, personal 
communication). It will be important to confirm these observations by examining 
more cases and without collagenase treatment of tissue. 
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Chapter 4: T cell adhesion pathways in Hod2ldn's lymphoma. 
4.1 Introduction. 
For T cells to enter HL tumours, they must recognise and bind to the appropriate 
adhesion molecules at the endothelial surface. Initial T cell-endothelial interactions 
are classically mediated by selectins, which capture flowing cells and induce them to 
roll on the luminal surface. The cell interacts with chemokines immobilised on the 
glycocalyx (Tanaka et al., 1993) which signals an increase in both the affinity of the 
a/ß integrin heterodimer and the lateral mobility of receptors throughout the cell 
membrane (Kucik et al., 1996). Understanding the expression of adhesion molecules 
and their counter-receptors is vital in elucidating the pathways responsible for 
adhesion of T lymphocytes from the systemic circulation. In addition, adhesion 
molecules are likely to be important in the interaction of infiltrating T cells with 
stromal cells (i. e fibroblasts), and H-RS tumour cells. 
HL arises within a lymph node. Therefore, this tumour can be considered both an 
inflammatory site as well as a secondary lymphoid organ (albeit with disrupted tissue 
architecture). In normal lymph nodes, L-selectin-PNAD interactions promote capture 
and rolling of naive and central memory T cells on the endothelial surface (Gallatin et 
al., 1983). Activation of CCR7 by CCL21/SLC and CXCR4 by CXCL12/SDF-1 
triggers stable adhesion of specific T cell populations via LFA-I-ICAM-1 interactions 
(Stein et al., 2000). The extent to which this well characterised LN adhesion pathway 
operates in the context of HL is unclear. 
To address which pathways are important in T cell adhesion to the HL tumour 
vasculature, an investigation of the expression of cell adhesion molecules on tumour 
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infiltrating T cells by flow cytometry was undertaken. The corresponding ligands 
were identified by IHC. To address the functional significance of these pathways, a 
rotary tissue-binding assay was explored to examine T cell adhesion to HL vascular 
endothelium. 
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4.2 Results. 
4.2.1 Adhesion molecule expression on tumour infiltrating lymphocytes. 
Flow cytometry was employed to examine the expression of adhesion molecules on 
CD3+, CD4+ and CD8+ T cell subsets isolated from HL tumours. Cells were gated as 
before to identify these T cell subsets (see Figure 3.1). Most HL CD3+ T cells (n=9) 
expressed LFA-1 (99 ±1% SD), PSGL-1(70 ± 17 % SD), VLA-4 (92 ±6% SD) and 
07 (67 ± 29 % SD) with no significant difference between CD4+ and CD8+ T cell 
subsets (Figure 4.1A). CD62L was expressed on 41 ± 16 % SD of CD3+ cells 
whereas CLA expression was very weak (7 ±4% SD) (Figure 4.1A). Cell surface 
levels as detected by MFI did not differ between T cell subsets (Figure 4.1B). 
For comparison, T cells were isolated from tonsil (n=3) and examined for the same 
markers (Figure 4.1C). LFA-1 expression was consistently high (94 ± 11 % SD of 
CD3+ T cells) and equally represented on CD4+ and CD8+ subsets. PSGL-1 (54 ± 13 
% SD), VLA-4 (74 ±9% SD) and ß7 (40 ± 15 % SD) were also expressed on TL- 
derived T cells (Figure 4.1C). Each of these adhesion molecules was expressed at 
higher levels and on a greater proportion of CD8+ rather than CD4+ T cells (Figure 
4.1C and 4.1D). The only significant difference between HL and tonsil T cells was an 
increased frequency of VLA-4+/CD3+ and CD4+ expressing T cells in HL (P<0.05 
CD3; p<0.05 CD4 t test) (Figure 4.1A, C). 
HL-derived T cells were also compared with T cells from CRC (n=5) and RCC (n=2) 
(Figure 4.2). CRC-derived T cells exhibited a similar pattern of adhesion molecule 
expression to HL-derived T cells with high-level expression of all the adhesion 
markers except CLA, which was very weak (5 ±3% SD), and CD62L which was 
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Figure 4.1 Phenotypic analysis of adhesion receptor expression on freshly 
isolated T cells from HL. 
Flow cytometry was employed to determine the expression of adhesion receptors on 
CD3, CD4 and CD8 T cell subsets. Mean percent expression was determined on HL 
(A) and tonsil (C) T cells. Mean channel fluorescence was compared on HL (B) and 
tonsil (D) T cells. 
Cells were washed twice (PBS/2 % FCS), collected (538 g /5 minutes), and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of adhesion receptor antibodies (CLA, (rat IgM), CD62L (mIgGi), 
LFA-1 (mlgGi), PSGL-1 (mIgGi), VLA-4 (mIgG3), 07 (rat IgG2a)) in a final 
volume of 50 µl. The reaction was incubated on ice for 30 minutes. The cells were 
washed twice in PBS/2 % FCS. Visualisation was achieved with either anti-mouse or 
anti-rat IgG (biotin conjugated) followed by streptavidin Alexa 488. Cells were 
washed and incubated with normal mouse serum for 20 minutes. Finally, cells were 
incubated with saturating concentrations of anti CD3-PC5 (clone UCHT1) and anti- 
CD4-PE (clone 13B8.2) conjugated antibodies. The reaction was incubated on ice for 
30 minutes. The cells were washed twice in PBS/2 % FCS. Cells were either analysed 
immediately or fixed in 2% paraformaldehyde. Cell analysis was performed by flow 
cytometry. Results were analysed using the software package WinMDI (written by 
Joe Trotter). Data represent mean +/- SD. Tissue infiltrating lymphocytes were 
isolated from HL (n=9) and tonsil (n=3) cases. 
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expressed on 21 ± 16 % SD of CD3+ T cells (Figure 4.2A and 4.2B). This pattern of 
expression was also observed for T cells from RCC except PSGL-1 was expressed on 
only 12 ±4% SD T cells (Figure 4.2C). MFI values for adhesion molecules were not 
significantly different between subsets from either tissue (Figure 4.2B and 4.2D) 
except for LFA-1 in RCC with higher cell surface levels on CD8+ T cells (Figure 
4.2D) 
4.2.2 Expression of endothelial cell adhesion molecules in HL tumours. 
Having characterised adhesion molecule expression on T cells from HL tumours, 
expression of the corresponding ligands in tumour tissue was examined by IHC. 
As LFA-1 was expressed on virtually all HL T cells, the expression of the ligand 
ICAM-1 was examined in tissue sections from HL cases (n=10). ICAM-1 was 
expressed at high levels on the vascular endothelium as well as on H-RS cells (Figure 
4.3A). In addition, there was strong reactivity throughout the lymphoid stroma. 
Staining was compared with isotype controls (Figure 4.3B) and positive control 
staining in tonsil (Figure 4.3C). 
High-level expression of VLA-4 on HL-derived T cells was the rationale for 
examining VCAM-1 in HL tumours (n=10). The expression pattern of VCAM-1 was 
similar to ICAM-1 except H-RS staining appeared negative or weak (Figure 4.4A). 
There was strong staining of stromal cells (Figure 4.4A) and vessels (Figure 4.4B) 
compared with isotype (Figure 4.4C) and positive controls (Figure 4.4D). 
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Figure 4.2 Phenotypic analysis of adhesion receptor expression on CRC and 
RCC T cells. 
Flow cytometry was employed to determine the expression of adhesion receptors on 
CD3, CD4 and CD8 T cell subsets. Mean percent expression was determined on CRC 
(a) and RCC (c) T cells. Mean channel fluorescence was compared on CRC (b) and 
RCC (d) T cells. 
Cells were washed twice (PBS/2 % FCS), collected (538 g /5 minutes), and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of adhesion receptor antibodies (CLA, (rat IgM), CD62L (mIgG1), 
LFA-1 (mIgGi), PSGL-1 (mIgGI), VLA-4 (mIgG3), ß7 (rat IgG2a)) as described in 
the legend to figure 4.1. Cell analysis was performed by flow cytometry. Results were 
analysed using the software package WinMDI (written by Joe Trotter). Data represent 
mean +/- SD. Tissue infiltrating lymphocytes were isolated from CRC (n=5) and RCC 
(n=2) cases. 
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Figure 4.3 In situ expression of ICAM-1 in HL. 
5µm paraffin sections from HL cases (n=10) were stained with an antibody to ICAM- 
1 (clone 84H10) (15 µg/ml) demonstrating vascular and H-RS reactivity (A). This 
staining was compared with isotype negative (B) and hyperplastic tonsil positive (C) 
controls. 
For secondary detection sections were stained according to an indirect peroxidase 
based protocol (section 2.2.3.3.6). Immunohistochemical images were recorded by 
brightfield microscopy. Original magnification x600 (A, B, C). 
107 

Figure 4.4 In situ expression of VCAM-1 in HL. 
w 
;; 
5µm paraffin sections from HL cases (n=10) were stained with an antibody to 
VCAM-1 (2G7) (20 µg/ml) to determine H-RS (A) and vascular reactivity (B). This 
was compared with isotype negative (C) and hyperplastic tonsil positive (D) controls. 
For secondary detection sections were stained according to an indirect peroxidase 
based protocol (section 2.2.3.3.6). Immunohistochemical images were recorded by 
brightfield microscopy. Original magnification x600 (A, B, C) x 100 (D). 
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As well as examining the expression of ligands for receptors identified on HL T cells, 
expression of the orphan receptor VAP-1 in HL was also studied. VAP-1 has no 
known ligand on T cells, yet functionally is important in T cell trafficking to LN and 
chronic inflammatory sites (Salmi et al., 1997). 
IF was employed to examine VAP-1 expression in frozen HL tissue (Figure 4.5) 
(n=10). Triple labelling experiments detected expression on the vascular endothelium 
(including HEVs), but not on tumour cells or tissue infiltrating T cells (Figure 4.5A). 
Vascular expression was confirmed by co-staining with the endothelial marker CD31 
(Figure 4.5B). Note that VAP-1 expression did not always colocalise with CD31. 
Rather CD31 expression was luminal whereas VAP-1 expression was often 
subendothelial (Figure 4.5C). This was observed in HL tissue as well as in tonsil and 
liver (data not shown). Furthermore, VAP-1 was only expressed on CD31+ vessels, 
but not all CD31+ vessels expressed VAP-1 (Figure 4.5D). 
4.23 Functional analysis of receptor-ligand pathways in HL. 
To determine the functional relevance of specific receptor ligand pathways in HL, a 
modified Stamper-woodruff ex vivo tissue binding assay was explored. This assay is 
designed to study the ability of lymphocytes to bind vessels in frozen tissue sections. 
T cells are added to snap frozen tissue sections and allowed to adhere under rotary 
conditions. The number of cells binding to vascular endothelium in the presence of 
blocking antibodies can then be analysed by microscopy. 
Given the limited availability of clinical material from HL patients, initial studies 
aimed at setting up this tissue-binding assay using tissue from tonsil or liver, and IL -2 
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Figure 4.5 In situ expression of VAP-1 in HL. 
A) HL sections (n=10) were stained with an anti VAP-1 antibody (1B2) to determine 
expression. 
5µm cryostat sections were fixed in 100 % acetone. Sections were blocked in PBS/20 
% Normal goat sera for 30 minutes. Staining was performed employing a 2-step 
protocol. Anti-VAP-1 (clone 1B2) (5µg/ml) was incubated overnight (4°C) Reactivity 
was visualised by incubation with anti-mouse IgG1 (biotin conjugated) followed by 
streptavidin Alexa 350. Sections were subsequently blocked with PBS/20 % normal 
mouse sera. Anti-CD30-FITC (clone Ber-H2) and anti-CD3 (Rabbit) was incubated at 
room temperature for 45 minutes. Visualisation was achieved with the addition of 
anti-FITC Alexa 488 (B) and anti-rabbit Alexa 594 (C) secondary reagents for the 
CD30 and CD3 antigens respectively. Images were recorded by confocal microscopy 
(Zeiss LSM510) employing laser lines at 351,488 and 543 nm. Original 
magnification x630 (A, ) x400 (B, C) x100 (D). 
B-D) Expression by vessels was confirmed by co-staining with anti CD31 (B). 
Vessels did not always co-localise with CD31 (C), and not all CD31 positive vessels 
were VAP-1 positive (D). 
Dual staining was achieved as above, except CD31-FITC (clone B-B38) was 
employed instead of CD30, and VAP-1 was visualised with streptavidin Alexa 594 
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expanded lymphoblasts from the peripheral blood of healthy donors. The role of 
VAP-1 in tissue binding was of particular interest because not only is this molecule 
expressed on vessels in HL, but the ability to block T cell adhesion to vessels in tonsil 
and liver using the anti VAP-1 antibody 1B2 had been reported previously. 
VAP-1 is known to mediate CD8+ T cell adhesion. Therefore CD8+ T cells were 
enriched from peripheral blood by negative magnetic selection (see section 2.2.2.3) 
and activated with PHA (lOug/ml). These cells were then expanded in vitro in 
medium containing IL-2 (50 IU/ml). Note that negative selection obtained cell 
populations that were typically >90% CD8+. 
Initial studies on T cell adhesion to liver tissue were possible with 105-cells/tissue 
section. However, with tonsil tissue, more cells (3 X 10) were required to achieve 
sufficient numbers of bound cells. The temperature of the assay is important because 
the role of tethering interactions in cellular adhesion may be masked at 37°C where 
integrin interactions are likely to dominate. This can be reduced by incubation at a 
lower temperature. Therefore when examining VAP-1 function the assay was 
conducted at 7°C (Stamper and Woodruff, 1976). To further reduce the influence of 
non-specific interactions, the assay was incubated on a rotating shaker (60 rpm). 
To enhance the ability to detect VAP-1 dependent adhesion, sections were blocked 
with the 1B2 antibody, which in addition to blocking would identify VAP-1+ vessels. 
Therefore, any blocking effect would not be underestimated by looking at VAP - 
vessels (which would be, if vessels were highlighted with anti-CD31 antibody). 
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Using these conditions it was possible on a single occasion to partially block 
lymphocyte binding to VAP-1+ vessels in tonsil using the anti VAP-1 antibody 1B2 
(Figure 4.6), with a reduction in lymphoblast binding of 24 ±5% SD compared with 
isotype control antibody (p<0.01 t test) (Figure 4.7A). However, these results were 
not reproducible and consequently attempts to use this assay on HL tissue were 
unreliable (possibly due to the poor condition of tissue sections available for this 
work) (Figure 4.7B). Therefore, it was not possible to explore the functional role of 
VAP-1 and other identified adhesion molecules in HL. 
P, 
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Figure 4.6 Lymphoblast binding to tonsil endothelium under rotary conditions. 
Fewer T cells bound to the vascular endothelium following pre-treatment of sections 
with blocking concentrations (50 µg/ml) of anti-VAP-1 mAb (clone 1B2) (A) 
compared with control mAb (B). The adherent T cells were detected by enumerating 
numbers of cells bound to VAP-1 stained endothelium. Micrographs have been 
focused at the level of adherent lymphoblasts. 
Cryostat sections (10 µm) of control or tumour tissue were cut onto vectorbond coated 
glass slides and fixed in acetone for 10 minutes. IL-2 expanded lymphoblasts were 
adjusted to a concentration of 3x 107 cells/ml of medium (RPMI 1640 and 0.5 % 
BSA). Sections were preincubated with isotype negative control mAb or blocking 
anti-VAP-1 mAb (clone 1B2) (50 µg/ml) for 30 minutes at room temperature. 100 91 
of cell suspension was added to each section with constant rotation (60 rpm) for 30 
minutes at 4 °C. Sections were gently washed with cold PBS to remove nonadherent 
lymphocytes and fixed in acetone for 10 minutes. Vascular endothelium and adherent 
lymphocytes were identified by anti-VAP-1 immunostaining, and developed with 
APAAP and fast red. The sections were counterstained with Mayer's Hematoxylin. 
Data represent mean t SD of triplicate sections. Lymphocytes adherent to vascular 
endothelium was counted using an ocular grid on every section. Original 
magnification x200 (A, B). One hundred vessels were randomly selected and counted 
on every tissue section. The number of lymphocytes adherent to endothelium in the 
presence of control mAb defined 100 % binding, and the number binding to vascular 
endothelium in the presence of blocking mAb was expressed as a percentage of this. 
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Figure 4.7 Evaluating the role of VA-P-1 in T cell adhesion to HL tumours 
employing an in vitro adhesion assay. 
Assay conditions were optimised in tonsil with demonstration (inconsistent) of 
blocking activity of VAP-1 (Figure 4.7A). VAP-1 function was evaluated in HL tissue 
(Figure 4.7B). Data represent mean ± SD of triplicate sections. The assay was 
performed as described in the legend to Figure 4.6. 
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43 Discussion. 
The role of adhesion molecules in T cell homing to normal lymphoid organs and sites 
of chronic inflammation have been well characterised. However, their role in T cell 
recruitment into human tumours is poorly understood. Indeed, in a number of tumours 
including melanoma, the vasculature may have downregulated expression of adhesion 
molecules (Piali et al., 1995). Furthermore, these tumour vessels may be unresponsive 
to pro-inflammatory cytokines that upregulate adhesion receptor expression (Carlos, 
2001). 
We examined the expression of adhesion receptors on freshly isolated T cells from 
HL tumours and compared them with T cells isolated from tonsil and two solid 
tumours. LFA-1 was expressed on virtually all infiltrating T cells and the 
corresponding ligand ICAM-1 was detected on HL vessels. Therefore, this pathway is 
likely to be important in mediating T cell adhesion to tumour vascular endothelium. 
Likewise, VLA-4 was detected on HL TIL and the corresponding ligand VCAM-1 
was highly expressed in HL tissue. This suggests that VLA-4-VCAM-1 interactions 
may also be functionally important in adhesion. The detection of VCAM-1 on stromal 
cells implicates this pathway in recruitment and retention of T cells within the tumour. 
It will be important to investigate the functional contributions of pathways like LFA- 
1-ICAM and VLA-4-VCAM-1 in HL, considering the important homeostatic and 
inflammatory roles played by these receptor-ligand pairs. The availability of reporter 
antibodies like mAb 24 (specific to the activated form of LFA-1) (Dransfield and 
Hogg 1989) and 12G10 (VLA-4 specific) (Mould et al. 1995), aid in determining the 
proportion of T cells that express the conformationally active form of these integrins. 
Having defined the relevant chemokine receptors expressed on HL T cells (section 3), 
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it will be interesting to investigate how these receptors influence integrin function. 
Knowledge of the inside-out signalling events during integrin activation is the subject 
of considerable interest (reviewed in section 1.2.1.3.2). 
PSGL-1 was expressed on a majority of T cells and it will be important to determine 
whether ligands like P-selectin are expressed within HL tissue. CLA was absent on T 
cells from all tissues examined in agreement with a tissue specific role for CL A in 
skin homing (Picker et al., 1990). CD62L is known to play an important role in 
recruiting T cells to LN via HEVs (Gallatin et al., 1983). Consistent with this role, it 
is significant that CD62L was expressed on HL and TL-derived T cells but only 
weakly expressed on a fraction of T cells from CRC and RCC tumours. In addition, 
CD62L may facilitate LN exit by binding the mannose receptor on lymphatic 
endothelium allowing entry into the efferent lymphatics (Irjala et al., 2001a). It will 
be important to examine the expression of CD62L ligands in situ. Recent evidence has 
shown that CCR7/CD62L expressing cells are also present at sites of organised 
lymphoid neogenesis. These can develop during chronic inflammation with infiltrates 
that consist of follicular structures and specialised HEV-like vessels (Hjelmstrom, 
2001). Thus, CD62L plays a complex role by mediating entry of cells into lymphoid 
sites. 
The observation that VAP-1 is not expressed by all CD31+ vessels in HL and is 
differentially expressed on both the luminal and/or subendothelial surfaces may 
reflect an important regulatory mechanism for T cell recruitment. VAP-1 was i'" 
originally implicated in the tethering step of adhesion, however flow based 
experiments highlight a role for this molecule in TEM (Lalor et al. 2002). The ligand 
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for VAP-1 is unknown although the monamine oxidase activity of this receptor 
implies a novel mode of adhesive function. It is thought that VAP-1 engages 
lymphocyte expressed primary amines (Smith et al. 1998). Treatment with semi- 
carbazide, a specific inhibitor of VAP-1 enzyme activity, inhibits adhesion and TEM 
to a similar extent as the 1B2 blocking mAb. More recently, an inhibitory peptide has 
been shown to block VAP-1 dependent lymphocyte-endothelial interaction under 
conditions of flow (Yegutkin et al. 2004). 
The Stamper-Woodruff tissue binding assay was initially developed to study 
lymphocyte binding to HEV in rat LN (Stamper and Woodruff, 1976). Since then, 
numerous modifications of this assay have been adapted to define the molecular 
pathways important in T cell adhesion in contexts such as chronic inflammation and 
cancer. For example, T cells employ PSGL -1 and P-selectin for adhesion to bronchial 
endothelium (Ainslie et al., 2002). In chronic inflammatory liver disease, MAdCAM- 
1 is aberrantly expressed and mediates adhesion of a407 T cells (Grant et al., 2001). 
Furthermore in epithelial tumours such as hepatocellular carcinoma, T cells adhere to 
vascular endothelium in a VAP-1/ ICAM-1 dependent manner (Yoong et al., 1998). 
We attempted to define which receptor-ligand pathways dominated T cell adhesion to 
HL vascular endothelium by evaluating a modified tumour tissue-binding assay. We 
attempted to block VAP-1 mediated binding to evaluate its role in T cell adhesion. 
Initial findings confirmed reports that VAP-1 mediates functional T cell binding to 
tonsil HEVs (Salmi et al., 1997) However, the assay proved to be unreliable because 
of low reproducibility of results possibly owing to the poor condition of tissue 
available for this work. For these reasons it proved 
impossible to extensively address 
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T cell binding to HL vascular endothelium. Importantly, the role of VAP-1 in T cell 
adhesion has been examined in other tumours (Irjala et al., 2001b). In these studies, 
the binding of TH, lymphokine activated killer and Natural killer cells to tumour 
vessels was established and shown to bind in a VAP-1 dependent manner. 
In addition to binding vessels, adhesion molecules are also important in the direct 
interaction of T cells with stromal cells (including H-RS cells) and extracellular 
matrix components (Buckley et al., 2001). Thus, T cells interact with H-RS cells 
through their TCR but also through adhesion receptors like LFA-1 following 
redistribution of such integrins to the immunological synapse (Sanders et al., 1988; 
Sims and Dustin, 2002). We have observed in situ expression of the adhesion 
molecule ICAM-1 by the malignant H-RS cells. ICAM-2, LFA-1 and LFA-3 
expression has also been reported (Ellis et al., 1992). Furthermore, in vitro studies 
with H-RS cell lines implicated LFA-3/ICAM-1 interactions (and to a lesser extent 
LFA-1/ICAM-1 interactions) in functionally mediating T cell-H-RS adhesive 
interactions (Sanders et al., 1988). 
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Chapter 5: Characterising T cell clones generated for adoptive cell 
therapy of Hodgldn's lymphoma. 
5.1 Introduction. 
Defining pathways of T cell trafficking in HL should increase the ability to deliver 
therapeutic effector T cells to tumour deposits for cellular based therapies. The 
rationale for developing adoptive cell therapy for cancers like HL is that T cells can 
be optimally activated and selected for antigenic specificity ex vivo and large numbers 
of T cells may be infused. Furthermore, characterisation of clones before infusion 
provides a more comprehensive understanding of the reasons for the success or failure 
of this type of approach. 
EBV-associated tumours like HL provide an important model system for the 
evaluation of cellular based therapies. T cell responses to this virus have been 
extensively characterised in healthy virus carriers and patients with EBV-associated 
malignancy. In recent years a number of studies have emerged demonstrating both the 
safety and efficacy of infusing cancer patients with in vitro expanded T cells. In the 
EBV setting, the potential of adoptive immunotherapy for EBV malignancies has 
been elegantly demonstrated in the context of EBV associated immunoblastic 
lymphoma (Rooney et al., 1998). 
Immunoblastic lymphoma has the complete latent viral program of gene expression 
(Latency III), including the immundominant family of EBNA3 proteins (see Figure 
1.7). However, in the setting of HL and NPC, both tumours demonstrate a restricted 
pattern of viral gene expression (latency type II) in the neoplastic cells. Therefore, 
only T cell responses to the viral proteins EBNA1, LMP1 and LMP2 will target the 
tumour. EBNA1 was considered an immunologically silent protein because an 
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internal glycine-alanine repeat domain within this molecule prevented processing 
through the HLA class I pathway and presentation to CD8+ T cells (Levitskaya et al., 
1995). Recently however, CD8+ T cell clones, specific for EBNA-1 were shown to 
recognise EBV infected B cells (Lee et al., 2004; Tellam et al., 2004; Voo et al., 
2004). Therefore, CD8+ as well as CD4+ T cell responses to EBNA1 ((Leen et al. 
2001) may yet be exploitable in the control of HL. Responses to LMP2 (Chapman et 
al., 2001) and to a lesser extent LMP1 have also been detected at low frequencies in 
the peripheral blood of healthy donors as well as some HL patients. 
With an interest in T cell targeting of EBV associated tumours, a phase I clinical trial 
was undertaken within our institute to generate clones for adoptive therapy for several 
human malignancies (including HL). This chapter details the characterisation of the 
homing phenotype and function of clones generated for adoptive T cell therapy of HL, 
and compares this phenotype with that of TILs isolated from HL tumours. T cell 
clones generated with the same protocol but targeting melanoma antigens were also 
examined for comparison. 
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5.2 Results. 
5.2.1 Phenotypic characterisation of T cell clones. 
PBL were isolated from patients and stimulated with autologous DC pulsed with 
peptides (50 µg/ml) representing defined epitopes in tumour-associated antigens. The 
culture media contained IL-2 (10 IU/ml) and IL-7 (5 ng/ml). 7 days later the 
polyclonal T cell culture was restimulated with DC + peptide and fed with medium 
containing 50 IU/ml IL-2 and 5ng/ml IL-7. On day 14, cultures were cloned and 
screened for antigen specific responses by IFN-y ELISA and positively identified 
clones were grown to large cell numbers employing a rapid expansion protocol 
(REP). Dr. Steve Lee kindly provided these clones for phenotypic analysis of homing 
markers. 
5.2.1.1 T cell clones generated in vitro express different homing receptors compared 
with TIL freshly isolated from HL tumours. 
Due to the lack of HL patients available for recruitment to the trial, a limited number 
of EBV specific clones were available for analysis. Five LMP2 specific CD8+ clones 
were generated from a HLA-matched sibling donor (Donor 727) and were expanded 
to sufficient cell numbers to analyse homing marker expression. As T cell clones 
generated were all CD8+ T cells, the mean expression of homing markers between the 
CD8 T cell subset from HL tumours (n=9) and T27 clones (n=5) were directly 
compared. 
V 
A high proportion of CD8+ HL-derived TIL and CD8+ T27 clones expressed CXCR3 
(60-70 %) and CXCR4 (65-85 %) (Figure 5.1A). However, levels of expression of 
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Figure 5.1 Comparison of CXC chemokine receptor expression on T27 clones 
and CD8+ TIL. 
Flow cytometry was employed to determine the percent expression (A) and mean 
channel fluorescence (B) of CXC chemokine receptors on T cell clones and HL CD8+ 
TIL (described in Chapter 3). 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CXC chemokine receptor antibodies in a final volume of 50 µl 
((CXCR3 (mIgGi), CXCR4 (mIgG2b), CXCR5 (mIgG2b), CXCR6 (mIgG2b)). The 
reaction was incubated on ice for 30 minutes. The cells were washed twice in PBS/2 
% FCS. Visualisation was achieved with either anti-mouse or anti-rat IgG (biotin 
conjugated) followed by streptavidin Alexa 488. Cells were washed and incubated 
with normal mouse serum for 20 minutes. Cells were incubated with saturating 
concentrations of anti-CD8-TRICOLOR (clone MHCD0806) conjugated antibody. 
The reaction was incubated on ice for 30 minutes. The cells were washed twice in 
PBS/2 % FCS. Cells were either analysed immediately or fixed in 2% 
paraformaldehyde. Cell analysis was done by flow cytometry. Results were analysed 
with the software package WinMDI. Data represent mean ± SD. 
Tissue infiltrating lymphocytes were isolated from HL cell suspensions (n=9), and 
clones from patient T27 (n=5). Values were corrected for background staining by 
subtracting the isotype control value. 
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CXCR4 were significantly higher on clones than TIL (Figure 5.1B) (p<0.05, Mann 
Witney test). CXCR5 and CXCR6 were expressed on few cells in TIL or 727 clones 
(Figure 5.1A). 
CC chemokine receptors were also compared, with few cells in HL-derived TIL or 
T27 clones expressing CCR1, CCR2, CCR3 or CCR6 (Figure 5.2A). CCR4 was 
virtually absent on CD8+ TIL but showed variable expression on T27 clones (Figure 
5.2A and 5.2B). Thus, fewer than 20 % of cells from three T27 clones expressed the 
CCR4 receptor but 48 % of col cells and 83 % of c174 cells expressed CCR4. CCR5 
was detected on 36 ± 24 % SD of clones but was present on 15 ± 10 % SD of TIL 
(Figure 5.2A). This corresponded with higher cell surface levels on clones (Figure 
5.2B). However the only statistically significant difference between T27 clones and 
HL-derived TIL was the expression of CCR7, which was absent on T27 clones but 
expressed on 57 ± 20 % SD of CD8+ TIL (p<0.001, Mann Witney test). 
For adhesion molecule expression, between 70-100 % of HL-derived CD8+ TIL and 
T27 clones expressed LFA-1, PSGL-1, VLA-4 and P7 (Figure 5.3A) with no 
significant difference between clones and TIL in the percent of cells expressing these 
receptors. However, T27 clones had higher cell surface levels of all four of these 
receptors than TIL (Figure 5.3B). CD62L expression was detected on T27 clones (41 
±7% SD) and TIL (27 ± 15 % SD) (Figure 5.3A) whereas neither of these cell 
populations expressed significant levels of CLA (Figure 5.3A and 5.3B) 
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Figure 5.2 Comparison of CC chemokine receptor percent expression on T27 
clones and CD8+ TIL. 
Flow cytometry was employed to determine the expression (A) and mean channel 
fluorescence (B) of CC chemokine receptors on T cell clones and HL CD8+ TIL 
(described in Chapter 3). 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CC chemokine receptor antibodies in a final volume of 50 µl 
((CCR1 (mIgG2b), CCR2 (mIgG2b), CCR3 (rIgG2a), CCR4 (mIgGI) CCR5 
(mIgG2a), CCR6 (mIgG2b), and CCR7 (rIgG2a)). The reaction was incubated on ice 
for 30 minutes. The cells were washed twice in PBS/2 % FCS. Visualisation was 
achieved as described in legend for Figure 5.1. Cell analysis was performed by flow 
cytometry. Results were analysed with the software package WinMDI. Data represent 
mean ± SD. 
Tissue infiltrating lymphocytes were isolated from HL cell suspensions (n=9), and 
clones from patient T27 (n=5). Values were corrected for background staining by 
subtracting the isotype control value. 
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Figure 5.3 Comparison of adhesion receptor expression on T27 clones and CD8+ 
TIL. 
Flow cytometry was employed to determine the percent expression (A) and mean 
channel fluorescence (B) of adhesion receptors on T cell clones and HL CD8+ TIL 
(described in Chapter 3). 
Cells were washed twice (PBS/2% FCS) and collected (538 g /5 minutes), 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of adhesion receptor antibodies in a final volume of 50 µl ((CLA 
(rIgM), CD62L (mlgGI), LFA-1 (mlgGI), PSGL-1 (mlgGI), VLA-4 (mlgGI), 07 
(rIgG2a)). The reaction was incubated on ice for 30 minutes. The cells were washed 
twice in PBS/2 % FCS. Visualisation was achieved as described in legend for Figure 
5.1. Cell analysis was done by flow cytometry. Results were analysed with the 
software package WinMDI. Data represent mean ± SD. 
Tissue infiltrating lymphocytes were isolated from HL cell suspensions (n=9), and 
clones from patient T27 (n=5). Values were corrected for background staining by 
subtracting the isotype control value. 
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5.2.1.2 Comparison of CD4/CD8 clones from HL, NPC and melanoma patients. 
To analyse the homing phenotype of clones generated by this protocol, the study was 
extended to include clones from other EBV (NPC) and non-EBV (melanoma) 
associated cancer patients (see table 2.2). The rationale was to address whether there 
was a general homing phenotype for clones generated by this protocol, or whether 
there were differences based on factors like CD4/CD8 status, antigen specificity, or 
donor specific differences. 
CD4 (n=12) and CD8 (n=7) clones were studied and there was considerable 
heterogeneity between individual clones of both subsets. CXCR3 was expressed on a 
majority of both CD4+ (71 ± 18 % SD) and CD8+ clones (56 ± 29 % SD) (Figure 
5.4A). CXCR4 was expressed on more CD8+ clones (64 ± 19 % SD) than CD4+ 
clones (25 ± 15 % SD) (p<0.01, Mann Whitney test) (Figure 5.4A). CXCR5 and 
CXCR6 were typically expressed on a small proportion of clones examined, in both 
the CD4+ and CD8+ subset (Figure 5.4A). 
CCR1, CCR2, CCR6 and CCR7 were weakly (< 10 %) represented on all clones 
(Figure 5.4B). CCR3 and CCR4 were expressed on a variable proportion of cells 
depending on the individual clone examined (Figure 5.4B). CCR5 was expressed on 
the highest percent of cells (from the CC chemokine receptor family) for both CD4+ 
(52 ± 33 % SD) and CD8+ (32 ± 22 % SD) T cell clones (Figure 5.4B). The inter- 
clonal heterogeneity of expression of CC chemokine receptors meant that there were 
no significant differences in expression between the CD4+ and CD8+ populations. 
126 
Figure 5.4 Comparison of CD4+ and CD8+ clones from HL, NPC and melanoma 
patients. 
Flow cytometry was employed to determine the percent expression of CXC (A) CC 
(B) and adhesion receptor expression (C) on CD4 (n=12) and CDS (n=7) T cell clones 
from HL, melanoma and NPC patients. 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes), and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CXC, CC, and adhesion receptor antibodies as described in the 
legends for Figures 5.1-3. Cell analysis was done by flow cytometry. Results were 
analysed with the software package WinMDI. Values were corrected for background 
staining by subtracting the isotype control value. 
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Most adhesion receptors examined were expressed on the majority (65-100 %) of the 
cell population for all clones (Figure 5.4C). However, CLA expression was absent 
from virtually all clones except c73 from patient T29 that expressed CLA on 28 % of 
the cell population (Figure 5.4C). There was no difference in adhesion receptor 
expression between CD4+ and CD8+ subsets except for CD62L expression, which 
was on few CD4+ clones, but was expressed on all CD8+ clones tested (46 ± 20 %) 
(p< 0.01 Mann Witney test) (Figure 5.4C). 
5.2.1.3 Phenotypic heterogeneity between individual donors. 
The same panel of clones were analysed with respect to individual donors to 
determine inter-patient variation in expression of homing markers. 
Although there was intra-patient clonal heterogeneity, there were significant inter- 
patient differences in mean expression of receptors on cells. In the CXC chemokine 
receptor family, this was observed with CXCR4 and CXCRS (Figure 5.5A). Clones 
from donor T27 had more CXCR4+ cells (68 ± 19 % SD) than T19 (P< 0.05, 
Kruskall-Wallis test). T30 clones (59 ± 24 % SD) had more CXCR5+ cells than T27 
(P< 0.05, Kruskall-Wallis test). 
In a similar manner, differential expression of CC chemokine receptors on clones 
from individual donors was observed for CCR3, CCR5 and CCR7 (Figure 5.5B). T18 
clones expressed more CCR3 (30 ± 15 % SD) on cells than T30 clones, which were 
negative (P< 0.05, Kruskall-Wallis test). CCRS was expressed on a majority of cells 
from patient T19 (81 ±6% SD). This contrasted with clones generated from the other 
patients where CCR5+ expression was present but on no more than 40 % of the 
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Figure 5.5 Comparison of homing expression clones generated from individual 
donors. 
Flow cytometry was employed to determine the percent expression of CXC (A) CC 
(B) and adhesion receptor expression (C) on donor (n=6) derived T cell clones from 
HL, melanoma and NPC patients. 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CXC, CC, and adhesion receptor antibodies as described in the 
legends for Figures 5.1-3. Cell analysis was done by flow cytometry. Results were 
analysed with the software package WinMDI. Values were corrected for background 
staining by subtracting the isotype control value. (*) represents significant differences 
between donors. 
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population, with the exception of T27 c15 (77 %). CCR7 was expressed on few cells 
and differences in expression are unlikely to be functionally relevant. 
Adhesion receptor expression tended not to vary between donors. Only VLA 
expression significantly differed between donors T18 and T30 (Figure 5.5C). 
5.2.1.4 The role of antigenic specificity on the phenotype of T cell clones. 
T cell clones were analysed based on their antigenic specificity. Clones (n=7) specific 
for epitopes from EBV proteins were compared with clones (n=12) specific to 
melanoma antigens. Expression was compared for CXC, CC, and adhesion receptors 
(Figure 5.6). For most receptors there was considerable heterogeneity in their 
expression even amongst clones of the same antigenic specificity. This meant that 
there were no significant differences between the two antigenic specificities. The 
notable exception was CXCR4 (Figure 5.6A), where clones specific for EBV antigens 
expressed CXCR4 on a greater number of cells (61 ± 20 % SD) than clones specific 
for melanoma antigens (27 ± 18 % SD) (p<0.01 Mann Witney test). There was also a 
significant difference between groups for CCR7 (Figure 5.6B), however the 
proportion of cells expressing this receptor was low (<15 %) and are unlikely to be 
physiologically relevant. 
5.2.1.5 Activation of T cell clones alters their expression of homing receptors 
To enhance T cell recruitment to tumours clones can either be selected based on their 
homing phenotype or cultured to alter it. To test whether the homing phenotype could 
be altered during culture, the influence of resting or activation of T cell clones from 
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Figure 5.6 Analysis of the influence of antigenic specificity on the homing 
phenotype of T cell clones. 
Flow cytometry was employed to determine the percent expression of CXC (A) CC 
(B) and adhesion receptor expression (C) on T cell clones from EBV (n=7), 
melanoma (n=12). 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x 105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CXC, CC, and adhesion receptor antibodies as described in the 
legends for Figures 5.1-3. Cell analysis was done by flow cytometry. Results were 
analysed with the software package WinMDl. Values were corrected for background 
staining by subtracting the isotype control value. 
131 
A 
120 
100 
80 
60 
40 
20 
0 
D<0.01 
® " " 
" " o 0 
" 1 
" i o " 8 _ 
" " ° 
- - o o 
o " 0 
M kn 
O 
. r, 
0 
c 
O 
O 
r-. 
U 
. r, 
. r, 
O 
bA 
as 
4- 
V 
U 
B 
120 
100 
80 
60 
40 
20 
0 
c 
120 
100 
80 
60 
40 
20 
0 
n<n nc 
" 
" o o 
" - 
" s o 
° t o 
o ° " = " o " " 8 ° " 
UUUUUUU 
o "ß "ö 
- "ö - "4 " "o "® 
o 
" 
" g 
- I 
0 
S 
" 
" 
0 
- 
o 
® " 
0. 
" EBV 
0 Melanoma 
melanoma patients T29 and T30 was examined. Clones (n=3) were treated as follows 
and examined for mean percent expression of homing markers. 
On day 14 of the REP cycle, a sample of cells was analysed (day 14) for receptor 
expression. The remainder were split and treated in three ways (see section 2.2.2.5). 
Clones were maintained in culture containing IL-2, washed extensively and 
resuspended in media without IL-2, or activated with 100 ng/ml anti-CD3/CD28.24 
hours later clones were analysed for homing marker expression. 
The influence of continued culture with or without IL-2 had little influence on homing 
marker expression (Figure 5.7-5.9). In contrast, activation with 100-ng/ml anti- 
CD3/CD28 had a considerable influence on levels of CXCR3 receptor expression 
with downregulation to virtually undetectable levels for all three clones (Figure 5.7B). 
A similar decrease although less dramatic was observed for CXCR6 (Figure 5.7A, B). 
An activation induced increase in expression for CXCR4 and CXCR5 was only 
observed for clone 19 (Figure 5.7B). 
Although there were few changes in expression of CC chemokine receptors between 
day 14, IL-2 and resting conditions (Figure 5.8A), activation promoted a decrease in 
the numbers of CCR2 (only T30 c19) and CCR4 expressing clones (Figure 5.8A, B). 
T30 c19 exhibited a moderate increase in expression of CCR3 and CCR7 although it 
was limited to this one clone (Figure 5.8B). There was no difference in mean levels of 
CCR1, CCRS and CCR6 between treatments (Figure 5.8A). 
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Figure 5.7 The influence of different culture conditions on CXC chemokine 
receptor expression 
Flow cytometry was employed to determine the mean percent expression (A) and 
individual values (B) of CXC chemokine receptors on T29 c73, c121 and T30 c19 T 
cell clones from melanoma patients after altering in vitro culture conditions (see 
2.2.2.5 for details). 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CXC chemokine receptor antibodies in a final volume of 50 Al 
((CXCR3 (mIgGi), CXCR4 (mIgG2b), CXCR5 (mIgG2b), CXCR6 (mIgG2b)). The 
reaction was incubated on ice for 30 minutes. The cells were washed twice in PBS/2 
% FCS. Visualisation was achieved as described in the legend for Figure 5.1. Cell 
analysis was done by flow cytometry. Results were analysed with the software 
package WinMDI. Data represent mean ± SD. Values were corrected for background 
staining by subtracting the isotype control value. 
133 
A 
120 
X 100 
80 
o ¢" 60 
äý ö 40 
20 
0 
ß. i 
Ü 
Chemokine Receptor 
B 
CXCR3 
140- 
120- 
100- 
80- 
60- A 
40 0 
20   
0 
0 20 40 60 
CXCR5 
1400- 
1200- 
1000- 
0 800- 
600- 
EI 400 200 
0 
80 100 0 
CXCR4 
CXCR6 
  Day 14 
 I L-2 
O Rest 
D Act. 
700 0 100 
600 80 0 
500 60 400 A 
300 40 
LýA 200 20 
100 
0 
00 
0 20 40 60 80 100 0 20 40 60 80 100 
Percentage positive cells of total population 
A T29 c 121 
Q T29 c73 
0 T30c19 
20 40 60 80 100 
Figure 5.8 The influence of different culture conditions on CC chemokine 
receptor expression 
Flow cytometry was employed to determine the mean percent expression (A) and 
individual values (B) of CC chemokine receptors on T29 c73, c121 and T30 c19 T 
cell clones from melanoma patients after altering in vitro culture conditions (see 
2.2.2.5 for details). 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CC chemokine receptor antibodies in a final volume of 50 µl 
((CCR1 (mIgG2b), CCR2 (mIgG2b), CCR3 (rIgG2a), CCR4 (mIgGl) CCR5 
(mIgG2a), CCR6 (mIgG2b), and CCR7 (rIgG2a)). The reaction was incubated on ice 
for 30 minutes. The cells were washed twice in PBS/2 % FCS. Visualisation was 
achieved as described in the legend for Figure 5.1. Cell analysis was performed by 
flow cytometry. Results were analysed using the software package WinMDI (written 
by Joe Trotter). Data represent mean ± SD. Values were corrected for background 
staining by subtracting the isotype control value. 
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Figure 5.9 The influence of different culture conditions on adhesion receptor 
expression. 
Flow cytometry was employed to determine the mean percent expression (A) and 
individual values (B) of adhesion receptors on T29 c73, c121, and T30 c19 T cell 
clones from melanoma patients after altering in vitro culture conditions (see section 
2.2.2.5 for details). 
Cells were washed twice (PBS/2% FCS) and collected (538 g /5 minutes), 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre titred 
concentrations of adhesion receptor antibodies in a final volume of 50 µl ((CLA 
(rIgM), CD62L (mIgGl), LFA-1 (mIgGi), PSGL-1 (mIgG1) VLA-4 (mIgGl), beta 7 
(rIgG2a)). The reaction was incubated on ice for 30 minutes. The cells were washed 
twice in PBS/2 % FCS. Visualisation was achieved as described in the legend for 
Figure 5.1. Cell analysis was performed by flow cytometry. Results were analysed 
with the software package WinMDI. Data represent mean ± SD. Values were 
corrected for background staining by subtracting the isotype control value. 
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Expression of LFA-1, VIA-4 and 07 (2/3 clones) decreased upon activation (Figure 
5.9A, B). CD62L was expressed on few cells but for c73 where CD62L was expressed 
on most cells, activation strongly downregulated expression (Figure 5.9B). The 
number of PSGL-1+ cells was also down regulated with activation for T30 c19 
(Figure 5.9A, B). However, T29 c73 and 121 significantly upregulated PSGL-1 
expression with IL-2 or resting conditions and slightly with activation. (Figure 5.9B). 
CLA had no discernible change in expression with treatment (Figure 5.9A, B). 
5.2.1.6 The influence of successive REP cycles on phenotype. 
To obtain sufficient cell numbers for infusion of patients, clones often require 
multiple cycles of expansion to generate enough cells. To examine whether the 
homing phenotype altered between cycles of expansion, clones were analysed at the 
end of each cycle (day 14) for two cycles of expansion. Four clones from patients 
T27, T29 and T30 were examined for expression of CXC, CC chemokine and 
adhesion receptors (Figure 5.10-12). 
Expression of most markers remained consistent with little difference in percent 
expression (<20 %) and MFI on the cells analysed. Exceptions included 727 c15, 
which had a moderate increase (20-30 %) in the number of cells expressing CXCR4 
(Figure 5.10), CCRS (Figure 5.11) and CLA between the first and second REP. 
Conversely, CD62L expression decreased on a similar number of cells from c15. 
(Figure 5.12). 730 c19 exhibited a dramatic decrease in the number of CXCR5+ cells 
(Figure 5.10) and increase in the number of CCR2 (Figure 5.11) expressing cells 
between the two cycles of expansion (-40 %). T29 c121 also displayed differences 
(-20-30 %) in the number of expressing cells for CXCR3, CXCR4 (Figure 5.10) and 
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Figure 5.10 The influence of cycles of rapid expansion on CXC chemokine 
receptor expression. 
Flow cytometry was employed to determine the percent expression and MFI of CXC 
chemokine receptors on T27 c15, T29 c73, c121, and T30 c19 T cell clones from two 
cycles (14 days) of expansion. 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CXC chemokine receptor antibodies in a final volume of 50 µ1 
((CXCR3 (mIgGi), CXCR4 (mIgG2b), CXCR5 (mIgG2b), CXCR6 (mlgG2b)). The 
reaction was incubated on ice for 30 minutes. The cells were washed twice in PBS/2 
% FCS. Visualisation was achieved as described in the legend for Figure 5.1. Cell 
analysis was performed by flow cytometry. Results were analysed with the software 
package WinMDI. 
Values were corrected for background staining by subtracting the isotype control 
value. Open symbols represent the first expansion cycle. Filled symbols denote the 
second REP cycle. 
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Figure 5.11 The influence of cycles of rapid expansion on CC chemokine 
receptor expression. 
Flow cytometry was employed to determine the percent expression and MFI of CC 
chemokine receptors on T27 c15, T29 c73, c121, and T30 c19 T cell clones from two 
cycles (14 days) of expansion. 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of CC chemokine receptor antibodies in a final volume of 50 µl 
((CCR1 (mIgG2b), CCR2 (mIgG2b), CCR3 (rIgG2a), CCR4 (mIgGi) CCR5 
(mIgG2a), CCR6 (mIgG2b), and CCR7 (rlgG2a)). The reaction was incubated on ice 
for 30 minutes. The cells were washed twice in PBS/2 % FCS. Visualisation was 
achieved as described in the legend for Figure 5.1. Cell analysis was done by flow 
cytometry. Results were analysed with the software package WinMDI. 
Values were corrected for background staining by subtracting the isotype control 
values. Open symbols represent the first expansion cycle. Filled symbols denote the 
second REP cycle. 
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Figure 5.12 The influence of cycles of rapid expansion on adhesion receptor 
expression. 
Flow cytometry was employed to determine the percent expression and MFI of 
adhesion receptors on T27 c15, T29 c73, c121, and T30 c19 T cell clones from two 
cycles (14 days) of expansion. 
Cells were washed twice (PBS/2% FCS), collected (538 g /5 minutes) and 
resuspended at 1-5x105 cells/ml in PBS/2 % FCS. Cells were incubated with pre-titred 
concentrations of adhesion receptor antibodies in a final volume of 50 µl ((CLA 
(rIgM), CD62L (mIgGi), LFA-1 (mIgGi), PSGL-1 (mIgGi) VLA-4 (mIgGi), beta 7 
(rIgG2a)). The reaction was incubated on ice for 30 minutes. The cells were washed 
twice in PBS/2 % FCS. Visualisation was achieved as described in the legend for 
Figure 5.1. Cell analysis was done by flow cytometry. Results were analysed with the 
software package WinMDI. 
Values were corrected for background staining by subtracting the isotype control 
value. Open symbols represent the first expansion cycle. Filled symbols denote the 
second REP cycle. 
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CD62L (Figure 5.12). For CXCR3 and CXCR4 this was more obvious when 
considering MFI values, however CD62L had weak levels of expression (Figure 
5.10). A more striking difference in the proportion of CCR4 expressing cells (-45 %) 
(Figure 5.11), and a large difference in proportion of PSGL-1 expressing cells (-70 
%) was observed for c121 (Figure 5.12). T29 c73 had moderate differences in cell 
numbers expressing CXCR3, CXCR4 (Figure 5.10) and CLA (Figure 5.12) although 
CLA levels were very weak. A large difference in PSGL-1+ expressing cells was 
observed (Figure 5.12). In summary, there does not appear to be (in this limited panel 
of clones) a consistent pattern of altered expression of homing markers between 
cycles of cell expansion. Nevertheless, some markers can vary dramatically on 
individual clones. 
5.2.2 Functional analysis. 
5.2.2.1 Migration of clones to purified chemokine. 
In order to determine whether the identified receptors were functional, Transwell 
chemotaxis assays were employed to determine the ability of clones to migrate to 
recombinant chemokine. Sufficient cell numbers from T29 c73 and c121 were 
available to study chemotaxis to recombinant CXCL10/IP-10, CXCL12/SDF-1 and 
CCL17/TARC, as these clones expressed detectable levels of CXCR3, CXCR4 and 
CCR4 respectively. 
The strongest response was to the chemokine CCL17/TARC with migration levels 
peaking at 100 ng/ml for both c121 (39 %) and c73 (75 %) (Figure 5.13A). Weaker 
dose dependent responses were observed to CXCL10/IP10 (Figure 5.13B) with 
migration peaking at 400 ng/ml for c73 (15 %). The response to c121 does not peak in 
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Figure 5.13 Migration of melanoma clones to purified chemokine. 
Clones 73 and 121 from patient T29 were analysed for chemotaxis to purified 
CCL17/TARC (A), CXCL1O/ IP-10 (B), and CXCL12/SDF-I (C) 
Cells were washed twice in RPMI 1640 and enumerated. The pellet was incubated 
with 100tCi [51 Cr]O4 for I to 2 hours at 37 °c/ 5% CO2. The cells were washed 
twice with RPMI 1640 (to remove any unincorporated chromium). Cells were 
resuspended at 5x 106 cells/ml in RPMI 1640/0.5 % BSA and 100 µl of cell 
suspension was added to the upper chamber of a 3-µm pore size transwell filter. The 
transwell was then added to the well of 24 well Tissue culture plate containing 600 Al 
stimulus. The transwell chamber was incubated at 37°C/ 5% CO2 for 3 hours and the 
migrated cell population were quantitated using a gamma counter. Background 
migration was assessed by using chemotaxis media alone as a stimulus and 100 % 
migration was defined by adding 100 µl of cell suspension directly to the bottom of 
the chamber. Data represents results of triplicate determinations ± SD 
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the dose range tested but levelled out at -9%. The weakest response tested was to the 
chemokine CXCL12/SDF-1, although peak levels of migration did not occur in the 
range tested. When 400-ng/ml chemokine was tested, migration was measured at 10 
% (c73) and 4% (c121) of the total input. 
5.2.2.2 The adhesion of therapeutic EBV specific T cell clones under physiological 
shear. 
To examine the ability of clones to bind endothelial adhesion molecules in response to 
chemokines, two T cell clones from donor 127 were examined for their ability to bind 
purified VCAM-1 under conditions of flow. The rationale for choosing VCAM-1 was 
that expression had been detected in HL tissue and VIA-4 was expressed on T cell 
clones (and HL TIL). In addition, CXCR3 (CXCL9/CXCL10/CXCL11) and CXCR4 
ligands (CXCL12/SDF-1) were tested for their ability to modulate T cell adhesion to 
VCAM-1, as these chemokine receptors were expressed on both clones and tumour- 
infiltrating T cells. 
PBL were used as a control cell population and showed a greater number of cells that 
adhered/million cells perfused/mm2 of a VCAM-1 coated microslide compared with 
T27 col and c174 (p< 0.001, ANOVA) (Figure 5.14A). Co-immobilisation of 
CXCR3L or CXCL12/SDF-1 ligands with VCAM-1 reduced the number of adherent 
PBL compared with VCAM-1 alone. In contrast, clones exhibited no significant 
difference in total adhesion with co-immobilisation of CXCR3L or CXCL12/SDF-1 
When analysing the proportion of cells that rolled, (Figure 5.14B) PBL exhibited no 
significant change upon addition of CXCR3 ligands. However, there was a dramatic 
decrease in rolling with the addition of CXCL12/SDF-1 (p< 0.001, ANOVA). This 
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Figure 5.14 Adhesion of donor T27 clones to VCAM-1 under physiological flow. 
T27 c41 and c174 were examined for adhesion to purified VCAM-1 under 
physiological shear. Total adhesion (A), rolling (B), and static shape change (C) were 
determined. PBL were included as a control population. 
Glass capillary tubes were coated with 5 µg/ml purified VCAM-1 (1h/37 °C) and co- 
immobilised with CXCR3L (CXCL9,10, and 11 (0-1000 ng/ml for 1h/37 °C) or 
CXCL12/SDF-1 (1000 ng/ml for Ih/37 °C). This was connected to the flow system as 
previously described (Lalor et al., 1997). Lymphocytes (106 cells/ml) were perfused 
through the microslide at a shear stress of 0.05 Pa. Adherent lymphocytes were 
observed by phase-contrast microscopy using an Olympus IX50 inverted microscope. 
Adhesion was converted to cells per square millimeter and corrected for the number 
of lymphocytes perfused (i. e., adherent cells per square millimeter per 106 perfused). 
Phase contrast video recordings made during lymphocyte perfusion were analysed 
off-line to determine the percentage of rolling cells, statically adherent cells, and total 
adhesion. Rolling cells moved slowly over the microslide surface during 5-10 s of 
observation, while stationary adherent cells made no discernable movement over the 
same period. 
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corresponded with an increase in the proportion of cells that had undergone static 
shape change with the addition of CXCL12/SDF-1 (p< 0.001, ANOVA) (Figure 
5.14C). In assessing rolling and static shape change for col and c174, the addition of 
CXCR3 or CXCR4 ligands had no significant effect. Notably, clones exhibited 
similar proportions of cells that had undergone static shape change (Figure 5.14C) as 
PBL, potently induced by binding CXCL12/SDF-1. 
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5.3 Discussion. 
With the ability in recent years to clone and expand large numbers of antigen specific 
T cells, interest in cellular based therapies has increased. For T cell based therapies to 
be successful, clones must be specific for their target antigen, be optimally activated, 
persist in vivo and traffic to tumour deposits. At present, the optimal culture 
conditions that provide these ideal properties have not been determined. This may be 
influenced by many factors including the presence of IL-2, IL-15, and CD4+ clones to 
provide T cell help. 
This study has evaluated homing receptor expression and function on T cell clones 
generated for a phase I clinical trial of adoptive T cell therapy. We have compared 
clones generated for therapy of HL, with freshly isolated TIL from HL tumours. HL 
clones were also compared with clones produced for treating another EBV associated 
malignancy (NPC) and a non-EBV related tumour (melanoma). Furthermore, we were 
interested in whether the homing phenotype of clones was influenced by their target 
antigen specificity, CD4/CD8 status or the donor. 
53.1 Exploiting HL T cell homing pathways for therapy. 
A comparison of CD8+ clones from donor T27 with CD8+ TIL revealed that many 
receptors showed comparable expression on the two cell types although there were 
notable differences that are likely to have important implications for T cell homing to 
HL tumour deposits. 
Most notably the chemokine receptor CCR7 was absent from clones but highly 
expressed on infiltrating T cells in keeping with its role in recruiting T cells to 
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secondary LNs (Stein et al., 2000). The absence of CCR7 on clones implies that other 
chemokine receptor ligand pathways must to be exploited to activate integrins on 
HEV bound lymphocytes. CCR7 is not always expressed on T cells found in LN sites 
and recently a role for CXCR4 has been implicated in central memory T cell homing 
in a murine model (Scimone et al., 2004). Since CXCR4 is expressed on T27 clones, 
this may be sufficient for recruitment to HL via endothelial expressed CXCL12/SDF- 
1. However, the efficiency of this pathway in specific recruitment is likely to be low 
as mice deficient in CCR7 dependent trafficking have a paucity of LN T cells. In 
addition, high-level expression of CXCR4 on clones compared with TIL may retain 
them at sites of CXCL12/SDF-1 expression within the tumour similar to that observed 
in inflammatory sites (Buckley et al., 2000). 
Alternatively, CXCR3 (like HL TIL) was expressed on HL clones and may provide a 
general passport for entry into HL since this tumour is essentially an inflammatory 
site (Kunkel et al., 2002). The expression of CXCR3 ligands on the tumour 
vasculature is unclear and requires further examination. We have analysed 
CXCL10/IP-10 expression, which was absent from vessels but present on tumour 
cells. However, this does not discount CXCR3 dependent adhesion via CXCL9/MIG 
or CXCL11/ITAC. High expression of CXCL1O/IP10 by H-RS cells implies this 
receptor-ligand pathway may be important in chemotaxis to tumour cells. 
There were differences between clones and TIL in CC chemokine receptor 
expression. CCR4 was absent from intra-tumoural CD8+ T cells and functionally; 
chemotaxis experiments (Chapter 3) suggest HL TIL are unable to migrate to purified 
CCL17/TARC. In contrast, CCR4 was expressed on some T27 CD8+ clones. This is 
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potentially important as H-RS cells secrete high levels of CCR4 ligands (Ohshima et 
al., 2003; van den Berg et al., 1999). The ability to generate CCR4+ CTL clones that 
can functionally migrate to purified CCR4 ligands or expressing H-RS cell lines, will 
lend support to the hypothesis that CCR4+ CTL clones (upon entering HL tumours) 
would migrate to H-RS cells in a CCR4 dependent manner. CD8 TIL do not directly 
rosette around H-RS cells in situ (Poppema et al., 1982) and perhaps the absence of 
CCR4 on CD8+ TIL explains this. CCRS was expressed on a high proportion of cells 
from T27 clones but was expressed on a minority of TIL. Expression of a CCR5 
ligand CCL5/RANTES was reported in HL (Maggio et al., 2002). The authors 
reported IHC staining of macrophages, T cells and endothelial cells. Therefore, CCR5 
expression on clones might be exploited for both T cell adhesion and chemotaxis 
within the tumour. 
This study has allowed a comparison of CD8+ HL clones with freshly isolated CD8+ 
TIL. It is recognised that CD4 "help" is a likely requirement for clones to persist in 
vivo (Shedlock and Shen, 2003) and it will be important to compare the homing 
phenotype of tumour specific CD4+ clones with CD4+ TIL. 
53.2 Heterogeneity of clonal homing phenotype. 
The selection of antigen specific clones (both EBV and non-EBV specific) based on - 
IFN-y expression allowed us to test the hypothesis that clones would express a 
polarized type 1 homing phenotype including CXCR3, CCR5 and CXCR6 (Sallusto 
et al., 1998). Although a number of clones did express a type 1 homing phenotype, 
there was considerable variation in the proportion of the cell population expressing 
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these receptors. In addition, some clones expressed CCR3 and CCR4, a marker 
characteristic of a type 2 homing profile (Sallusto et al., 1998). 
This heterogeneity in the number of receptor expressing cells in a given clonal 
population provides a rationale for phenotyping clones prior to infusion to select those 
expressing high levels of the appropriate homing receptors. The reasons for this 
heterogeneity are interesting considering they arise from one site (i. e. the blood rather 
than different tissue sites) and are cultured under identical conditions. These 
differences perhaps reflect the ability of chemokine receptor expression to vary with 
CD4/CD8, target antigen specificity or donor status. For example CXCR4 was 
expressed predominantly on CD8+ clones from donor T27 and on EBV specific 
effectors. However, given the limited number of clones examined it was not possible 
to determine which of these associations was most important. However, Inter-clonal 
variability in the number of expressing cells meant that overall there were few 
significant differences in expression based on these three parameters. 
533 The Function of T cell clones generated for adoptive cellular therapy. 
For effective ACT, T cells require not only the correct homing phenotype, but they 
must persist and function correctly in vivo. Of the clones phenotyped in this study, six 
clones from three patients have so far been successfully infused in this trial. These 
clones have been analysed for persistence in vivo by ELlspot (by Dr Steve Lee) with 
blood samples collected pre-infusion, then 15 minutes, 1 day, and 7 days post 
infusion. This was then repeated for subsegqnnt infusions with collection of patient 
samples extending out to 14 days, 6 weeks and 8 weeks where possible after the final 
infusion. 
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To date, we have demonstrated that T cell therapy is feasible, with the successful 
infusion of CD4+ and/or CD8+ T cells. The treatment was well tolerated, and for 5/6 
patients, cells expanded in vivo, persisted (1-14 days; one case >2 months) and were 
functional immediately ex vivo. Homing in vivo was not monitored in this initial trial 
but in future will be of interest. 
To analyse the function of T cell clones, we first confirmed that CD8+ T27 clones and 
CD8+ TIL expressed adhesion molecules on a similar proportion of cells for all of the 
receptors examined. Clones expressed higher cell surface levels and this is likely to be 
functionally important. Furthermore, with the exception of CD62L and CIA, most 
adhesion receptors were expressed on a majority of the cell populations. Although not 
examined in this study, other factors such as integrin clustering at the membrane and 
the proportion of integrins in the active conformer (Hogg et al., 2002) will be relevant 
in functional adhesion and cell-cell/matrix interactions within the tumour 
microenvironment. Having confirmed expression of VLA-4 on clones (and HL TIL), 
and expression of the corresponding ligand (VCAM-1) in HL tissue, we tested the 
homing function of two LMP2 specific clones (c41 and c174) generated for our 
current trial of adoptive cellular therapy. We tested the ability of these two clones to 
adhere to purified VCAM-1 (co-immobilised with chemokine) under physiological 
shear. Compared with PBL, clones 41 and 174 arrested rapidly from flow without the 
need for rolling. This is likely to be a consequence of the activated states of their 
integrins as reflected by a lack of requirement for chemokine to induce shape change 
(note both clones expressed CXCR3 and CXCR4). Total adhesion of PBL to VCAM- 
1 (without chemokine), was greater than both clones 41 and 174 and may reflect the 
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concentration of VCAM-1 used. Titration of VCAM-1 may allow clones to better 
adhere to lower concentrations of VCAM-1 than PBL (Lalor et al., 1997). Although 
these results are preliminary, they suggest that clones expanded in vitro for 
therapeutic use may have a loss of tissue tropism because adhesion is independent of 
chemokine triggering. Consequently, they will tend to adhere non-specifically to 
endothelium under conditions of low shear stress such as occur in the lung, liver and 
spleen. This is consistent with observations in humans where infused T cells rapidly 
become trapped in such tissues (Chin et al., 1993). These results suggested exploring 
the ability to manipulate adhesion molecule expression and function on T cells 
prepared for infusion. 
5.3.4 Altering the phenotype of T cell clones. 
The ability to alter homing expression was evaluated by resting or activating clones. 
Short-term culture of clones in the absence of IL-2 appeared to have no effect on their 
homing phenotype although extending the resting period may address this. However 
there is an increased likelihood of cell death, which may be prevented by culturing 
cells in type 1 interferons (Pilling et al., 1999) In contrast, stimulation with anti- 
CD3/CD28 resulted in downregulation of a number of adhesion receptors after 24 
hours. It will be important to monitor the kinetics of re-acquisition of these integrins. 
Therapeutically, short-term downregulation of adhesion receptors may allow a greater 
degree of systemic recirculation before reacquiring receptor expression. Activation 
also has a profound effect on chemokine receptor expression. This was more complex, 
with upregulation of some receptors and downregulation of others. The ability to 
strongly downregulate expression of CXCR3 on clones is interesting as CXCR3 is 
typically associated with activation (Qin et al., 1998). Although less unambiguous, 
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other markers associated with an inflamed phenotype, include CCR2, CCR4 and 
CXCR6, which were also downregulated (on clones expressing these markers). There 
was a concomitant increase in expression of homeostatic receptors including CXCR4, 
CXCR5, and CCR7. It will be important to expand this study to include more clones. 
One study has examined polyclonal CTL lines for expression following TCR 
stimulation with anti- CD3/CD28 (Sallusto et al., 1999a). The authors describe a 
similar short-term shift in chemokine receptor expression with downregulation of 
"inflammatory" chemokine receptors like CCR1, CCR2, CCR3, CCR5, CCR6 and 
CXCR3 within six hours. There was a concomitant increase in homeostatic receptors 
including CCR4, CCR7, CCR8 and CXCR5 over 2-3 days. IL-2 reversed these trends 
for CCR3, CCR5, CCR7, CCR8 and CXCR5. The ability to upregulate CCR7 
expression on clones may provide a phenotype conducive to directing them into HL 
tumour deposits. However, the ability CCR7 positive clones to display immediate 
effector function (if necessary? ) will have to be examined (Sallusto et al., 1999b). Our 
study has demonstrated the ability to modulate homing receptor expression upon 
activation. However, it will be important to confirm these results with functional 
assays of migration and adhesion. Furthermore, the importance of cytokines like IL-2, 
IL-15, and IFNs in modulating homing expression as well as enhancing cellular 
expansion and survival of therapeutic T cell clones in vitro will be an important area 
of investigation to improve T cell based therapies. 
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Chanter 6: Concluding Discussion. 
This thesis addresses the possibility of aT cell-based therapy for HL, by exploring the 
molecular mechanisms of T cell homing to this tumour. HL is an attractive target for 
immunotherapy as the tumour is heavily infiltrated with T cells in contrast to other 
tumours like colorectal hepatic metastases (Yoong et al., 1998). Furthermore, the 
malignant H-RS cells lie within a background of reactive cells including T cells. In 
contrast, other solid tumours may have infiltrates that are located at peritumoural 
margins rather than infiltrating the tumour parenchyma. 
The work has focused on two main areas of research. Firstly, we have exploited the 
observation that T cells infiltrate HL tumours and have attempted to elucidate the 
relevant homing pathways. This involved examining the homing phenotype of TIL 
isolated from HL tumours by analysing the expression of chemokine (chapter 3) and 
adhesion receptors (chapter 4). With identification of the relevant receptors, 
expression of the corresponding ligands was determined by IHC. Where possible this 
work was extended to include functional studies. Chemotaxis of healthy donor 
derived lymphoblasts to HL cell lines was demonstrated to define pathways of T cell 
homing in vitro. Complementing this, it was important to determine whether freshly 
isolated T cells from HL are able to migrate to the purified chemokine (known to be 
expressed in situ). Preliminary investigations demonstrated migration of non- 
expanded TIL to CXCL12/SDF-1 but not CCL17/TARC. Secondly, we have 
examined the phenotype and function of these molecules on T cell clones prepared for 
a clinical trial of adoptive T cell therapy for HL and other human malignancies 
(chapter 5). 
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6.1 Do HL-derived TIL have distinct homing properties? 
The distinctive phenotype of TIL from HL compared with TIL from other solid 
tumours suggests that different tumours recruit T cells employing dissimilar homing 
pathways. This is unsurprising considering the requirements for recruitment to a LN 
in HL compared with recruitment to peripheral tissue. However, this is the first 
detailed study to show such differences and the results have implications for therapy. 
Based on these results, we can propose a model of T cell homing into Hodgkin's 
tumours (Figure 6.1). Firstly, T cells expressing CD62L capture and roll on o-glycan 
linked core proteins (including PNAd) expressed on tumour vessels. VAP-1 expressed 
on the endothelium may also promote subset specific recruitment of CD8+ T cells by 
binding surface exposed primary amines. T cell expression of CCR7 and CXCR4 then 
allows engagement of CCL21/SLC and CXCL12/SDF-1 respectively, presented on 
the luminal surface by the glycocalyx. This activates Integrins such as LFA-1 and 
VLA-4, which causes cell arrest, and TEM into the tumour parenchyma. T cell 
expressing VIA-4 might also be directly captured from the circulation onto vessels 
expressing VCAM-1. T cells can then respond to CXCR3, CXCR4, and CCR7 
ligands within the tumour promoting directed migration, with CXCR3+ T cells 
migrating to H-RS cells in response to CXCL10/IP10 expression. In addition, small 
populations of CXCR6 (CD8), CCR4 (CD4) and CCR5 (CD4 and CD8) expressing T 
cells may localise in proximity to H-RS tumour cells. 
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Figure 6.1 A model of T cell homing in Hodgkin's lymphoma. 
A model for T cell homing is proposed where T cells expressing L-selectin capture 
and roll on o-glycan linked core proteins (including PNAd) expressed on tumour 
vessels. Endothelial expressed VAP-1 may also promote subset specific recruitment 
of CD8+ T cells by binding surface exposed primary amines. T cell expression of 
CCR7 and CXCR4 allows engagement of CCL21/SLC and CXCL12/SDF-1 
respectively, posted on the luminal surface by the glycocalyx. Integrins including 
LFA-1 and VLA-4 are activated and facilitate firm arrest. These LFA-1/ICAM-1 and 
VLA-4NCAM-1 adhesive events promote TEM into the tumour parenchyma. T cells 
then respond to CXCR3, CXCR4, and CCR7 ligands within the tumour promoting 
directed migration. In addition, small populations of CXCR6 (CD8), CCR4 (CD4) 
and CCR5 (CD4 and CD8) T cells may respond to local chemokine gradients 
positioning them in proximity to H-RS tumour cells. 
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6.2 What is the nature of the H-RS microenvironment? 
HL is a complex model in which to evaluate T cell homing as the distinction between 
those cells that are recruited in response to a target antigen or simply migrate, as part 
of routine homeostatic trafficking is unclear. An inflammatory versus a homeostatic 
response is likely to be determined by the degree to which the nodal architecture has 
been effaced with tumour. This is further complicated by the classification of HL into 
distinct subtypes and an incomplete association of EBV with HL (40 % of cases). Too 
few samples were studied in this work but it will be interesting to determine if 
different homing phenotypes exist based on HL subtype or EBV status. 
The ability of rare H-RS cells to survive in the face of an overwhelming reactive 
infiltrate remains enigmatic, as H-RS cells appear capable of processing and 
presenting antigen to T cells (Lee et al., 1998). This includes viral antigens from EBV 
but may also include other target antigens including MAGE A4 which is expressed in 
30 % of HL cases (mainly EBV- cases) (Chambost et al., 2000). Furthermore, H-RS 
cells express high levels of adhesion receptors and co-stimulatory molecules (Ellis et 
al., 1992). The homing phenotype of TIL suggests a complex infiltrate that may be 
composed of TO (CXCR3, CCR5, CXCR6) and T112 (CCR3, CCR4) like T cells. T 
cells immediately surrounding H-RS cells are CD45RA- (Poppema, 1989) suggesting 
a memory phenotype and express activation markers including CD38 and CD69. In 
addition, they are predominantly CD4+/CD57+, which is normally ascribed to a 
germinal centre population of helper T cells (Bowen et al., 1991). Furthermore, 
polyclonal populations of CD4+ T cells rosýtting H-RS cells were microdissected 
from tissue, arguing against an antigen specific T cell response (Roers et al., 1998). 
Taken together it has been proposed that a non-specific population of T112 T cells 
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locally interacts with H-RS cells aiding in their survival and proliferation in much the 
same way follicular homing CD4+ T cells rescue B cells from apoptosis (Choe et al., 
1996). H-RS cells secrete cytokines and chemokines that were thought to promote the 
recruitment of this TH2 population of T cells. H-RS cells can induce fibroblasts to 
secrete eotaxin in an in vitro co-culture model (Jundt et al., 1999) promoting 
recruitment of CCR3 expressing TH2 cells. We report expression of CCR3 on few 
infiltrating T cells suggesting this may not be a major recruitment pathway. 
Chemokines like CCL17/TARC and MDC/CCL22 are directly produced by H-RS 
cells and have been implicated as an important mechanism for recruiting TH2 cells 
(van den Berg et al., 1999). We detected this receptor on a minor population of CD4+ 
TIL, which may play a role in microenvironmental homing. However, these pathways 
are unlikely to be a major pathway for bulk T cell recruitment. An alternative 
hypothesis reinterpreting this published data argues that the infiltrate comprises a 
predominantly regulatory T cell population (Marshall et al., 2004). This was 
supported by the observation that TIL were anergic to mitogen, poorly proliferates, 
and had few cells expressing a TH1 or TH2 cytokines compared with autologous PBL. 
Furthermore, TIL contained large populations of both IL-10 secreting and 
CD4+CD25+ regulatory T cells. Thus, the presence of regulatory T cells in HL 
tumours may explain H-RS cell survival. 
6.3 Analysis of T cell clones and implications for therapy. 
A phase I clinical trial of adoptive T cell therapy was initiated. This allowed us to 
explore an EBV-associated tumour as a suitable model for T cell immunotherapy. The 
ability to isolate and expand large numbers of antigen specific T cell clones from 
cancer patients in vitro precludes a number of uncertainties that arise with vaccination 
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strategies. Specificity, function, and the numbers of CTL can be defined in vitro 
before infusion. Infusion of antigen specific T cell clones into patients represents the 
"gold standard" regarding target antigen choice and aids the rational development of 
therapeutic vaccines. However, there are important considerations regarding the wide 
scale applicability of adoptive T cell therapy, which is technically demanding 
(requiring extensive safety and toxicity screening), expensive and tailored to the 
individual patient. In addition, in spite of knowledge of specificity, function and cell 
numbers, there remain important questions regarding the ability of such cells to 
persist in vivo and traffic to tumour deposits. 
To evaluate the homing phenotype of cells generated using this protocol, and to 
determine the ability of infused clones to traffic to HL tumour deposits, we analysed 
homing receptor expression and function on EBV specific clones and compared them 
with clones specific to melanoma antigens. In general, clones expressed a polarised 
chemokine receptor phenotype with expression of CXCR3, CCR5 and CXCR6 
(characteristic of type 1 response). This is consistent with the fact that they were 
selected in vitro based on IFN-y production. However, some clones expressed 
markers indicative of a type 2 response including CCR3 and CCR4 implying clones 
may need to be phenotyped before infusion to ensure trafficking to the tumour. 
Furthermore, there was considerable heterogeneity in the proportion of clonal 
populations expressing these receptors. This meant there were few significant 
differences in expression based on antigen specificity, CD4/CD8 or donor status. 
The homing phenotype of CD8+ T cell clones from donor 727 was compared with 
HL CD8+ TIL. There were few differences in expression of receptors with the 
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exception of CCR4 and CCR7. The presence of CCR4 expression on T27 clones may 
allow microenvironmental positioning within HL tumours based on high expression 
of CCR4 ligands detected in situ by us and others (van den Berg et al., 1999). 
However, the lack of expression of CCR7 on these cells indicates that clones may 
need to exploit alternative pathways to enter HL tumours. VLA-4 is highly expressed 
on HL TIL and clones, and may be activated by chemokine receptors like CXCR3 and 
CXCR4, suggesting these clones may still be able to enter HL tumours binding 
vessels by exploiting these alternative adhesion pathways. 
Flow based adhesion studies of T cell clones adhering to purified VCAM-1 
demonstrated the clones were unaffected by co-immobilising VCAM-1 with 
chemokine. The implication is that clones have highly activated integrins that can 
bind counter receptors independently of chemokine signalling. However, the concern 
is that clones have lost tissue tropism and will not efficiently traffic to tumour 
deposits. 
The implication from these functional studies is that strategies are needed to alter the 
homing phenotype of T cell clones to restore tissue tropism. Activation of clones with 
anti-CD3/CD28 was examined as a possible way to downregulate integrin receptors in 
the short term and upregulate receptors like CCR7 that confer specificity for LN. 
Although limited in the numbers of clones analysed, activation appeared to switch 
expression from an inflammatory to a homeostatic homing phenotype. For therapy of 
HL, it may be desirable to have a population of clones that display a more central 
memory phenotype. Namely, they express high levels of CCR7 and CD62L and are 
able to enter LN. Furthermore, they would posses enhanced proliferative capacity and 
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persist in vivo (Sallusto et al., 1999). The ability to derive central memory cells in 
vitro for cellular therapy remains a significant challenge considering that clones 
produced by this protocol tend to be virtually all effector T cells (personal 
communication S. Riddell). Furthermore, the capacity of central memory clones to 
mediate efficient target cell killing will need to be examined although studies in 
animal models suggest central memory rather than effector memory cells are more 
effective in clearing viral and bacterial model infections (Wherry et al., 2003). Other 
approaches to achieve efficient homing include retroviral transduction of antigen 
specific clones with the appropriate chemokine receptor (i. e. CCR7). This approach 
has been successfully demonstrated with retroviral transduction of CXCR2 into T 
lymphoblasts, which then could migrate to a melanoma cell line in a CXCL1/Gro-a 
dependent manner (Kershaw et al., 2002). Alternatively, cells of the correct homing 
specificity (i. e. TIL) could be selected and transduced with cloned TCRs specific to 
the required target antigen (Kessels et al., 2001). It will be important to ensure 
modified T cells retain their homing phenotype after such manipulation in vitro. 
6.4 Animal models of T cell homing. 
Upon identification of T cell homing function in vitro, it will be important to confirm 
the in vivo relevance of these pathways. Previous studies have demonstrated that 
human chemokine function can be analysed in vivo in a SCID mouse model (Taub et 
al., 1996). SCID mice received an intraperitoneal injection of human PBL. They were 
then injected subcutaneously with recombinant human chemokine. CD3+ T cells were 
shown to accumulate at the injection site. It will be interesting to assess chemokine- 
mediated infiltration of HL tumours in vivo. This could be done by injecting SCID 
mice subcutaneously with chemokines known to be expressed by H-RS cells in situ or 
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alternatively with chemokine expressing H-RS cell lines (Borchmann et al., 2003). 
Human TIL are then adoptively transferred into these mice and stained for appropriate 
human T cell surface markers to assess the extent of T cell infiltration of the injection 
site. Blocking studies with neutralising antibodies to the relevant chemokine-receptor 
pathway would then confirm the role of that interaction in mediating infiltration. 
Xenograft models have been developed for investigating T cell trafficking including a 
SCID-hu Skin mouse model to investigate selective chemokine mediated homing of 
human T-lymphocytes to the skin (Carballido et al., 2003). Engraftment of human 
synovium onto SCID mice was used to examine the resulting effects of TNF injection 
in modulating leukocyte migration (Wahid et al., 2000) 
Promisingly for the study of migration in HL, SCID mice were transplanted with 
human peripheral LN to investigate CXCL12/SDF-1 dependent migration of human 
lymphocytes and a CXCL12/SDF-1 responsive cell line U937 (Blades et al., 2002). 
This model could be adapted transplanting HL LN to evaluate human T cell homing. 
Whether grafted tissue retains expression of human endothelial markers is something 
that would have to be validated but nevertheless would provide a useful in vivo model 
of T cell homing. 
6.5 Tracking infused T cells in humans. 
The ability to track infused cells in vivo has greatly aided in the elucidation of homing 
mechanisms. The availability of intravital microscopy and 2-photon imaging has 
provided a comprehensive understanding of trafficking in animal models (Iparraguirre 
and Weninger, 2003). Ultimately though, analysis of trafficking in humans requires 
alternative approaches. At present, infused cells are monitored by taking blood 
samples and looking for evidence of immune responses by ELISpot and chromium 
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release assays. Evidence of trafficking to, and function at, the site of the tumour are 
hard to determine. To address this problem, alternative approaches including genetic 
marking of infused cells (Heslop et al., 1994), as well as short term indium 111 
labelling has been employed (Dummer et al., 1993). Indium 111 labelling of cells 
provides real time monitoring of labelled cells. The advantages are that the half-life of 
indium-111 is short enough to be safe, yet long enough for in vivo circulation, 
however the resolution of this technique is low. Early studies of indium labelled TIL 
from patients with metastatic melanoma revealed trafficking of cells to tumour 
deposits (Fisher et al., 1989). More recently, labelling of Melan-A specific CTL lines 
allowed the identification of these cells at metastatic sites as early as 48 hours after 
infusion (Meidenbauer et al., 2003). 
To summarise, we have attempted to better understand the mechanisms of T cell 
recruitment to HL tumours. This information can then be applied to improve future T 
cell therapies by ensuring the appropriate homing receptors are expressed on antigen 
specific T cell effectors such that they efficiently traffic to HL tumour sites. 
t. 
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